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 Diabetes related chronic cardiovascular complications are the most popular and 
seriously threatening factor to the living quality of these patients. Therefore, prevention of 
long-term complications of diabetes is one of the major aims of treatment. Consequently, 
it is necessary to uncover the underlying mechanisms for the pathogenesis and 
pathophysiology of these disorders.  Hyperglycemia and hyperlipidemia are two primary 
causes for the development of cardiovascular complications in diabetes. Overwhelming 
evidence indicates that endothelial cell dysfunction in diabetes is characterized by 
diminished endothelium-dependent vascular relaxation, but the underlying molecular 
mechanism remains inconclusive. Since nitric oxide (NO) production from the 
endothelium is the major regulating factor in this event, the aim of this work was to 
extensively investigate the effects of high glucose and high fatty acids on NO production 
and possible alterations of signaling pathways implicated in this scenario. Exposure of 
cultured bovine aortic endothelial cells (BAECs) or human umbilical vein endothelial 
cells (HUVECs) to high glucose or high fatty acids for 5 or 10 days significantly reduced 
NO production evoked by bradykinin and ATP, phospholipase C-activating receptor 
agonists, in both a time- and dose-dependent manner. The diminished NO formation was 
probably due to an attenuation in bradykinin-induced elevations of intracellular free Ca2+ 
levels ([Ca2+]i) under these conditions. Both bradykinin-promoted intracellular Ca2+ 
mobilization and extracellular Ca2+ entry were affected. In addition, the basal and 
bradykinin-evoked formation of Ins(1,4,5)P3, one product of the activation of 
phospholipase C which leads to [Ca2+]i rises, was also deceased following high glucose 
culture. This abnormality was not attributable to a decrease of inositol phospholipids, but 
might be due to a reduction of the number of bradykinin receptors by high glucose and to 
a decrease in the affinity of bradykinin receptor by high fatty acids. On the contrary, 
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[Ca2+]i elevation and NO production evoked by a Ca2+ ionophore (ionomycin) were not 
affected by high glucose or high fatty acids. Furthermore, the adverse effects of high 
glucose and high fatty acids might be due to excessive activation of protein kinase C 
(PKC) and/or to increased production of free radicals, as PKC inhibitors and antioxidants 
could reverse high glucose- or high fatty acid-induced impairments on NO formation, 
[Ca2+]i rise, bradykinin receptor (receptor number as well as affinity), and cell 
morphology. These data indicate that chronic exposure to high glucose or high fatty acids 
reduce NO generation in endothelial cells probably by impairing at the receptor level at 
least partially through the over activation of PKC or formation of oxidants. This defect in 
NO release may contribute to the diminished endothelium-dependent relaxation and thus 







aFGF            acidic fibroblast growth factor  
AGEs            advanced glycation end-products 
Akt              protein kinase B  
ATP             adenosine 5’-triphosphate  
BAECs           bovine aortic endothelial cells 
BH4              (6R)-5,6,7,8-tetrahydrobiopterin 
BSA             bovine serum albumin 
DAF             2, 4,5-diaminofluorescein diacetate  
DAG            diacylglycerol  
DMEM          dulbecco’s modified eagle medium  
DMSO          dimethyl sulphoxide  
DTPA           diethylene-triamine-penta-acetic-acid  
DTT            dithiothreitol  
EDTA           ethylenediaminetetraacetic acid  
EGTA           ethylene glycol-bis (β-Aminoethyl ether)-N,N,N’,N’-tetraacetic acid  
eNOS           endothelial nitric oxide synthase isoform  
FCS            fetal calf serum  
HEPES          N-[2-hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] 
HUVECs        human umbilical vein endothelial cells  
iNOS           inducible nitric oxide synthase isoform 
IP3             inositol 1,4,5-triphosphate 
IP4             1,3,4,5-tetrakisphosphate  
L-NAME        NG-nitro-L-arginine methylester  
  11
NADH          nicotinamide adenine dinucleotide  
NADPH         nicotinamide adenine dinucleotide phosphate  
NO             nitric oxide 
nNOS           neuronal nitric oxide synthase isoform 
PC              phosphatidylcholine 
PE              phosphatidylethanolamine 
PI              phosphatidylinositol 
PIP             phosphatidylinositol-4-monophosphate 
PIP2            phosphatidylinositol-4,5-bisphosphate  
PKC            protein kinase C  
PLC            phospholipase C  
PMSF           phenylmethylsulfonyl fluoride 
ROS            reactive oxygen species  


















1.1.1. General overview of diabetes 
The term “diabetes” is associated with a heterogeneous group of disorders, including 
diabetes mellitus, gestational diabetes, impaired glucose tolerance, and diabetes 
secondary to pancreatic disease, hormonal alterations, or genetic syndromes 1. Of all these 
“diabetes”, diabetes mellitus refers to a number of disorders and is the most common and 
the most serious one. It affects about 6% of people in the developed countries and its 
prevalence is rising quickly in the economically fast-growing regions 2. For instance, the 
prevalence of diabetes has reached 9% in Singapore among people over 16 years old. 
Moreover, the incidence of diabetes mellitus appears to be rising. There are almost five 
times the number of people suffering from this disease today as compared to 10 years ago, 
and the worldwide diabetic population is expected to exceed 300 million by the year 2008 
3.  
Diabetes mellitus is an endocrine disorder that is characterized by a disruption of 
intermediary metabolism due to insufficient insulin activity, insulin secretion, or both. 
The unifying feature in untreated diabetes mellitus is the presence of persistently high 
glucose levels and disorders of fatty acids in the blood, accompanied by a variety of 
clinical and biochemical symptoms. This metabolic disease is roughly divided into two 
categories, type 1 or insulin dependent diabetes mellitus and type 2 or non-insulin 
dependent diabetes mellitus. Even though the classical distinction between them is not 
clear-cut as patients with non-insulin dependent diabetes mellitus may also require 
treatment with insulin, such classification will still be used in this thesis and for 
convenience, diabetes refers to diabetes mellitus.  
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There are many differences between type 1 and type 2 diabetes. Type 1 diabetes is 
characterized by an autoimmune response which destroys insulin-producing β cells in the 
pancreatic islets, generally occurring in youth under the age of 15. Therefore, it has also 
been called “juvenile onset” diabetes, and these patients always have very low levels of 
insulin because of β cell destruction. In contrast to type 1 diabetes, pancreatic β cells 
remain anatomically intact in type 2 diabetes at early stages, and insulin resistance is the 
primary defect 4, 5. This disease is preceded by a long period of asymptomatic 
hyperglycemia and hyperlipidemia due to decreased tissue sensitivity to insulin. In this 
non-specific reversible pre-diabetic state, β cells produce increased amount of insulin as a 
counter-regulatory effort to elevated glucose concentrations, and maintains 
normaglycemia. When β cells become exhausted, a deficiency in insulin secretion ensues 
and a sustained hyperglycemic state develops. Therefore, patients with type 2 diabetes 
typically have normal to high levels of insulin depending on the stage of the disease, but 
low insulin levels may occur with progressive hyperglycemia 1. This type of diabetes 
accounts for approximate 90% to 95% of all diabetic cases. Epidemiological 
investigations 6-10 suggested an increasing tendency in the future for type 2 diabetes 
epidemic due to secondary factors such as obesity, hypertension, and lack of physical 
activity resulting from the modern lifestyle. Inevitably, type 2 diabetes will emerge as one 
of the major threats to public health resources throughout the world at a huge economic 
and social cost.  
Although diabetes has been recognized for centuries, our understanding of the 
etiology and pathogenesis of the disease is still incomplete. It seems that both genetic and 
environmental factors play important roles in the development of type 1 diabetes. Several 
candidate regions, such as the HLA gene region and the IDDM2 locus 11, 12, have been 
identified to be associated with susceptibility to type 1 diabetes. On the other hand, our 
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knowledge about the etiology and pathogenesis of type 2 diabetes is less than satisfying. 
It is postulated that similar to type 1 diabetes, both genetic and environmental factors are 
involved. The interplay between these factors results in a variable deterioration in insulin 
sensitivity and insulin secretion.  
1.1.2.  Diabetes-related vascular complications 
The discovery of insulin in 1921 led to the belief that the main problem of diabetes 
mellitus had been solved. However, during the following years it became obvious that 
although patients with diabetes were surviving upon insulin administration, their living 
quality was challenged by the long-term complications. These complications are a 
heterogeneous group of clinical disorders occurring frequently in poorly controlled 
diabetes, which can affect the vascular system (both macroangiopathy and 
microangiopathy) resulting in serious morbidity and premature mortality (accounting for 
more than 80% of the overall mortality in diabetic individuals) 13. Macrovascular 
complications include coronary artery disease, atherosclerosis and peripheral vascular 
disease, while microvascular complications display retinopathy, nephropathy, and 
neurovascular defects associated with autonomic neuropathy.  
Both type 1 and type 2 diabetic patients suffer from long-term microvascular or 
macrovascular complications. However, macrovascular complications are a more 
life-threatening factor when compared with the effects of microvascular complications in 
diabetes.  It was reported that three out of four diabetes-related deaths are caused by 
heart and blood vessel (cardiovascular) diseases 14, 15. People with type 2 diabetes are 2-4 
times more likely to have macrovascular diseases than non-diabetic subjects 15. Moreover, 
type 2 diabetic patients have more opportunities to develop long-term complications due 
to their longer life span. These two reasons make diabetes related chronic macrovascular 
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complications the most popular and seriously threatening factor to the living quality of 
these patients. Therefore, prevention of long-term macrovascular complications of type 2 
diabetes is one of the major aims of treatment. Consequently, it is necessary to uncover 
the underlying mechanisms for the pathogenesis and pathophysiology of these disorders.  
Unfortunately, most of the current data were results from microvascular studies, and 
only a few investigations provide relevant information concerning diabetes-related 
macrovascular diseases. In other words, research on macrovascular complications has 
been largely overlooked. It should be noted that the mechanisms underlying these two 
diseases (micro- and macrovascular complications) might be quite different. It is well 
known that there are many differences between microvascular and macrovascular vessels 
in term of their structure, physiology and pathology. For example, the prevalence of 
macrovascular disorders is already increased prior to the onset of overt hyperglycemia in 
individuals with impaired glucose tolerance 16, while the microvascular disease is ‘clock 
starts ticking’ at the onset of hyperglycemia and not before 16. In addition, both insulin 
and basal glucose concentrations significantly regulate the glucose transport rate in 
microvascular endothelial cells, but not in macrovascular endothelial cells 17. Therefore, 
the effects of high glucose on microvascular and macrovascular endothelial cells might be 
fairly different. Furthermore, the potential biological processes of microvascular and 
macrovascular complications are different. For instance, increased sorbitol may play an 
important role in microvascular diseases while the activation of protein kinase C (PKC) 
may play a major role in macrovascular diseases 18, 19. However, these differences 
between macrovascular and microvascular vessels, as well as the possible different 
mechanisms underlying their vascular diseases were largely ignored. Most of the previous 
studies on diabetic-related complications were focused on microvascular diseases. The 
studies of macrovascular diseases, the leading cause of death in the diabetic population, 
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were far from satisfying. Thus, studies aiming to identify the mechanisms of 
macrovascular diseases in diabetes are essential.   
It is well known that a number of vascular cell types are involved in diabetes-related 
chronic vascular complications. In large blood vessels, the types of vascular cells 
involved are endothelial cells and smooth muscle cells, whereas in the capillaries, 
endothelial cells and pericytes are implicated. Since insulin resistance has been shown to 
be associated with impaired endothelial function 20, 21 and both of these events share 
common metabolic abnormalities, it has been suggested that endothelial dysfunction is an 
integral aspect of the insulin resistance syndrome. Furthermore, endothelial cells in 
vessels seem to first exhibit impairment due to their strategic anatomical position. 
Although the underlying molecular mechanisms of diabetes-related cardiovascular 
diseases are not clear, it appears that vascular endothelial dysfunction is a common 
feature in the development of chronic diabetes-related vascular diseases.  
1.2. Endothelial dysfunction and diabetes-related cardiovascular 
complications 
1.2.1. Endothelial function and dysfunction 
The endothelium, once considered a simple diaphanous cellular monolayer of cells 
covering the entire inner surface of all the blood vessels, has been established as a 
strategically located multifunctional organ since Furchgott and Zawadzki 22 showed in 
their historic experiment that the addition of acetylcholine to intact arteries resulted in an 
endothelium-dependent relaxation. It is undoubted that endothelial cells play a 
deterministic role in vascular tone, reactivity, inflammation, vascular remodeling, 
maintenance of vascular potency and blood fluidity 23-25. Dysfunction of the endothelium 
can be considered present when its properties, either at the basal state or after stimulation, 
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have changed in a way that is inappropriate with the preservation of organ function. Loss 
of the modulatory role of the endothelium may be a crucial initiating factor in the 
development of diabetic vascular diseases. In these diseases, endothelial dysfunction has 
been shown to be present in resistance and conduit vessels of the peripheral circulation, as 
well as in the coronary circulation. Markers of endothelial cell damage such as plasma 
levels of vWF, microalbuminuria and the transcapillary escape rate of albumin are 
increased in individuals with type 2 diabetes and in animal models in both in vivo and in 
vitro studies 26-37.  
Many of the endothelial functions mentioned above are maintained through 
regulatory substances secreted from endothelial cells, which may often have opposing 
actions. One group of these chemical mediators belongs to the vasoconstrictors, which 
include angiotensin converting enzyme, endothelins and so on. The actions of these 
vasoconstrictors are balanced by endothelium-derived relaxing factors, whose major 
component was eventually identified as nitric oxide (NO) 38. Other vasodilators include 
vasodilating prostaglandins and histamines, etc 39. In addition to serving as a modulator of 
vascular tone, these vasodilators also play a role in regulating arterial pressure, smooth 
muscle cell proliferation, and adhesion of platelets and inflammatory cells to the 
endothelial surface 40. These properties suggest that the level of vasodilators produced by 
the endothelium is pivotal in the regulation of endothelial functions.  
When the balance between vasoconstrictors and vasodilators is disturbed, either by 
reduced synthesis/release of dilating factors or by augmented synthesis/release of 
contracting substances, or both, endothelial dysfunction develops. Interestingly, the 
vasoconstrictor responses to different physiological or pharmacological factors are 
generally not altered. It is thus more likely that the synthesis/release of vasodilators are 
impaired. Among all vasodilators, NO is the most potent and crucial one, accounting for 
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69% of the basal norepinephrine release 41 in the control of vascular tone, and thus 
received the most interest in endothelial dysfunction studies. In addition to inducing 
vascular relaxation 22, NO also inhibits smooth muscle proliferation 42, platelet 
aggregation 43, leukocyte adhesion to vascular endothelium 44, and endothelial 
permeability 45.  
1.2.2. Endothelial NO production 
1.2.2.1. Endothelial nitric oxide synthase and production of NO in endothelial cells  
There are at least three distinct isoforms of nitric oxide synthase in the body, i.e. 
endothelial nitric oxide synthase (eNOS), immune or inducible nitric oxide synthase 
(iNOS) and neuronal nitric oxide synthase (nNOS). NO is synthesized from the precursor 
L-arginine in a reaction catalysed by these nitric oxide synthases. All three isoforms have 
some implications, physiologically or pathophysiologically, in the cardiovascular system. 
Both nNOS and eNOS are constitutively expressed and their activity is regulated by 
calcium/calmodulin, with calcium concentrations at least above 70 nM being required. 
This is in contrast to iNOS, which requires only 30 nM of calcium for activation because 
calcium/calmodulin is constitutively bound to this enzyme 46. Among these three isoforms, 
eNOS plays the major role in the stimulus-induced NO formation in physiological 
endothelial cells, which consists of two identical monomers of 135kD. 
The whole process of endothelial NO formation involves a series of signal 
transduction cascade in response to stimulation by certain receptor ligands or by 
longitudinal shear force in blood vessels, as shown in figure  A 47. Receptor agonists 
such as bradykinin, acetylcholine and adenosine 5’-triphosphate (ATP) bind to G 
protein-coupled receptors on the plasma membrane of endothelial cells, leading to the 
activation of phospholipase C-β (PLC-β). Activated PLC promotes hydrolysis of a 
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membrane lipid, phosphatidylinositol-4,5-bisphosphate (PIP2) into two second 
messengers, inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses into 
the cytosol and triggers a Ca2+ rise by binding to IP3 receptors and opening Ca2+ channels 
on the endoplasmic reticulum Ca2+ pool. Simultaneously, an influx of extracellular Ca2+ 
via plasma membrane Ca2+ channels occurs due to the depletion of the intracellular Ca2+ 
stores, an effect that may involve 1,3,4,5-tetrakisphosphate (IP4), which forms by the 
phosphorylation of IP3 48, 49. The nature and mechanism of activation of these Ca2+ 
channels by IP4 are unclear. The other second messenger, DAG, remains on the plasma 
membrane after formation and activates protein kinase C (PKC). 
Increased intracellular free Ca2+ ([Ca2+]i) level due to both mobilization from 
intracellular Ca2+ pools and Ca2+ entry from extracellular space, forms a complex with 
calmodulin, which activates eNOS in endothelial cells, producing NO in the presence of 
several cofactors, such as nicotinamide adenine dinucleotide phosphate (NADPH), flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN), 
(6R)-5,6,7,8-tetrahydrobiopterin (BH4) and zinc ions 50. The NO formation is a process of 
electrons transferring from NADPH-FAD-FMN to the heme of BH4 50. Once the [Ca2+]i 
levels falls below 70 nM, the activated form of eNOS (eNOS-calmodulin complex) 
dissociates, the flow of electrons from NADPH to the heme moiety of eNOS is therefore 
interrupted, and NO production is halted. The NO formed in endothelial cells diffuses 
into the subendothelial space and smooth muscle cells, and activates soluble guanylate 




Fig. A. The arginine/nitric oxide (NO) pathway. In response to a variety of stimuli, oxidation of 
arginine by eNOS produces NO. cGMP = cyclic guanosine monophosphate; GTN = glyceryl 
trinitrate; SNP = sodium nitroprusside. 
 
It is obvious that the formation of NO from endothelial cells is specifically regulated 
by the activation of eNOS. On the other hand, eNOS activity is closely modulated by 
transient changes in [Ca2+]i concentration. In unstimulated endothelial cells, the eNOS 
enzyme is tonically inhibited by protein-protein interaction with caveolin-1, the resident 
scaffolding protein in caveolae in the plasma membrane. Cellular stimulation with 
Ca2+-mobilization agonists such as bradykinin promotes calmodulin binding to eNOS and 
caveolin-1 dissociation from the enzyme, rendering the enzyme active; as [Ca2+]i returns 
to basal levels, calmodulin dissociates from the enzyme and the inhibitory eNOS-caveolin 
complex reforms 51.  
However, the activation of eNOS can also be regulated by phosphorylation. For 







endothelial NO release via the phosphorylation of eNOS rather than the regulation by 
Ca2+-calmodulin mentioned above, which will be discussed in detail below. 
1.2.2.2. Regulation of eNOS activation in endothelial cells: calcium vs. 
phosphorylation 
Although once reported as a constitutive enzyme, evidence has shown that eNOS 
gene expression is also regulated by a variety of stimuli such as shear stress 52, 53, 53-57, 
cytokines 58, 58 and sex hormones 52. Glucose overload has also been reported to 
upregulate eNOS expression 59 even thought it was not supported by other researchers 
60-63.  
However, eNOS seems to be mainly regulated by modulation of its activity. 
Physiologically, eNOS in endothelial cells is activated by two major modes 64, which 
involves Ca2+-dependent and Ca2+-independent pathways. The Ca2+-dependent pathway 
means activation of eNOS by the stimulation of cell surface receptors which activate 
G-protein-coupled PLC, resulting in an increase in [Ca2+]i by mobilizing intracellular 
Ca2+ stores and promoting Ca2+ entry 65-70, which has been discussed above. Bradykinin 
and ATP are two important endogenous activators of eNOS. These ligands bind to their G 
protein coupled receptors on the surface of the vascular endothelium and stimulates Ca2+ 
mobilization and influx, leading to vasorelaxation. 
The Ca2+-independent activation of eNOS differs from that activated by 
receptor-dependent agonists in that it is maintained over hours, can be observed in the 
absence of extracellular Ca2+ 71, and is not inhibited by calmodulin antagonists 72. For 
example, the basal activity of eNOS is reported at a Ca2+ concentration as low as 10 nM 
in lysates prepared from native endothelial cells 70.This regulation pathway produces 
subtle amount of NO and only plays a role in basic and non-stimulated NO production in 
endothelial cells, which may serve to ensure the continuous production of NO. An 
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increase in blood flow, and thus in longitudinal shear stress, as well as hypoxia stimulate 
endothelial NO release in this way.  
The Ca2+-independent activation of eNOS is regulated by a complex combination of 
protein-protein interactions and serine and tyrosine phosphorylation. Details of the 
mechano-transduction for this mode of activation is unclear, thought this action may be 
mediated via integrins and G-proteins and involve tyrosine phosphorylation and protein 
kinase B (also named Akt) 54, 55, 73. A study reported that the stretch-activated cation 
channel present in endothelial cells is activated by fluid shear stress in a tyrosine 
kinase-dependent manner 74. It is also possible that the shear force may induce the 
endothelium to release some active molecules which bind to PLC-activating receptors in 
endothelial cells 55.  
Multiple protein kinases, such as adenosine 3’- monophosphate (AMP) -activated 
protein kinases, PKA, PKB, are able to modify eNOS activity through effects on serine 
phosphorylation at position 1177, which increases eNOS activity. In contrast, 
phosphorylation of the threonine at position 497 yields attenuated eNOS activity 75. PKC 
promotes both the dephosphorylation of Ser-1177 and the phosphorylation at Thr-497, 
resulting in attenuated enzyme activity 76. In addition, conformational changes in eNOS 
caused by mechanical strain on caveolae could also be a phosphorylating stimulator for 
eNOS 77.  
Although a significant portion of the NO produced by unstimulated endothelial cells 
may be formed via Ca2+-independent pathways 78, an increase in the intracellular free 
Ca2+ concentration is the essential trigger for maximum activation of eNOS by receptor 
ligands. Therefore, signal transduction cascades involving Ca2+ mobilization and changes 
in [Ca2+]i levels represents a key determinant for eNOS activity and redistribution.  
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1.2.3. Endothelial NO production and diabetes-related cardiovascular complications  
There is substantial evidence that vasodilation mediated by endothelium-derived NO 
following stimulation of PLC-activating agonists is impaired in diabetic animal models 
and in patients with type 1 or type 2 diabetes. However, the impairment of 
endothelium-dependent relaxation was not associated with impairment of 
endothelium-independent relaxation to nitrosovasodilators such as nitroglycerin and 
sodium nitroprusside, which may be considered as exogenous mimics of NO and thus 
activate soluble guanylate cyclase in smooth muscle cells, resulting in arterial relaxation. 
Therefore, these results suggest that endothelial dysfunction in diabetes does not result 
from an inability of the smooth muscle cells to respond to NO, but reflect either an 
impaired production and release of this mediator from the endothelial cells or an 
increased NO degradation. The precise mechanism underlying the development of 
endothelial dysfunction and reduced NO formation in diabetes remains unclear, but 
probably involves uncoupling of eNOS activity (leading to reduced NO production) 47. 
However, which step(s) in the NO signaling pathway is impaired is quite ambiguous.  
Since the identification of endothelium-derived relaxing factor as NO in 1987 and 
the ensuing cloning of eNOS in 1992, exhaustive efforts have been put forth to 
understand the regulatory mechanisms related to changes in eNOS abundance and the 
biology of eNOS enzymatic activity. However, the signal transduction cascade for NO 
formation was largely ignored, especially in diabetic endothelial cells. And this is the 
reason for this thesis work to study the signal transduction implicated in NO generation 
and the regulation of eNOS activity in endothelial cells in two artificial diabetic 
environments, i.e. hyperglycemia or hyperlipidemia. The aims of this study are to identify 
the potentially impaired step(s) in the signaling transduction cascade for NO production 
and the possible underlying mechanisms.  
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1.3. Hyperglycemia and endothelial dysfunction 
1.3.1. Hyperglycemia, a possible risk factor of diabetes-related cardiovascular 
diseases and endothelial dysfunction 
Whether hyperglycemia causes cardiovascular complications has long been debated. 
A major difficulty in the early studies on this topic was that it was almost impossible to 
achieve good control of blood glucose (the studies done then were largely cross-sectional 
or retrospective and should therefore be interpreted with caution). This problem was 
lessened by the pivotal development of continuous subcutaneous insulin infusion by Keen 
et al 79 in the 1970’s, together with home blood glucose monitoring, which allowed 
near-normoglycaemia to be attained consistently. Since then overwhelming studies have 
been performed 80-82, and now the ‘glucose hypothesis’ has been proposed to explain the 
role of hyperglycemia in the development of vascular complications of diabetes.  
The ‘glucose hypothesis’ attributes the diabetic complications to chronic 
hyperglycemia. It postulates that hyperglycemia causes complications, and that correction 
of hyperglycemia prevents them. Numerous retrospective studies have demonstrated 
associations of the degree and duration of hyperglycemia with the severity of 
microvascular and neuropathic complications in both type 1 and type 2 diabetes 18, 19, 83, 84. 
On the other hand, abundant evidence from animals and clinical studies showed that 
effective control of hyperglycemia in diabetes may prevent or reverse the subsequent 
microvascular complications 85, 86. Among overwhelming evidence, two landmark studies 
should be noted: the Diabetes Control and Complications Trial, and the United Kingdom 
Prospective Diabetes Study. Results from both studies revealed that intensive blood 
glucose control of type 1 and type 2 diabetic patients successfully delayed the onset and 
retarded the progression of diabetic retinopathy, nephropathy, and neuropathy 80, 86, 87. 
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The conclusion drawn from the above and numerous other studies is that hyperglycemia 
is a major risk factor of endothelial dysfunction in diabetic microvascular diseases.  
However, unlike the strong causal link between glucose and microvascular 
complications, the association of hyperglycemia with macrovascular complications is 
quite vague. It is undoubted that there is an association between plasma glucose levels 
and diabetic vascular complications. Numerous studies have shown that cardiovascular 
diseases are substantially more common in patients with type 2 diabetes than in 
non-diabetic individuals 86, 86, 88-93. Furthermore, the excessive risk for macrovascular 
complications in diabetes cannot be explained by abnormal levels of conventional 
cardiovascular risk factors. Since 1993, several prospective studies have shown that 
glycemic control is important for reducing cardiovascular risk 94-105. Therefore, it is 
reasonable to conclude that hyperglycemia seems to be a risk factor for cardiovascular 
diseases in patients with type 2 diabetes.  
However, whether the relationship between glucose level and cardiovascular 
diseases is cause and effect, and what is the roles of hyperglycemia itself in the 
development of cardiovascular endothelial dysfunction are still undecided 104, 106-109. Both 
the Diabetes Control and Complications Trial 80, 91, 92 and the United Kingdom 
Prospective Diabetes Study 87 found that improved glycemic control had a minor effect 
on coronary artery disease. The results of the United Kingdom Prospective Diabetes 
Study showed that intensive blood glucose control was associated with a reduction in the 
risk of cardiovascular disease but that the p value was 0.052; and this result is on the 
margin of traditional statistical threshold. Furthermore, while observational studies in 
type 2 diabetic patients consistently found diabetes duration to be a strong, or the 
strongest, predictor of microvascular complications, a similar association with 
macrovascular cardiovascular disease was inconsistently observed 86, 110. These results 
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suggested that more information is still needed to identify the role of hyperglycemia in 
the pathogeneses of cardiovascular diseases in type 2 diabetes. Therefore, studies on the 
effects of hyperglycemia itself as a cardiovascular risk factor in type 2 diabetes are 
necessary.  
However, investigation of the pathogenesis of hyperglycemia on diabetic 
complications is hampered mainly for two reasons. First, there are no suitable animal 
models at present. Although certain biochemical and histological alterations can be 
observed in many models of laboratory animals, they differ in several aspects from the 
diabetic complications seen in humans and therefore their clinical relevance is uncertain. 
Second, it is very difficult to establish causal relationship between any observed change 
and macrovascular diseases in human diabetes since a multitude of metabolic and 
structural abnormalities concomitantly occur during the long-term course of diabetes. For 
example, even after rigorous patient selection, mild dyslipidaemia or hypertension was 
often present, this makes it impossible to separate the role of high glucose from other risk 
factors in diabetes mellitus. Therefore, the issue of direct benefit of glucose control has 
not yet been settled in an in vivo study where other risk factors are controlled and glucose 
control is the major outcome. In this regard, in vitro cell culture systems have the 
advantage that i) any putative metabolic component can be modulated in the cell culture 
medium and its time- and dose-dependent effects on the cultured cells may be monitored, 
ii) the causal action of possible mediators may be proven by the addition of neutralizing 
antibody or inhibitors, and iii) vascular cells possibly involved in the pathogenesis of 
diabetic macroangiopathy are available for these studies 111. Thus, this thesis study was 
performed on bovine aortic endothelial cells and human umbilical vein endothelial cells 
in culture. Only high concentrations of glucose or fatty acids were used in the culture 
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medium to identify the specific roles of these components in the development of 
endothelial dysfunction.  
1.3.2. Literature review of mechanisms of high glucose induced endothelial 
dysfunction  
1.3.2.1 The possible cellular mechanisms for the development of diabetic-related 
chronic complications 
High concentrations of extracellular glucose can damage vascular cell function by 
acting at the level of the plasma membrane or by increasing the flux and concentration of 
glucose inside the cell, but the underlying mechanisms remain incompletely understood. 
There are several well-studied theories regarding how hyperglycemia may produce 
complications of diabetes. These theories can be classified into those that emphasize the 
toxic effects of hyperglycemia and its pathophysiological derivatives on tissues directly, 
and those that ascribe pathophysiological importance to a sustained alternation in cellullar 
signaling pathways induced by the products of glucose metabolism. Until very recently, 
four main hypotheses are largely recognized: increased formation of glucose-derived 
advanced glycation end products, increased glucose flux through the aldose reductase 
pathway, glucose-induced activation of PKC isoforms, and formation of excessive 
oxidants.  
Non-enzymatic glycation 
This mechanism ascribes hyperglycemia-derived vascular cell dysfunction to the 
spontaneous formation of glucose adducts to basic amino acids and other 
amino-containing molecules. When the extracellular concentration of glucose is excessive, 
non-enzymatic glycosylation of plasma membrane and circulating proteins is increased. 
The early non-enzymatic glycation products are reversible, while they later become 
irreversibly modified products of glucose called advanced glycation end-products (AGEs) 
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via slow and complex processes including glycation, glycol-oxidation and auto-oxidative 
glycosylation 112. These AGEs are internalized and transferred into the subendothelial 
space via receptors expressed on the vascular endothelial cell surface and cause changes 
in signal transduction in these cells, which acts in favor of a pro-inflammatory milieu. In 
addition, recent study has shown that AGEs are implicated in the increased expression of 
vascular endothelial growth factor, which can increase retinal angiogenesis. Furthermore, 
AGEs may impair endothelium-dependent relaxation through oxidative modification of 
low-density lipoprotein (LDL) (AGEs can induce excessive cross-linking of collagen and 
other extracellular matrix proteins, which could lead to the accumulation of LDL 
particles). Accumulated LDL in turn directly inactivates or disrupts the formation of NO 
113.  
Moreover, the effects of AGEs also involve extracellular protein glycosylation, such 
as basement membrane, vascular adhesion molecules, cytokines, and matrix proteins.  
Increase in aldose reductase activity 
High glucose concentrations can induce an increase in aldose reductase activity 
(which is only activated when extracellular glucose concentrations rise to hyperglycemic 
levels), resulting in sorbitol accumulation in endothelial cells 114-116. This is because 
sorbitol is generated more rapidly than it is metabolized to fructose in the presence of 
high glucose. The consequence of increased intracellular sorbitol is the rise in 
intracellular osmolarity and a reduction in intracellular myo-inositol content. Thus the 
metabolism of inositol phospholipids and membrane function are altered, leading to 
additional changes such as decreased Na+/K+-adenosine-triphosphatase activity and 
increased PKC activity.  
Furthermore, aldose reductase consumes NADPH to reduce glucose to sorbitol, 
which is then oxidized to fructose via sorbitol dehydrogenase. The decline in cellular 
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NADPH may decrease NO generation in endothelial cells 117 and alter the cellular redox 
balance. This polyol pathway is thought to play a major role in the development of 
microvascular endothelial dysfunction, which causes neuropathy and retinopathy 118, 119.  
Formation of excessive oxidants and activation of PKC 
This hypothesis (generation of too much oxidants) is the most popular and appealing 
one in explaining the mechanism by which hyperglycemia ultimately causes diabetic 
complications, which will be discussed in detail in section 1.6. 
Another and perhaps even more important pathway, by which a rise in intracellular 
glucose concentration can cause detrimental changes in endothelial cells, is through 
excessive activation of PKC. This mechanism will be thoroughly discussed in section 1.5.  
These diabetes-affected biochemical pathways are not mutually exclusive, but rather 
interactive. For example, activation of aldose reductase induced by high glucose uses 
nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH) which drives the 
pentose phosphate pathway, inhibits glyceraldehyde-3’phosphate dehydrogenase, 
increases formation of dihydroxyacetone phosphate, and subsequently of DAG that 
activates PKC 120. Oxidative stress appears to be induced by high glucose due to an 
increased generation of superoxide radicals in the mitochondria, hyperglycemic activation 
of endothelial NADPH-oxidase, and other pathways. Oxidative stress may also activate 
PKC and mitogen activated protein-kinase signaling pathways. On the other hand, an 
increase of PKC activity can affect the production of oxidants and advanced glycation 
end-products by activation of oxidases such as NADP oxidase 121.  
The relevance of each of these four pathways (AGEs, aldose reductase, oxidant and 
PKC) is supported by animal studies in which the inhibitors of these pathways prevented 
various hyperglycemia-induced abnormalities. However, most of these studies were 
performed with microvascular endothelial cells. Endothelial cells from different vascular 
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beds exhibit metabolic and structural differences and may be affected differently by 
hyperglycemia 122. Furthermore, the mechanisms of endothelium-dependent 
vasodilatation may be distinct. Therefore, information from microvascular endothelial 
cells can not be extrapolated to macrovascular endothelium. Unfortunately, much less 
studies on macrovascular vessels was conducted.  
1.3.2.2 Possible mechanisms for the role of high glucose in macrovascular 
endothelial dysfunction: alteration in the signal transduction pathway for 
NO formation 
Overwhelming investigations have demonstrated that NO signaling pathway is 
impaired by hyperglycemia or high glucose concentrations in endothelial cells 26, 28, 30, 36, 
117, 123-135, 135-139. However, elucidations to the reduction and/or quenching of NO in 
cardiovascular endothelial cells in diabetes are controversial.  
A few studies have been executed to discover the underlying mechanism for the 
reduction and/or quenching of NO in short-term cultured endothelial cells at different 
glucose concentrations 138, 140-146. However, the results from these studies are conflicting 
and not conclusive. For example, Sobrevia et al reported that acute elevation of glucose 
concentrations caused a marked increase in basal [Ca2+]i and NO production in isolated 
human endothelial cells 140. These effects were also observed by other studies in 
macrovascular endothelial cells from different species 138, 141-143. Nonetheless, such effects 
might be reversible, because the increased bradykinin-stimulated [Ca2+]i and NO 
production in high glucose conditions were reversed to normal after glucose 
concentrations returned to the control level 141. In contrast, some researchers reported that 
acute elevation of glucose concentrations impaired agonist-stimulated [Ca2+]i rise and NO 
formation in endothelial cells 141, 144-146. The alterations of [Ca2+]i rise and NO production 
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induced by high glucose might not be due to an osmotic effect, since neither elevated 
mannose nor sucrose concentrations could reduce the production of NO 141.  
A few studies have been conducted in short-term high glucose cultured endothelial 
cells to further explain the mechanism for the altered agonist-stimulated [Ca2+]i profile 
and NO production. It was reported that there is no directly intrinsic defect in G-protein 
initiated [Ca2+]i increases, but a site proximal to G-protein activation, such as ligand 
receptor or the activation of PLC, may be important in causing adverse effects by 
elevated glucose 141. However, this opinion was refuted by Catalano et al 147 as well as 
other researchers 136, 148. They claimed that endothelium-derived NO formation was not 
impaired, but actually enhanced by short-term high glucose. Their results implicated 
factors other than diminished NO production, such as reduced bioavailability of NO 
probably due to increased inactivation, which may contribute to the high incidence of 
vascular disease in patients with type 2 diabetes. They deemed that the increased NO 
inactivation in acute glucose-overloaded endothelial cells was due to the augmented 
production of superoxide anion, O2-. 
It seems that the reaction of endothelial cells to high glucose concentrations depends 
on the disease duration. In their studies, Pieper et al 149 demonstrated a triphasic response 
of increased, unaltered and impaired endothelium-dependent relaxation dependent on the 
duration of diabetes in animal models. They found that endothelium-dependent relaxation 
in response to acetylcholine was increased at 24 hrs following injection with 
streptozotocin, normal after 1 and 2 weeks later, and impaired at 8 weeks. This finding 
was supported by the work of other investigators 144, 149-154. These data might provide an 
explanation for the incompatible results from the investigations mentioned above. In 
addition, these data obviously indicate that different biochemical mechanisms may be 
involved in the acute and chronic action of hyperglycemia. Thus, the explanations for the 
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short-term effects of high glucose concentrations cannot be extrapolated to long-term 
situations. Furthermore, considering the chronic course of diabetes, the long-term action 
of high glucose concentrations on cultured endothelial cells would be more relevant to 
endothelial dysfunction in vivo. Hence, a better understanding of the biochemistry and 
pathology of chronic hyperglycemia-induced processes is essential, as it may unmask new 
preventive strategies to reduce morbidity and mortality in diabetes due to long-term 
cardiovascular complications. Unfortunately, compared with the short-term action of high 
glucose on endothelial cells, less is known about its long-term effects. Only one paper 
was found in the literature concerning the long-term effects of high glucose on [Ca2+]i in 
endothelial cells 144.  
1.4. High fatty acids and endothelial dysfunction 
1.4.1. Dyslipidemia, another risk factor for diabetes-related cardiovascular diseases 
The fact that cardiovascular risk factors cluster among individuals with insulin 
resistance syndrome strongly suggests the existence of common pathogenetic 
denominator(s). Results from the University Group Diabetes Program and the United 
Kingdom Prospective Diabetes Study 80, 86, 87 indicate that the death rate of macrovascular 
diseases is not significantly different between intensively controlled glucose groups and 
untreated control (diabetes) groups at any end-point. These data suggest that there must 
be existence of other risk factors apart from high glucose, accounting for the higher 
incidence of macrovascular diseases or endothelial dysfunction in diabetes.  
Dyslipidemia, such as high fatty acids, might be one of these candidates for the 
development of diabetic-related cardiovascular diseases in type 2 diabetes mellitus. This 
notion was supported by the following evidence. Circulating levels of free fatty acids are 
elevated in diabetes because of their excess liberation from adipose tissue and diminished 
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uptake by skeletal muscles 155, 156 long before hyperglycemia becomes apparent. In 
addition, high circulating levels of fatty acids are predictive of conversion from impaired 
glucose tolerance to clinical diabetes 157-160. Furthermore, high fatty acid level persists 
despite the usual hypoglycemia therapy which is coincidental with the consistent 
activation of PKC in diabetic endothelial cells 161. Taken together, these investigations 
have implicated an elevation in circulating fatty acids as a possible risk factor for the 
development of diabetic-related cardiovascular diseases in diabetic patients.  
The progress in recognizing the role of high fatty acids in the pathogenesis of 
endothelial dysfunction in diabetes is also full of extensive investigations by many 
researchers. In 1957, it was first recognized that type 2 diabetes was associated with 
increased plasma non-esterified fatty acid levels 162. Thereafter, intensive studies have 
been conducted to explore the relationship between glucose and fatty acids 162-165. Now it 
is believed that elevation of plasma fatty acid concentration increases hepatic glucose 
output and/or diminishes its suppression by insulin through the substrate competition 
between fatty acids and glucose for metabolizing into the Krebs cycle. The excessive 
metabolism of fatty acids leads to a reduction in glucose oxidation and reduces tissue 
glucose uptake by feedback mechanisms. Raised fatty acids impair insulin’s effect on 
glucose uptake in skeletal muscle and the vascular endothelium and thus could have 
detrimental effects on the vasculature, leading to premature cardiovascular disease. This 
suggests that impaired endothelial function in insulin-resistant humans may be secondary 
to the elevated blood concentration of fatty acids and other lipids 166. These results raise 
the hypothesis that fatty acids could contribute to hyperglycemia development, and 
functional and structural vascular changes among diabetes mellitus.  
In support of these observations, similar and direct effects of non-esterified fatty acid 
on the vascular system have been observed in many in vivo and in vitro studies. Acute 
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elevations (3-9 folds) of circulating fatty acids concentrations from exogenous or 
endogenous sources in healthy normotensive volunteers impaired endothelium dependent 
vasodilatation 167. For example, it was reported that elevated fatty acids impaired the 
lower extremity vascular response to methacholine (an endothelium-dependent 
muscarinic dilator) in healthy normotensive volunteers, but had no effect on 
endothelium-independent vasodilatation 155, 167-170. In addition, a few studies indicated 
that non-esterified fatty acids caused a concentration-dependent decrease of 
endothelial-mediated relaxation 171-175. A series of clinical research on diabetic patients 
conducted by Steinberg et al 167, 172, 174 demonstrated that acute elevation of circulation 
fatty acids also impaired endothelial function, but had no effect on 
endothelium-independent vasodilatation. Moreover, it was also reported that some fatty 
acids in the composition of serum lipids could damage endothelial function 166. 
Overwhelming evidence from in vitro endothelial cell cultures also demonstrated that 
fatty acids affect endothelial function. Taken together, these data indicate that excessive 
presence of non-esterified fatty acids, due to increased endogenous lipolysis or 
administration of exogenous fatty substrates, can cause endothelial dysfunction 171.  
However, until more recently, evidence implicating the underlying mechanisms of 
fatty acids in hemodynamic and vascular abnormalities was lacking. It was proposed that 
free fatty acids might impair endothelial function through several mechanisms. Raised 
level of fatty acids may cause vascular endothelial dysfunction either indirectly by 
increasing release of vasoconstrictor substances such as endothelin 1 or through a direct 
effect on the endothelial NO system, or both. In addition, elevated level of fatty acids 
could also induce formation of oxygen radicals that could quench NO and thus result in 
reduced NO reaching vascular smooth muscle cells. Each of these hypotheses was 
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supported by several investigations; and because of the crucial role of NO in endothelial 
function, the NO system is the most concerned one.  
1.4.2. Literature review of the mechanisms with which fatty acids affect NO-related 
signaling pathway in endothelial cells  
It has been demonstrated that short-term overload in fatty acids impaired endothelial 
NO production 172, 176, 177 in vivo or in vitro. For example, a short-term exposure to fatty 
acids caused decreased NO-dependent basal flow 47. Furthermore, it has been shown that 
fatty acids reduced acetylcholine-dependent vascular reactivity in human subjects, 
implying that NO-mediated signaling was impaired 168, 169. The notion that raised level of 
fatty acids impairs endothelial NO production is supported by in vitro studies using 
cultured endothelial cells. NO formation was significantly inhibited by treatment of 
bovine aortic endothelial cells (BAECs) with 100 µmol/l of fatty acids composed of 
palmitic acid for 3 hrs or even a shorter time 177, 178. Therefore, a modulating effect of 
fatty acids on endothelium-dependent NO production, and thereby on endothelial function, 
was postulated.  
However, studies on the mechanisms underlying the modulating effects of fatty acids 
on the decreased NO system was largely missing. Because solid evidence has shown that 
the eNOS protein content was not altered by raised fatty acids, it was proposed that fatty 
acids impaired NO production by decreasing the efficiency of NO signal transduction 
from ligand-receptor to NO formation  171, 178, 179. 
However, the explanation for reduced NO signaling in high fatty acid cultured 
endothelial cells is far from satisfying. Some investigators 177, 180 observed that very short 
term (3 min) overload with fatty acids impaired NO production from BAECs through 
inhibition of Ca2+ mobilization or capacitative Ca2+ influx in cultured endothelial cells. 
However, these inhibited Ca2+ mobilization or capacitative Ca2+ influx were induced by 
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mechanisms independent of the receptor-mediated PLC-coupled system because of 
unchanged IP3 formation evoked by receptor agonist. Their results also suggested that 
these inhibitory effects were not due to the oxidation of fatty acids because co-incubation 
of antioxidant with fatty acids could not prevent the inhibition of NO release 177, 180. 
Nonetheless, this conclusion was conflicting with results from other short-term studies 
which showed that overall intracellular stored Ca2+ and intracellular Ca2+ release were 
enhanced (incubation time with fatty acids was 5 hrs), while the attenuated eNOS activity 
was associated with O2- release 179.  
Fatty acids might also regulate eNOS activity via Ca2+-independent pathway 
including activation of PKC and increased production of oxygen-derived free radicals, 
which will be discussed in detail in section 1.6 of this chapter. For instance, co-infusion 
of the antioxidant ascorbic acid improved endothelium-dependent vasodilation in humans 
treated with free fatty acids, indicating that oxidative stress might mediate the 
abnormality 168. Another proposed mechanism is that the inhibition of eNOS is mediated 
by a PKC-dependent mechanism. It has been demonstrated that elevation of free fatty 
acid levels activate  PKC and decrease phosphatidylinositol 3-kinase activity in 
endothelial cells 121, 181-183, which could inhibit the activity of the phosphatidylinositol 
3-kinase pathway, thereby limiting activation of Akt and subsequent phosphorylation of 
NOS 181. Whether short-term fatty acid-induced endothelial dysfunction is also caused by 
other unknown mechanisms remains to be clarified. 
All the investigations mentioned above are from short-term incubation of endothelial 
cells with fatty acids. The long-term effects of fatty acids on endothelial dysfunction, 
which is more relevant to diabetic related cardiovascular complications, have not been 
reported. Thus, the present study was also designed with this goal in mind to elucidate the 
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chronic effects of free fatty acids, another risk factor of diabetes, on the NO signaling 
pathway in culture endothelial cells.  
1.5. PKC and endothelial dysfunction 
PKC consists of a family of multifunctional isoenzymes, which play a central role in 
signal transduction and intracellular crosstalk by phosphorylation at serine/threonine 
residues of substrate proteins. To date 12 isoforms have been identified with both tissue 
and functional specificity. These isoforms can be separated into three groups: 
conventional PKCs (α, βI, βII, and γ) are Ca2+-dependent and activated by both 
phosphatidylserine  and the second messenger DAG; novel PKCs (δ, ε, η, and θ) are 
Ca2+-independent and regulated by DAG and phosphatidylserine; and atypical PKCs (ζ 
and λ) are Ca2+-independent and do not require DAG for activation, although 
phosphatidylserine may regulate their activity 184.  
A role for PKC in mediating endothelial dysfunction has been postulated by many 
researchers. In vitro studies have shown that incubation of isolated aortic rings with high 
glucose caused endothelial dysfunction 35. However, such high glucose-induced 
endothelial dysfunction could be corrected by PKC inhibitors 35, 185. These in vitro 
observations were supported by in vivo studies demonstrating that treatment with PKC 
inhibitors ameliorated vascular complications in both diabetic patients and animals 
models 185-187. However, the mechanisms by which PKC-mediated endothelial 
dysfunction and the reasons that inhibition of PKC activity ameliorates endothelial 
dysfunction in diabetes are not well understood. 
1.5.1. Possible mechanisms of hyperglycemia-induced PKC activation 
Intracellular release of DAG is the primary factor leading to translocation of PKC 
from the cytosol to the membranes and its activation. Various species of DAG (varying in 
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the composition of fatty acids) are generated from 4 principal sources as shown in figure 
B, i.e., 1) classical receptor-mediated, PLC-catalyzed hydrolysis of inositol phospholipids 
as mentioned before; 2) the release of DAG from phospholipase D-mediated hydrolysis of 
phosphatidylcholine (PC); 3) release of free fatty acids from precursor lipids by the action 
of phospholipase A2; and 4) de novo synthesis of DAG from phosphatidic acid via 


















       Fig. B. Four principal pathways for DAG formation. PLD, phospholipase D; PLA2, 
phospholipase A2. G-3-P, glyceraldehydes-3-phosphate. 
 
The de novo synthesis pathway is mainly responsible for hyperglycemia-induced 
DAG formation in cardiovascular tissues in diabetes 187. Elevated glucose levels increase 
glycolytic pathway flux in the diabetic state and lead to an elevation in the levels of 
intracellular glyceraldehydes-3-phosphate. Increased production of this intermediate can 
stimulate excessive de novo synthesis of DAG through glycerol 3-phosphate 189 bypassing 
the normal regulatory system, and causing disturbances in many cellular functions. 
Meanwhile, high glucose levels also increase the turnover of PC to DAG 190. Thus, 
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glucose overload may promote accumulation of DAG in diabetic tissues by de novo 
synthesis of DAG from phosphatidic acid and by releasing DAG from phospholipase 
D-catalyzed hydrolysis of PC. The chronically elevated levels of DAG can, in turn, 
activate PKC. For instance, a 3-fold increase in PKC activity in diabetic vessels has been 
reported 191. Furthermore, the DAG-PKC system can also be activated by reactive oxygen 
intermediates and AGEs 192. Pathophysiological studies have revealed that PKC-β and 
PKC-δ are primarily implicated in hyperglycemia-induced vascular dysfunction 193.  
1.5.2. Possible mechanisms of free fatty acid induced PKC activation  
A recent study has shown that fatty acids play an important role in modulating PKC 
activity in vascular cells, independent of de novo DAG synthesis 194. Increased formation 
of DAG via fatty acids as described in Fig. B, through the activation of phospholipase A2, 
by itself, is sufficient to activate PKC 194. In addition, DAG-mediated activation of PKC 
is augmented by specific free fatty acids and their CoA esters. For example, oleic acid 
appeared to activate PKC synergistically with DAG 194, 195, and it has been suggested that 
cis-unsaturated fatty acids act as enhancer molecules 196. Fatty acids also increase the 
affinity of cPKC for Ca2+ such that PKC activation occurs at lower or even basal Ca2+ 
concentrations 197. Thus, in diabetes increased free fatty acid concentrations could 
enhance PKC activation.  
1.5.3. Activation of PKC and endothelial dysfunction 
There is increasing evidence implying that PKC activation is an important 
biochemical mechanism in diabetes-related endothelial dysfunction. Treatment by PKC 
inhibitors attenuated diabetic-related microvascular as well as cardiovascular diseases in 
clinical therapy. However, the underlying mechanisms for the effects of PKC inhibitors 
and the relationship between activated PKC and endothelial dysfunction are still unclear. 
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One mechanism proposed is that inhibition of eNOS is mediated in a 
PKC-dependent way. As mentioned in the previous section on eNOS regulation, PKC 
activation may attenuate eNOS activity by promoting the phosphorylation of Thr-497, 
resulting in reduced NO production 76. The regulation of PKC in other steps of the 
signaling pathway for NO formation has also been reported. Curtis et al 198 demonstrated 
that PKC-β play a role in mediating store-operated Ca2+ influx in retinal arterioles from 
rats having sustained increased blood glucose. In addition, PKC inhibition in vivo 
markedly improved endothelial dysfunction, normalized vascular superoxide levels, and 
increased vascular NO bioavailability significantly 199. Nonetheless, further studies are 
needed to clarify the underlying mechanisms for the effects of PKC activation on 
NO-related signal transduction pathway.  
1.6. The role of oxidative stress in diabetic endothelial dysfunction 
Oxidative stress essentially refers to an imbalance between reactive oxygen species 
(ROS) and antioxidant defenses, which results in a net overproduction of ROS. The 
genesis of ROS involves the production of superoxide by the coupling of electrons to 
molecular oxygen, and its subsequent reduction to yield hydrogen peroxide and, finally, 
hydroxyl radicals (OH). There are several specific biochemical sources of ROS in 
vascular cells, including mitochondrial electron transport, xanthine oxidase, 
cyclo-oxygenase, nitric oxide synthase and NAD(P)H oxidase. Accumulation of ROS 
and/or reactive nitrogen species, formed by reaction between superoxide and NO, directly 
impairs several cellular functions by oxidizing DNA, proteins and lipids. These highly 
reactive molecules also activate proinflammatory and pro-atherogenic intracellular 
signaling pathways involving PKC and mitogen-activated protein (MAP) kinase, and 
impair insulin sensitivity by inactivating phosphoinositide 3 -kinase and Akt signaling 47. 
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1.6.1. Oxidative stress in endothelial cells cultured at high concentrations of glucose  
Increased oxidative stress in diabetes has been consistently demonstrated in 
experimental studies 200. The primary causal factor is hyperglycemia, although the 
dose-response relationship between hyperglycemia and oxidative stress remains 
undefined. Elevated blood glucose levels drive production of ROS via multiple pathways 
(Fig. C) 201, resulting in uncoupling of mitochondrial oxidative phosphorylation and 
eNOS activity, reducing NO availability and generating further ROS. 
Glycoxidation of glucose generates ROS, such as superoxide, hydrogen peroxide and 
hydroxyl radical. These molecules accelerate the formation of AGEs, which in turn 
generate more free radicals 200, 202, 203. Increased cellular uptake of glucose stimulates 
PKC activity as discussed in section 1.5, which, amongst other effects, activates 
peroxidase enzymes and the cyclo-oxygenase pathway 204, with resultant overproduction 
of oxidative molecules. Shunting of glucose through the polyol pathway depletes NADPH 
115, which decreases glutathione-redox cycling, an important mechanism for scavenging 
free radicals 205. Increased polyol activity also stimulates the cyclo-oxygenase pathway by 
generating NADH 200. Decreased tissue concentrations of antioxidants in diabetic patients, 
such as vitamin E, superoxide dismutase and catalase, have also been demonstrated in 
vitro 206. Although it is extremely difficult to measure free radicals in vivo, some 
supportive evidence for the notion of increased oxidative stress in diabetes and its 
association with poor metabolic control and coronary heart disease has been derived from 





Fig. C. Pathogenesis of hyperoxidative stress in non-insulin dependent diabetes. In boxes 
are shown mechanisms that are directly related to hyperglycemia.  
 
1.6.2. Oxidative stress and fatty acids 
        It was reported that elevated fatty acids levels stimulated ROS production in 
cultured aortic endothelial cells 121. Furthermore, this increased production of ROS was 
completely restored to control values by diphenylene iodonium and significantly inhibited 
by PKC inhibitors, suggesting that fatty acids might stimulate ROS production through 
PKC-dependent activation of NAD(P)H oxidase in cultured vascular cells 121. Evidence 
also showed that elevated fatty acids could increase oxidant production by ß oxidative 
phosphorylation via mitochondrial metabolism 201, resulting in the uncoupling of 
oxidative phosphorylation and eNOS activity 209-211. As a consequence of eNOS 
uncoupling, the production of NO is decreased, and electrons are transferred to molecular 
oxygen to form further superoxide and peroxynitrite, a highly potent oxidant as shown in 
Fig. D.  This latter situation is exacerbated because fatty acids not only induce a state of 
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oxidative stress, but also impair the endogenous antioxidant defenses by decreasing 
intracellular glutathione 212, 213. 
                     
       Fig. D. Uncoupling of eNOS activity. 
 
1.6.3. The protective role of antioxidants in diabetic endothelial dysfunction  
The fact that decreased tissue concentrations of antioxidants were observed and the 
central role of oxidative stress in regulating the bioavailability of NO would suggest that 
antioxidants and other agents that reduce oxidative stress should aid in restoring 
endothelial function in diabetic patients 200, 214, 215. Because oxidative stress may 
contribute to diabetic cardiovascular complications, it raises the question of whether 
antioxidants as therapeutic agents can prevent or delay the onset of complications in 
diabetic states.  
However, at present there is evidence both for and against the therapeutic effects of 
antioxidants in patients with type 2 diabetes. Although several antioxidants, including 
ascorbic acid (vitamin C), (+)-α-tocopherol acetate (vitamin E), folic acid and 
ubidecarenone, have improved vascular function in diabetic patients 200, 214, 215, other 
studies have been negative. Observational studies have shown the associations of 
(+)-α-tocopherol acetate and beta-carotene supplementation with a reduction in 
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cardiovascular events. However, these effects have not been supported in large-scale 
randomized clinical trials of both primary and secondary prevention 131, 216-218.  
Oral supplementation with the tocopherol analogue raxofelast improved forearm 
microcirculatory endothelial function in type 2 diabetic patients 219, but neither direct 
tocopherol supplementation (1600 IU/day for 8 weeks) 220 nor ascorbic acid (1.5 g/day for 
3 weeks) was effective 221. In contrast, improvement in microcirculatory endothelial 
function has been reported in patients with type 2 diabetes following intra-arterial 
administration of ascorbic acid 222 or folic acid 223. These data imply that the effects of 
antioxidants on endothelial dysfunction are far from conclusive. Whether antioxidants 
play a protective role in reversing endothelial dysfunction and how they execute this 
potentially protective role needs further investigations both in vivo and in vitro.    
1.7. Aims, strategy and significance of this study 
Like treatment for any other chronic illness, the goals of therapy for diabetes are to 
alleviate the acute symptoms and prevent long-term complications. While the initial goals 
can be reasonably achieved in most instances, the long-term complications, especially 
vascular diseases, had proved to be more challenging. Diabetes-specific microvascular 
complications are a major cause of blindness, renal failure and nerve damage. 
Diabetes-accelerated atherosclerosis leads to an increased risk of myocardial infarction, 
stroke and limb amputation.  
To date, not all of the risk factors for diabetes-related cardiovascular diseases have 
been identified. Even after decades of vigorous studies, a causal relationship between 
high glucose and cardiovascular diseases still cannot be solidly established. Increasing 
glucose levels might be only a promoter to exacerbate the underlying risk factors for 
cardiovascular diseases. Thus what are the possible underlying risk factors, how high 
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glucose activates the underlying risk factors and what is the role of high glucose itself in 
the pathogenesis of endothelial dysfunction needs to be further clarified.  
However, direct clinical studies in patients with diabetes are almost inevitably 
confounded by the high prevalence of other cardiovascular risk factors that are known to 
affect the pathogenesis of these diseases, which makes investigations of the specific 
effects of high glucose in diabetic patients impossible. Hence, studies in which the roles 
of high glucose are separated from the other possible risk factors should be carried out in 
vitro.  Furthermore, the effects of fatty acids, the other high prevalence risk factor of 
cardiovascular diseases, also needs to be investigated in vitro for similar reasons. 
The endothelium plays a critical role in the pathogenesis of diabetic vascular 
dysfunction and, obviously, is also a paramount tissue in the prevention or delay of 
cardiovascular diseases. Therefore, it was chosen as the research target for this study. 
Furthermore, there are convincing reasons for us to pay attention to the possibly different 
mechanisms existing between micro- and macrovascular endothelial cells; this study was 
thus performed only on endothelium of large vessels, i.e., endothelial cells from aorta or 
umbilical vein.  
Attenuated availability of NO accounts for the majority of what is described as 
endothelial dysfunction characterized by reduced endothelium-dependent vascular 
relaxation, which could be the initial stage during the development of diabetes-related 
cardiovascular diseases. Dysfunction of the endothelial NO pathway may involve 
impaired signal transduction, decreased eNOS activity, reduced intracellular availability 
of L-arginine, and/or increased inactivation of NO by superoxide anions or oxidized low 
density lipoproteins 224. Even though the whole signaling pathway for NO formation is 
largely clear in normal endothelial cells, the pathophysiological molecular mechanism in 
diabetes mellitus is uncertain. In other words, whether one or several steps of the 
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signaling pathway for NO production are affected by glucose or fatty acids in endothelial 
cells is unclear. Accordingly, this study had focused on the effects of chronic high 
glucose and fatty acids on the signal transduction for NO production in cultured 
endothelial cells, in particular aiming at the chain events of agonist 
receptor-PLC-IP3-Ca2+-eNOS-NO. In addition, the possible protective effect of 
antioxidants and PKC inhibitors on the impairment of this signaling pathway was also 
investigated.  
If the key signaling events by which high glucose or fatty acids exerts adverse 
effects were defined, such knowledge could be used to develop novel and more effective 
therapeutic approaches for managing diabetic cardiovascular complications. The studies 
on antioxidants and PKC inhibitors in this project would also shed light on their clinical 
application in the prevention/reversal of effects of diabetes-related risk factors such as 
high glucose and fatty acids.  
 




MATERIALS AND METHODS 
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2.1. Materials 
General laboratory chemicals and solvents were of reagent grade. Special reagents 
and chemicals used in this study are listed below in detail according to their sources: 
Amersham Pharmacia Biotech, Buckinghamshire, HP, UK 
D-myo-Inositol-1, 4, 5-trisphosphate (IP3) [3H] assay system 
γ-32P 
Bio-Rad Laboratories, Hercules, CA, USA 
Bio-Rad Protein Assay Dye Reagent Concentrate and Protein Standard 
Coomassie Brilliant Blue R-250 (protein assay dye reagent) 
Immun-blot polyvinylidine difluoride (PVDF) membrane (0.45 µm)  
Nitrocellulose membrane (0.45 µm) 
Kaleidoscope prestained standards 
Stock solution for electrophoresis, 30% Acrylamide/N,N’-methylenbisacrylamide  
(total monomer to crosslinker ratio at 37.5:1) 
Boehringer Mannheim Gmbh, Mannheim, Germany 
Ac-leu-leu-argininal ½ H2SO4 (leupeptin)  
Bovine serum albumin (BSA) 
N-[2-hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] (HEPES) 
Calbiochem, La Jolla, CA, USA 
4,5-Diaminofluorescein Diacetate (DAF-2 DA) 
Ampicillin, sodium salt 
ATP-free DMEM medium 
Bisindolylmaleimide I 
GÖ6976 
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Clonetics, Walkersville, MD, USA 
Bovine aortic endothelial cells (BAECs) 
Human umbilical vein endothelial cells (HUVECs) 
E. Merck, Darmstadt, Germany 
β-Mercaptoethanol 




Falcon, Millville, NJ, USA 
Cell culture dishes  
Cell culture flasks  
Cell culture plates 
Cryotubes 
Pipette (1 ml, 5 ml, 10 ml, and 30 ml) 
Fisher Scientific, Leicestershire, UK 
N-butanol 
Tween-20 
Gibco-Invitrogen Corporation, Grand Island, NK, USA 
Fetal calf serum (FCS) 
Human recombinant acidic fibroblast growth factor (aFGF) 
Gentamicin sulfate  
New born calf serum (NBCS) 
Penicillin-streptomycin 
ICN Biomedicals Inc, Aurora, OH, USA 
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3-(3-cholamidopropyl) dimethylammonio-1-propane sulfonate (CHAPS) 
J. T. Baker, Phillipsburg, NJ, USA 
Tris hydroxymethyl-aminomethane (Tris) 
Molecular Probes, Eugene, OR, USA 
Fura-2/acetoxymethylester (Fura-2/AM) 
NeoMaker, Fremont, CA, USA 
Tubulin-β Ab-4, positive loading control for Western blotting 
PerkinElmer Life Science, Boston, MA, USA 
Bradykinin, [2,3-prolyl-3,4-3H(N)] 
Glucose  
Pharmacia Biotech AB, Stockholm, Sweden 
Ammonium persulphate (ASP) 
Bromophenol blue 
Tetramethylethylenediamine (TEMED) 
Pierce, Rockford, IL, USA 
Supersignal West Dura; extended duration substrate 
Supersignal West Pico; chemiluminescent substrate 
Western blotting stripping buffer 
Santa Cruz Biotechnology, Santa Cruz, CA, USA 
Anti-rabbit IgG-HRP conjugate 
Sigma Chemical Co., St. Louis, MO, USA 
(+)-α-tocopherol acetate (vitamin E) 
Acetic acid 
Adenosine 5’-triphosphate (ATP) 
Ammonium hydroxide 








DMEM medium, with L-glutamine and sodium bicarbonate 
Diethylene-triamine-penta-acetic-acid (DTPA) 
Ethidium bromide (EB) 
Ethanol  
Ethylene Glycol-bis (β-Aminoethyl ether)-N,N,N’,N’-Tetraacetic acid (EGTA) 




Gelatin (for cell culture) 
Gentamicin  
Glycerol 
Leupeptin, trifluoroacetate salt  
MCDB 131 medium, with L-glutamine and without sodium bicarbonate 
Methanol 
Mouse monoclonal anti-β-tubulin 
N-[2-hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] (HEPES) 
N-acetyl-L-cysteine  
N-methyl-D-glucamine 
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NG-nitro-L-arginine methylester (L-NAME) 
O-phenylenediamine dihydrochloride 
Oleic acid, sodium salt 
Oxalic acid 
Palmitic acid, sodium salt 
Penicillin 
Pepstatin 






Phenylmethylsulfonyl fluoride (PMSF) 
Sodium dodecyl sulphate (SDS) 
Sodium azide 





Upstate Biotechnology, Lake Placid, NY, USA 
Anti-eNOS/NOS III (rabbit polyclonal IgG) 
Anti-iNOS/NOS II (rabbit polyclonal IgG) 
Whatman, Clifton, NY, USA 
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TCL plates 
2.2. Cell culture, storage and treatment 
The reasons for the use of cultured cells as my experimental system were described 
in the Introduction chapter. Expression of eNOS takes place mainly in the conduit vessels 
and large resistance arteries with decreasing intensity towards the capillaries. Therefore, 
bovine aortic endothelial cells (BAECs) and human umbilical vein endothelial cells 
(HUVECs) were used in this study. 
2.2.1. Cell culture 
BAECs (passage 4 to12) and HUVECs (passage 4-8) were maintained in MCDB 131 
culture medium supplemented with 10% decomplemented fetal calf serum (v/v), 50 µg/ml 
gentamin sulfate, 100 µg/ml streptomycin, 2.5 µg/ml ampicillin, 1 µg/ml hydrocortisone, 
0.02 µg/ml aFGF, 0.002% (v/v) 17.7 U/ml heparin in a 5% CO2 incubator at 37°C. The 
cells were harvested upon reaching confluence, and passed weekly by trypsinization and 
seeded at a density of 1.0 x 106/ml in T 75 culture flasks. The medium was changed every 
48 hrs.  
During passing, the cells were rinsed twice with 37°C phosphate-buffered saline 
(PBS) and incubated in 0.025% trypsin [5:45:50 of 0.5% trypsin stock: PBS 
(Ca2+/Mg2+-free): EDTA (0.54 mM)] for 1 min at 37°C to allow detachment. Cold MCDB 
131 medium with 10% new born calf serum (NBCS) was added to terminate 
trypsinization. The resulting cell suspension was transferred to autoclaved centrifuging 
tube, centrifuged at 1300 g at room temperature for 5 min. After discarding the 
supernatant, the cells were resuspended in MCDB 131 medium with 10% fetal calf serum 
plus antibiotics and ready for seeding. 
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2.2.2. Cell storage 
The cells in culture flasks were trypsinized and centrifuged as described above, and 
the pellet were resuspended in fresh freezing medium (growth medium with 20% 
decomplemented fetal calf serum and 10% DMSO) at a density of 10∼30 x 106 cells/ml. 
Cryotubes were filled with the cell suspension medium to the mark (1 ml), and placed 
upright in water at 4°C for 1 hour. Afterwards, the tubes were wrapped with paper, left at 
-20°C for another 1 hr, and then at -70°C overnight. They were transferred into a liquid 
nitrogen tank for long term storage. 
2.2.3. Treatment of cells in culture  
For experiments, cells were grown in culture flasks. When cells approached 
approximately 90% confluence, test agents (glucose, fatty acids, antioxidant or PKC 
inhibitors) were added to the medium for various time periods. The medium was changed 
every 24 hrs during these periods to provide sufficient nutrients. The concentration of 
fetal calf serum in culture medium was reduced to 2% when cells were treated with high 
glucose concentrations, in order to slow down the growth rate and avoid apoptotic cell 
death. When cells were treated with fatty acids in culture, the serum concentration was 
kept at 10% in the medium and cells were subcultured at the 5th or 6th day.  
In all subsequent experiments after cell culture, high concentrations of glucose or 
fatty acids were not applied in any utilized medium and solution, and neither were 
antioxidants nor PKC inhibitors present, in order to avoid possible acute effects of these 
test agents on the endothelial cell function to be examined. 
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2.3. Preparation of stock mixture of fatty acids  
The stock mixture of oleic acid and palmitic acid were prepared as described by 
Unger et al 225, 226. In brief, BSA (22%) stock (11x) solution in medium MCDB131 was 
prepared one day before and left at 4ºC overnight. The next day, the two fatty acids were 
weighed (oleate: palmitate; 2:1) and put in a glass beaker to make 22 mmol/l fatty acid 
mixture. Five ml of double distilled water was added to the mixed chemicals. The mixture 
was stirred while heated at no more than 50ºC for at least one hour until the mixture 
became like whipped cream, and then 22% BSA stock solution was added. The solution 
was kept stirring until the fatty acids were completely dissolved. The mixture was 
sterilized by filtration through a 0.22 µm filter, and the stock was stored at -20°C. Fatty 
acids are very difficult to dissolve. Complete solubilization is necessary to prevent 
lowering of fatty acid concentrations during the filtration process.  
2.4. Assay for protein concentrations  
Protein contents were measured by Bio-Rad assay system based on the shift of 
absorption wavelength after Coomassie brilliant blue G-250 dye binding to protein. The 
density changes of fluorescent represent various concentrations of protein. The dye binds 
primarily to basic (especially arginine) and aromatic amino acid residues. The assay is 
useful for measuring proteins and polypeptides with molecular weight (MW) greater than 
3,000 - 5,000 (KD), dependent on the charged groups.   
Aliquots (5 µl) of samples or protein standard (181.25 - 1450 µg/ml) were mixed 
with Coomassie brilliant blue G-250 dye (195 µl/well) in 96-well plates and incubated at 
room temperature for 10 min. The absorbance at 595 nm was measured with a microplate 
reader. The protein concentrations in samples were calculated by comparing the standard 
curve obtained from known concentrations of protein which was run in parallel.  
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2.5. Determination of NO production 
NO generation in living cells can be monitored by using a membrane-permeable 
indicator, 4,5-diaminofluorescein diacetate (DAF-2/DA), which is trapped within cells 
after hydrolyzed to DAF-2 by intracellular esterases 227, 228. DAF-2 is able to react rapidly 
with NO in the presence of oxygen to yield a highly fluorescent compound, 
triazolofluorescein. The reaction between DAF-2 and NO is irreversible 227, 228; therefore, 
the accumulated level of DAF-2 fluorescence reflects the total amount of cellular NO 
production during the period. The major advantage of using DAF-2 is that it enables the 
measurement of intracellular NO production in living cells after any arbitrary 
pretreatment of the cell. In addition, the DAF-2 detecting system negates the potential 
influence of variability in endogenous guanylate cyclase or the oxidant produced (because 
it reacts very fast with NO) within endothelial cells under high glucose or high fatty acid 
environments, thereby providing a more authentic measurement of NO released by the 
cells.  
BAECs or HUVECs cultured with different conditions were harvested after a short 
treatment (40 sec to 1 min) with 0.025% trypsin and 0.02% EDTA in PBS at 37°C, 
centrifuged, and then resuspended in DMEM containing 2% fetal calf serum. After 
incubation in a spinner for 2.5 hrs at 37°C to let cells recover from trypsinization shock, 
the cells were loaded with 2 nM DAF-2/DA for another 30 min at 37°C in the dark. The 
cells were then centrifuged, washed twice with DMEM and resuspended in a final 
concentration of 2.5 x 107 cells/ml. Aliquots of cells (200 µl, 5 x 106 cell) were added into 
96-well black plates. The plates were left at 37°C for 15 min for equilibration, then 
stimulants were added and incubation last for 3-6 hrs at 37°C in the dark. The 
fluorescence generated by NO production was monitored by a fluorescent plate reader 
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(Spectramax microplate spectrofluorometer; Molecular Devices, Sunnyvale, CA, USA) 
at excitation and emission wavelengths of 485 and 515 nm, respectively. 
2.6. Western blotting of eNOS and iNOS  
Cells cultured in dishes or multiwell plates were washed twice with cold PBS, 
scraped in a homogenizing buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 0.1 mM PMSF, and 10 µg/ml each of aprotinin, leupeptin, and pepstatin) by cell 
lifters, and sonicated on ice 3 times, 10 s each. The samples were aliquoted (40 µg/sample) 
and stored at -70°C if not immediately used for Western blotting. 
Aliquots of samples and protein standards were boiled in a loading buffer (100 mM 
Tris-HCl, pH 6.8, 200 mM DTT, 20% glycerol, 4% SDS, and 0.2% bromophenol blue) 
for 5 min. These samples were subjected to a 10% SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and proteins were then electro-transferred to nitrocellulose 
or polyvinylidine difluoride (PVDF) membranes. The membranes were blocked in TBST 
buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.2% Tween-20) containing 5% 
dried non-fat milk for 1 hr. Subsequently, the membranes were blotted with rabbit 
anti-eNOS (dilution 1:500) or anti-iNOS antibody (dilution 1:1000) in TBST buffer for 
1.5 hr. After three times washing in TBST (5 min each), the membranes were incubated 
with anti-rabbit IgG secondary antibody in TBST buffer for 60 min. The membranes were 
washed again for 3 times with TBST, 10 min each. All three processes and washing were 
carried out at room temperature. The light-emitting signals were detected using the 
enhanced chemiluminescence system (from Pierce) followed by exposure to x-ray films. 
The films were scanned by desktop scanner and saved as Tagged-Image File Format 
(TIFF) files. The optical density of bands on the films was semi-quantified by 
computer-assisted densitometry.  
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2.7. Measurement of cytosolic free Ca2+ concentrations using fluorescent probes 
Intracellular free Ca2+ concentration ([Ca2+]i) was measured by loading with the 
Ca2+-specific fluorescent probe fura-2/AM 229 and using the dual wavelength method. 
This is the easiest and most straightforward technique to load large number of cells 
simultaneously. Fura-2/AM is the lipid soluble form of fura-2, in which the carboxylate 
groups of this indicator are modified by acetoxymethyl esters resulting in a nonpolar 
compound that is permeable to cell membranes. Once inside the cell, these acetoxymethyl 
bases are hydrolyzed by intracellular esterases, and the resultant free Fura-2 now becomes 
a polar molecule that is no longer capable of freely diffusing through the cell membrane, 
essentially being trapped inside the cell. Fura-2 is a second generation dual wavelength 
ratiometric Ca2+ indicator, which binds Ca2+ with 1:1 stoichiometry. Ca2+-bound Fura-2 
emits much stronger quantum of fluorescence, the density of which reflects the level of 
free Ca2+ concentration. The Kd of Fura-2 for Ca2+ is 225 nM, and thus it gives rise to the 
most dramatic fluorescence changes in sensing the alterations of Ca2+ levels occurring in 
the most type of cells (70-1000 nM). The Ca2+-sensitive emission fluorescence (at ~505 
nM) of Fura-2 is augmented with increase in [Ca2+]i when excited at 340 nm. Opposite 
changes (decreasing) in the emission light occur when the Ca2+ dye is excited at 380 nm. 
Such features provide an excellent basis for excitation (340/380 nm) ratiometric 
measurement of [Ca2+]i, which avoids the interferences resulting from the variety of cell 
number, dye concentration and dye quenching.  
Cultured BAECs or HUVECs were harvested after a short treatment (40 sec to 1 min) 
with 0.025% trypsin and 0.02% EDTA in PBS, centrifuged, and then resuspended in 
DMEM containing 2% FCS. Cell were incubated in a spinner with stirring to recover the 
cells from detachment shock for 2.5 hrs at 37°C, followed by loading with 1 µM 
fura-2/AM for no more than 30 min (higher and longer loading will allow fura-2/AM to 
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permeate and be sequestered in intracellular organelles, which should be avoided) in the 
dark. BAECs or HUVECs were then centrifuged, washed twice with DMEM and 
resuspended in a final concentration of 1.25 x 106 cells/ml in a mixture of HEPES (20 
mM)-buffered Krebs-Ringer buffer (containing in mM: 126 NaCl, 5 KCl, 2.5 CaCl2, 1 
MgSO4, adjusted with NaOH to pH 7.4) and DMEM with 2% FCS (1:2). After a 15-min 
equilibration period at room temperature, aliquots of cell suspensions were centrifuged 
and added to a cuvette containing 2 ml warmed (37°C) HEPES-buffered Krebs-Ringer 
buffer. The cells could be kept at room temperature for up to several hours without 
significant loss of the dye and viability. The cuvettes were put in a 
thermostatically-controllable holder equipped with stirrer, and the fura-2-generated 
fluorescence was monitored with a spectrofluorometer (Perkin-Elmer LS-50B).  
For the detailed procedures of fluorescence detection please refer to the reference 229. 
In brief, for each determination, 1 µl MnCl2 (100 mM) and 2 µl 
diethylene-triamine-penta-acetic acid (DTPA, 100 mM) were first added to the cuvette to 
assess the extracellular Fura-2 contamination. Test agents (bradykinin, ATP, ionomycin, 
or thapsigargin) were then added 1-2 min later and the fluorescent signal trace was 
recorded for 3-5 min. At the end, 2 µl MnCl2 (100 mM) and 3 µl DTPA (100 mM) were 
added again to assess the extracellular fura-2 signal (The aim of such double tests of 
extracellular fura-2 fluorescence signal was to evaluate the leaking rate of loaded Fura-2). 
Thereafter, 10 µl Trion X-100 (10%) was added to get Fmax, followed by adding 40 µl 
EGTA (0.4 M, buffered to pH7.4 with 3 M Tris) and 40 µl Tris (3 M) to obtain Fmin. The 
fluorescence signals were recorded by ratiometry with emission wavelength of 515 nm at 
alternate 340/380 nm excitation wavelengths. [Ca2+]i values were calculated from fura-2 
fluorescence ratios (R) by the equation:  
[ ] ( ) ( )[ ]βRRRRKCa di −−=+ maxmin2  
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( 380380 SbSf=β ) 
where Kd is the dissociation constant (225 nM for fura-2); R is the ratio of fluorescence 
(F340/F380) at experimental point during the recording. Rmin and Rmax are the ratios 
(F340/F380) obtained at zero (<10 nM) and saturating free Ca2+ concentration (>1 mM), 
respectively. β is a factor that represents the fluorescence at 380 nm excitation (Sf380) 
under Ca2+-free conditions (<10 nM) divided by the fluorescence at the same wavelength 
(Sb380) under Ca2+-saturating conditions (>1 mM) 230. 
2.8. IP3 production assay 
The activation of PLC was examined by measuring one of its products (i.e. IP3). 
BAECs were cultured in 24-well plates under control or test conditions for various 
periods of time. The cells were washed twice with 3 ml warmed (37oC) KRB. After a 
15-min equilibration period in 0.3 ml KRB /well at 37oC, the cells were stimulated by the 
addition of 1 µM (final concentration) bradykinin for 5 or 60 s. The stimulation was 
stopped immediately at the appropriate time points and cells were lysed by adding ice 
cold HClO4 (20%; v/v). Following extraction of IP3 for 30 min on ice, lysates in the wells 
were transferred to clean Eppendorf tubes and sedimented by centrifugation at 2,000 x g 
for 15 min at 4oC. Supernatants were collected and adjusted to a pH of 7.5 by addition of 
1.5 M KOH containing 60 mM HEPES. Precipitated KCLO4 was sedimented and 
removed after centrifugation at 2,000 x g for 15 min at 4oC. The supernatants were 
transferred to new Eppendorf tubes. 
IP3 levels in the samples were measured by using a radioactive ligand binding assay 
system developed by Amersham Biosciences. The assay was conducted according to the 
manufacturer’s instruction and the contents of each tube (200 µl) were listed in the 
following table: 




TC NSB B0 Standards Samples 
50 µl assay buffer + + + + + 
50 µl distilled water   +   
100 µl distilled water +     
50 µl IP3 standards (0.19-25 
pmol) 
   +  
50 µl stock IP3 standard (250 
pmol) 
 +    
50 µl samples     + 
50 µl diluted tracer + + + + + 
50 µl binding protein  + + + + 
 
In brief, samples or standards were incubated with the thoroughly mixed ice cold 
assay buffer containing D-myo-[3H]inositol-1,4,5-triphosphate and IP3-binding protein 
for 15 min at 4oC. After centrifugation, the supernatants were discarded by decanting, 
whereas the pellets were fully resuspended in 500 µl distilled water and transferred into 
scintillation vials. In each vial, 5 ml of scintillation cocktail was added and thoroughly 
mixed by vortex and incubated at room temperature for 10 min. Subsequently, the 
radioactivity was measured for 5 min in a β-scintillation counter (Beckman). The average 
counts per min (cpm) for each standard and sample were collected to calculate the 
percentage binding as follows: 
% B/B0= (standard or sample cpm – NSB cpm)/ (B0 cpm – NSB cpm) x 100 
The standard curve was obtained by plotting the %B/B0 against the standard 
concentrations (0.19, 0.38, 0.76, 1.5, 3.1, 6.2, 12.5 and 25 pmol/tube, prepared within 1 hr 
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of being used) on semi-log graph paper. IP3 concentrations in the samples were obtained 
by compared with the standard curve.  
2.9. Assessment of bradykinin binding to its receptor 
Binding of bradykinin to its receptors in BAECs was assessed by radioligand 
saturation binding assay. A radioligand is a radio-labeled molecule that can associate with 
a receptor (like bradykinin [2,3-prolyl-3,4-3H] in this experiment), transporter, enzyme, or 
any site of interest. Measuring the rate and extent of binding provides information on the 
number of binding sites, and their affinity and accessibility for various drugs. Saturation 
binding experiments can be used to measure equilibrium binding of various 
concentrations of the radioligand. An analysis of the relationship between binding and 
ligand concentration can determine the number of receptors (or sites), Bmax, and the 
ligand affinity, Kd 69. These analyses depend on the assumption that the incubation is 
allowed to proceed to equilibrium and only a tiny fraction of radioligand binds to the 
receptors.  
Cells were grown in 6-well culture plates under control or test conditions for various 
periods of time. After two washes with 4 ml of ice-cold PBS and a rinse with 2 ml of 
binding buffer (modified Hanks’ balanced salt solution; replacement of 120 mM NaCl 
with N-methyl-D-glucamine, reduction by half of the concentrations of CaCl2, MgCl2, 
and MgSO4, and supplement with 0.1% BSA, 5.6 mM glucose, 2 g/l bacitracin and 10 
mM Hepes, pH 7.4), the cells were equilibrated in 2 ml of chilled binding buffer for 15 
min on ice. Afterwards, the medium was replaced by 1.5 ml of binding buffer containing 
0.5 nM of bradykinin [2,3-prolyl-3,4-3H] (90-120 Ci/mmol) with different concentrations 
of unlabeled bradykinin (0.1, 0.5, 1.0, 5, 10, 20, 30, or 50 nM) for 2 hr at 4oC. For 
assessing non-specific binding, cells were incubated in the presence of 5 µM of cold 
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(unlabeled) bradykinin. The medium was then removed and the cells were rapidly rinsed 
four times with a total of 20 ml of ice-cold rinsing buffer (modified HBSS containing 5.6 
mM glucose, 0.2% BSA and 10 mM Hepes; pH 7.4). Subsequently, the cells were 
detached by incubating with 1 ml of 0.1% trypsin at 37°C and transferred to scintillation 
vials. Five ml of scintillation cocktail was added to each vial and mixed thoroughly; 
radioactivity in the samples was determined by a β-counter.  
Bradykinin receptor number and affinity were calculated by the Scatchard plot. The 
form of Scatchard plot most frequently applied to the analysis of radioligand binding data 
is a plot of B/F on the ordinate versus B on the abscissa, (B/F versus B), where:  
B = Bound = concentration of ligand in the incubation present as ligand-receptor 
complex at equilibrium; and 
F = Free = concentration of free radioligand, present in the binding incubation at 
equilibrium 231.  
When a single ligand interacts with a single population of receptors possessing a 
single affinity for the ligand, a plot of B/F versus B is a straight line and possesses a slope 
= -1/KD. The χ intercept is an estimate of Bmax and the y intercept = Bmax / KD. 
2.10. Measurement of inositol phospholipids 
Cells seeded in 75-cm2 flasks were cultured under control or test conditions for 
various periods of time. On the day of experiment, cells were washed twice with warm 
(37°C) phosphate-free buffer, and then incubated in 4 ml of phosphate-free DMEM 
medium containing 10 µCi/ml 32Pi for 2 hr at 37°C. The labeling solution was aspirated, 
and unincorporated 32Pi was removed by washing twice with 5 ml of warm (37°C) PBS. 
Cells were harvested by trypsinization (0.025%) and transferred to glass tubes. Pellets 
were obtained by centrifugation at 4°C. Total cellular lipids were isolated by repeated 
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extraction with CHCl3-CHOH-2.4 N HCl (1.5:1:1.5) 232. Chloroform phases were 
evaporated under argon gas. Lipids were resuspended in 20-30 µl chloroform. 
Phospholipid standards and samples were spotted at 1.5 cm from the bottom of TLC 
plates, which were pre-activated by development in a 0.054 M oxalic acid solution (pH 
7.2, adjusted with KOH) followed by drying at room temperature and then heated at 
110°C for 15 min. The sample-loaded TLC plates were completely dried by air and 
developed successively in two different solvent systems at room temperature 233. The first 
acidic solvent system was composed of CHCl3-CHOH-CH3COOH-H2O (55:43:3:4). The 
development was stopped when the solvent front reached about 0.5 cm from the top of the 
plate. The plates were allowed to air dry before the second development in a basic solvent 
system composed of CHCl3-CH3OH-NH4OH-H2O (40:70:10:20). The development was 
stopped when the solvent front reached 25% of the distance of the first chromatography. 
The plates were allowed to dry at room temperature and the radiolabeled lipids were 
visualized by autoradiography using Kodak diagnostic film at -70°C for 12 hr. The spots 
corresponding to phosphatidylinositol (PI), phosphatidylinositol 4-monophosphate (PIP) 
and PIP2 were scraped into scintillation vials. One ml of methanol and 4 ml of 
scintillation cocktail were added in each vial and mixed well; the radioactivity was 
determined by a β-counter. 
2.11. Examination of cell morphology 
BAECs were cultured on chambered coverglass (Nalge Nuce, Naperville, IL) with 
test agents for indicated time periods. Non-adherent cells were removed by changing 
medium or washed away with warmed PBS. Morphology of living cells was examined 
under differential interference contrast (DIC) by a Curl Zeiss confocal microscope 
(objective: Plan-Neofluar, 20x /0.5). 
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2.12. Statistical analyses 
Each experiment was performed in duplicate and repeated at least four times on 
different days using independently cultured cells. All data are presented as the mean ± SE 
of the number (n) of independent experiments. Statistical analysis of the data was 
performed by the Student’s t test or one-way analysis of variance (ANOVA). When the 
analysis of ANOVA (F test; compare means between groups) concluded that significant 
differences existed, appropriate form of post hoc test or post-test was used to determine 
exactly which groups were significantly different from each other. The outcome of 
p<0.05 was considered statistically significant.  
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3.1. The effects of high glucose on the signaling pathway involved in NO 
production in endothelial cells  
3.1.1. Chronic exposure to elevated glucose concentrations impair agonist-induced NO 
formation in either BAECs or HUVECs  
It has been reported that bradykinin, a receptor agonist coupled to PLC, induces a 
dramatic redistribution of eNOS from the cell membrane to a distinct ring pattern around 
the cell nucleus and activates eNOS with the maximum effect at 1 µM 232. Therefore, 1 µM 
of bradykinin was used throughout this study as a PLC activator to stimulate NO 
production.  
The NO production kinetics in the presence of bradykinin (1 µM) was investigated, 
with the results shown in Fig. 1. It was found that bradykinin induced an increase in NO 
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Fig. 1.  Effect of 5-day 
culture in high glucose on NO 
production in BAECs 
stimulated by bradykinin. A: 
BAECs were cultured with 
control (5.6 mM) or elevated 
concentrations of glucose (G), 
either 22.2 or 44.4 mM, for 5 
days. Bradykinin (BK; 1 
µM)-stimulated NO production 
was measured in cell 
suspensions using the 
fluorescent probe DAF-2 DA, 
as described in details in the 
Materials and Methods section. 
The basal NO levels in the 
absence of stimulants remained 
almost unchanged over the 6-h 
incubation period (not shown). 
Each data point is the average 
of 7 experiments. (B) NO 
production during 120-min 
stimulated by 1 µM of BK or 
by 2 µM of ionomycin. Values 
are mean ± SEM of 7 
experiments. ** P< 0.01 vs. 
control.  
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production almost linearly over a 6-h period of incubation in control BAECs cultured with 
5.6 mM of glucose[0] (Fig. 1A). And such stimulated NO generation could be blocked by 
100 µM NG-nitro-L-arginine methylester (L-NAME), an inhibitor of eNOS and iNOS as 
well, suggesting that the detected fluorescent signal reflected the cellular NO production, 
thereby validating the method. Chronic exposure of BAECs to high glucose concentrations 
impaired bradykinin-induced NO production in a time- and concentration-dependent 
manner in BAECs (Fig. 1 and Fig. 2). For example, after a 5-day culture, the NO formation 
over 120-min stimulation was reduced by 31% and 39% (n=7, P<0.01) at 22.2 and 44.4 
mM of glucose, respectively (Fig. 1B). Further reduction of bradykinin-stimulated NO 
production in the same period (reductions of 32% and 49%, respectively) occurred 
following a 10-day culture with high glucose (Fig. 2B). 
 
 
Fig. 2.  Effect of 10-day culture in high 
glucose on NO production in BAECs 
stimulated by bradykinin. (A) NO production in 
BAECs cultured with control or elevated glucose 
for 10 days. Refer to the legend of Fig. 1 for other 
experimental details. Each data point is the 
average of 6 experiments. B: NO production 
during 120-min stimulated by 1 µM of BK or by 2 
µM of ionomycin. Bar values are mean ± SEM of 
6 experiments. ** P< 0.01 vs. control. 
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Similar inhibitory effects were also observed on NO production induced by purinergic 
stimulation with ATP (1 µM), another PLC-activator, after 5- or 10-day high glucose culture 
(Fig. 3A & 3B). Over 120 min incubation with ATP, 5-day high glucose culture decreased 
NO formation by 40%, 44% (n=6, P<0.01), while 10-day culture reduced it by 43% and 50% 
(n=6, P<0.01), at two different high glucose concentrations (22.2 and 44.4 mM), 
respectively. These results indicate that impaired NO production is not specific to 
bradykinin; rather it may be a common event occurring in BAECs when stimulated with 
PLC-activating receptor agonists. 
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Fig. 3. Effect of high glucose culture 
on ATP induced NO production in 
BAECs. BAECs were cultured with 
control (5.6 mM) or elevated 
concentrations of glucose (G), either 
22.2 or 44.4 mM, for 5 days (A) or 10 
days (B). ATP (1 µM)-stimulated NO 
production was measured in cell 
suspensions. The basal NO levels in the 
absence of stimulants remained almost 
unchanged over the 6-h incubation 
period (data not shown). Each data point 
is the average of seven experiments. 
Open circles, control cells; diamonds, 
cultured with 22.2 mM of glucose; 
triangles, cultured with 44.4 mM of 
glucose. 
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On the other hand, it was found that high glucose culture did not alter non-receptor 
agonist, ionomycin (a Ca2+ ionophore, which increases [Ca2+]i rises bypassing the activation 
of PLC), induced NO production in BAECs (n=5, P>0.05) (Fig. 1B and Fig. 2B). The 
observation that high glucose culture selectively inhibited NO production induced by 
receptor agonists suggests the existence of certain impairment(s) either at the level of 
trans-membrane receptors or in the signaling transduction pathway between agonist 
receptors and [Ca2+]i concentration.  
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Fig. 4.  Effect of chronic high glucose 
on bradykinin-induced NO production 
in HUVECs. HUVECs were cultured 
with control (5.6 mM) or elevated 
concentrations of glucose (G), either 22.2 
or 44.4 mM, for 5 days (A) or 10 days 
(B). Bradykinin (BK; 1 µM)-stimulated 
NO production was measured in cell 
suspensions. The basal NO levels in the 
absence of stimulants remained almost 
unchanged over the 6-h incubation period 
(data not shown). Each data point is the 
average of seven experiments. Open 
circles, control cells; diamonds, cultured 
with 22.2 mM of glucose; triangles, 
cultured with 44.4 mM of glucose. 
 
The effects of high glucose on NO production could also be observed in another type 
of endothelial cells, HUVECs, stimulated by either bradykinin or ATP (Fig. 4 & Fig. 5). 
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Bradykinin-induced NO formation over 120 min incubation was decreased by 40% and 
46% (n=6, P<0.01) after a 5-day culture in high glucose in HUVECs, while after a 10-day 
culture the NO production was down by 47% and 50% (n=6, P<0.01) during the same 
period. When HUVECs were stimulated with ATP, NO production decreased by 46% and 
49% (n=6, P<0.01) after 5 days incubation, and reduced by 51% and 53% (n=6, P<0.01) 
after 10 days culture with 22.2 and 44.4 mM of glucose, respectively. These results indicate 
that the impaired NO formation is not BAECs specific, but might be the universal effect of 
high glucose on endothelial cells. Furthermore, ionomycin-promoted NO formation in 
HUVECs was not altered by high glucose culture (data not shown), which again supports 
the notion that receptor agonists induced NO production was specifically impaired. 
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Fig. 5.  Effect of chronic high 
glucose on ATP stimulated NO 
production in HUVECs. 
HUVECs were cultured with 
control (5.6 mM) or elevated 
concentrations of glucose (G), 
either 22.2 or 44.4 mM, for 5 days 
(A) or 10 days (B). ATP (1 
µM)-stimulated NO production 
was measured in cell suspensions. 
The basal NO levels in the 
absence of stimulants remained 
almost unchanged over the 6-h 
incubation period (data not 
shown). Each data point is the 
average of seven experiments. 
Open circles, control cells; 
diamonds, cultured with 22.2 mM 
of glucose; triangles, cultured with 
44.4 mM of glucose. 
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3.1.2. Sustained high glucose had no effect on eNOS or iNOS expression at protein 
level in endothelial cells 
eNOS is the enzyme which catalyzes NO formation in endothelial cells. Activation or 
expression of eNOS might be among the factors that can affect NO production induced by 
agonists. Therefore, the decrease of bradykinin-induced NO production in high glucose 
cultured BAECs might be due to a reduction of eNOS mass and/or its activity. The possible 
change of eNOS mass in endothelial cells pretreated with chronic high glucose was 
examined by Western blotting. However, this possibility was ruled out by the results shown 
in Fig. 6 and Fig. 7, which show that there was no significant alteration in eNOS mass 
either in BAECs (Fig. 6) or HUVECs (Fig 7) cultured with high glucose for either 5 or 10 
days. These results suggest that the activity, rather than the mass, of eNOS in BAECs or 
HUVECs might be affected by high glucose treatment. Furthermore, the fact that high 
glucose appeared not to alter the motility of eNOS suggests that high glucose had not 
induced a post-translational modification of eNOS. Thus, the impairment in 
agonist-induced NO production might be due to alteration of the signaling pathway before 





1             2            3
Fig. 6. Detection of eNOS in BAECs by 
Western blotting. Lysates (40 µg of 
protein per lane) from BAECs exposed for 
5 days (A) or 10 days (B) to 5.6 mM (lane 
1), 22.2 mM (lane 2) or 44.4 mM (lane 3) 
of glucose were subject to 
SDS-polyacrylamide gel electrophoresis 
and blotted with a monoclonal antibody 
against eNOS. The results are 
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Fig. 7.  Detection of eNOS in HUVECs by 
Western blotting. Lysates (40 µg of protein 
per lane) from HUVECs exposed for 5 days 
(A) or 10 days (B) to 5.6 mM (lane 1), 22.2 
mM (lane 2) or 44.4 mM (lane 3) of glucose 
were subject to SDS-polyacrylamide gel 
electrophoresis and blotted with a 
monoclonal antibody against eNOS. The 
results are representatives of 6 experiments. 
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iNOS, another isoform  of NOS, was also detected in both BAECs and HUVECs 
(Fig. 8). The results indicated that the expression of iNOS could not be altered by high 
glucose in BAECs (Fig. 8A) and HUVECs (Fig. 8B) after either 5 or 10 days culture. These 
data implies that high glucose might not be an inducible factor, such as cytokines, for iNOS 
expression in endothelial cells. It was reported that the expression of iNOS is mainly 
regulated by sex hormones and cytokines. As iNOS plays a minor role in agonist-induced 
physiological NO formation in endothelial cells, the effects and regulation of iNOS on NO 
production were not further pursued in this study.   
3.1.3. Close correlation between [Ca2+]i levels and NO release in BAECs  
The use of the fluorescent probe DAF-2/DA to measure NO in living cells makes it 
possible to study the relationship between [Ca2+]i levels and NO production in intact cells. 
As discussed in Material and Methods, this DAF-2 detection system also avoids any 
potential variability within endothelial cells and provides an accurate measurement of NO 
released by the endothelium. With these advantages of the DAF-2 detection system, this 
investigation aimed to disclose whether there is a quantitative relationship between [Ca2+]i 
levels and the release of NO from BAECs. 
When BAECs were challenged by various concentrations of a Ca2+ ionophore, 
ionomycin, [Ca2+]i were elevated concomitantly in a concentration-dependent fashion (Fig. 











Fig. 8. Detection of iNOS by Western 
blotting in BAECs or HUVECs. Lysates (40 
µg of protein per lane) from BAECs (A) or 
HUVECs (B) exposed for 5 days  or 10 days 
to 5.6 mM (lane 1), 22.2 mM (lane 2) or 44.4 
mM (lane 3) of glucose were subject to 
SDS-polyacrylamide gel electrophoresis and 
blotted with a monoclonal antibody against 
iNOS. The results are representatives of 6 
experiments. 
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9A). Upon stimulation by the same concentrations of ionomycin, NO generation in these 
cells was also increased in a dose-dependent manner (Fig. 9B). A close correlation between 
ionomycin-stimulated NO production and ionomycin-evoked [Ca2+]i peak levels was 
observed (Fig. 9C). These results imply a close link between NO production and [Ca2+]i 
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Fig. 9. The relationship between 
[Ca2+]i and NO production. A. [Ca2+]i 
in BAECs was elevated to various 
levels by different concentrations 
(0.002 to 4 µM) of ionomycin. Each 
trace is the average of three to four 
experiments. B. NO formation 
stimulated by ionomycin at the same 
concentrations as in A. Each data 
point is the average of four 
experiments. Open circles, 4 µM; 
open diamonds, 0.4 µM; open 
triangles, 0.2 µM; crosses, 0.02 µM; 
double crosses, 0.005 µM; close 
circles, 0.002 µM. C. Correlation of 
ionomycin-stimulated NO production 
(30 min of incubation) with 
ionomycin-induced peaks of [Ca2+]i.  
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EGTA+BK; adding Ca2+ at 90 min 
Basal 
Basal, with EGTA 
 
Fig. 10. Requirement of Ca2+ entry 
from extracellular space for 
bradykinin-induced sustained NO 
production. In normal medium (with 
1.5 mM of Ca2+), 
bradykinin-stimulated NO production 
in BAECs was nearly linear during 
the period in which it was detected 
(closed triangles). 
Bradykinin-induced NO formation 
was blocked when extracellular free 
Ca2+ level was reduced to nominal 
Ca2+ free level by adding 3 mM of 
EGTA (open triangles; first 90 min). 
However, adding 3 mM of Ca2+ to the 
solution restored NO production at 
the normal rate (open triangles; 
beyond 90 min). Open circles, basal 
NO level without stimulation; closed 
circles, bradykinin stimulation in the 
presence of 3 mM of EGTA 
throughout the 180-min period. 
 
Receptor agonists such as bradykinin and ATP which activate PLC evoke [Ca2+]i rises 
by dual ways: Ca2+ mobilization from intracellular stores and Ca2+ influx from extracellular 
space 64-66,233,234. In order to further study the role of these two different [Ca2+]i sources in 
agonist-stimulated NO production, BAECs or HUVECs were incubated with bradykinin in 
the presence or absence of free Ca2+ in the extracellular space. The extracellular free Ca2+ 
levels were lowered to approximately 100 nM by introducing excess EGTA (Ca2+ chelator) 
in the medium. When cells were stimulated with bradykininin in the nominal Ca2+-free 
medium (100 nM) for 90 min, NO production was completely abolished (Fig. 10). 
Subsequently, addition of calcium to bring extracellular free calcium back to normal levels 
restored bradykinin-evoked NO formation (Fig. 10). These observations indicate that an 
increase in [Ca2+]i via Ca2+ entry is essential for bradykinin to induce a sustained NO 
production, while Ca2+ from intracellular stores play a minor role, at least in long-lasting 
NO production.   
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3.1.4. High glucose reduced receptor agonist induced [Ca2+]i rises but not ionomycin 
induced [Ca2+]i rises in BAECs or HUVECs 
eNOS is a Ca2+-calmodulin-dependent enzyme and is activated by an increase in 
[Ca2+]i elicited by stimulation of diverse G protein-coupled receptors on endothelial 
membrane. Bradykinin and ATP represent two important endogenous activators of eNOS 
in the vascular wall. In the vascular endothelium, bradykinin and ATP bind to and 
stimulate Ca2+-mobilizing receptors on the membrane, leading to NO formation as 
discussed in chapter One. Changes in [Ca2+]i represent a determinant factor for eNOS 
redistribution and subsequent activation. Consequently, the [Ca2+]i profile in endothelial 
cells, BAECs and HUVECs, were examined following high glucose culture.  
In control BAECs (cultured with 5.6 mM of glucose), stimulation by 1 µM of bradykinin 
resulted in a rapid increase in [Ca2+]i from a basal level of 107 ± 26 nM to a peak of 542 ± 
27 nM (the average [Ca2+]i levels for 30 s around the peak). In cells pretreated for 5 days 
with high glucose concentrations, the effect of bradykinin on [Ca2+]i was markedly 
inhibited; increments in the [Ca2+]i peak were decreased to 338 ± 11 nM at 22.2 mM and 
236 ± 15 nM at 44.4 mM, corresponding to a reduction of 38% and 56% (n=11, P<0.01), 
respectively (Fig. 11A, 11C). Exposure to high glucose concentrations for 10 days further 
inhibited the effect of bradykinin. [Ca2+]i increments were decreased from 524 ± 24 nM in 
control cells to 203 ± 20 nM and 169 ± 17 nM (equivalent to a reduction of 61% and 68%) 
after culture at 22.2 and 44.4 mM of glucose, respectively, (n=11, P<0.01) (Fig. 11B, 11C). 
However, basal [Ca2+]i levels were not affected by high glucose.  
 
 






































































































Fig. 11. Effect of high glucose 
culture on bradykinin-induced rise 
in [Ca2+]i in BAECs. Bradykinin 
(BK; 1 µM)-induced rise in [Ca2+]i in 
BAECs cultured for 5 days (A) or 10 
days (B) at control (5.6 mM) or high 
(22.2 or 44.4 mM) concentrations of 
glucose (G) were measured in cell 
suspensions using the fluorescent 
Ca2+ probe fura-2 as  described in 
the Materials and methods section. 
Each trace is the superposition of 11 
experiments. C. The average 
increases in [Ca2+]i during the initial 
30 s of bradykinin stimulation. Bar 
values are means ± SEM. ** p<0.01 
vs control (t test). Open bars, 5 days 
of culture; hatched bars, 10 days of 
culture 
 
When another receptor agonist, ATP, was used, [Ca2+]i increments in BAECs were 
also inhibited after high glucose culture (Fig. 12). In control cells, the [Ca2+]i peaks induced 
by ATP are much higher than those stimulated by bradykinin (Fig. 11 and Fig. 12). ATP 
increased [Ca2+]i from basal level of 76 ± 23 nM, to a peak of 732 ± 56 nM in control cells. 
However, after 5 days culture, [Ca2+]i rises were diminished by 30% and 40% (the 
corresponding [Ca2+]i peaks were 522 ± 47 nM and 466 ± 39 nM) (n=10, P<0.01), while 
after 10 days culture, 33% and 48% (n=10, P<0.01) of [Ca2+]i increments were inhibited in 
22.2 and 44.4 mM, respectively.  























































































Fig. 12. Effect of high glucose culture on 
ATP-stimulated rise in [Ca2+]i in BAECs. 
ATP (1 µM)-induced  rise in [Ca2+]i in 
BAECs cultured for 5 days (A) or 10 days 
(B) at control (5.6 mM) or high (22.2 or 
44.4 mM) concentrations of glucose were 
measured in cell suspensions using the 
fluorescent Ca2+ probe fura-2 as described 
in the Materials and methods section. Each 
trace is the superposition of 7 experiments. 
 
 
When HUVECs were used, it also showed that glucose overload impaired [Ca2+]i rises 
in a time- and dose-dependent manner under the stimulation of bradykinin (Fig. 13) or ATP 
(Fig. 14). Bradykinin-induced [Ca2+]i rises from the basal level to a peak of 470 ± 44 nM in 
control cells. However, after a 5-day culture with high glucose concentrations of 22.2 and 
44.4 mM, the peaks were down to 388 ± 36 nM and 267 ± 38 nM (decreased by 20% and 
43%; n=7, P<0.01), while after a 10-day culture the reduced percentages were 42% and 
57% (the corresponding peaks were 249 ± 33, 185 ± 21 nM; n=7, P<0.01), respectively. 
When cells were stimulated by ATP, the inhibition of [Ca2+]i rises by excessive glucose 
(22.2 and 44.4 mM) on HUVECs after 5 days culture was by 33% and 47% (peaks were 
down from 602 ± 33 nM in control cells to 402 ± 34, 318 ± 42 nM in high glucose; n=6, 
P<0.01). After 10 days culture, the two high glucose concentrations further weaken [Ca2+]i 
increments respectively by 35% and 60% (n=6, P<0.01). These results and those from 
BAECs suggest that reduced NO production stimulated by bradykinin or ATP stimulation 
in these high glucose cultured cells might result from a diminished [Ca2+]i response. 













































































Fig. 13. Effect of high glucose 
culture on bradykinin-stimulated 
rise in [Ca2+]i in HUVECs. 
Bradykinin (BK, 1 µM)-induced  
rise in [Ca2+]i in HUVECs cultured 
for 5 days (A) or 10 days (B) at 
control (5.6 mM) or high (22.2 or 
44.4 mM) concentrations of 
glucose were measured in cell 
suspensions using the fluorescent 
Ca2+ probe fura-2 as described in 
the Materials and Methods section. 
























Fig. 14. Effect of high glucose 
culture on ATP-induced rise in 
[Ca2+]i in HUVECs. The average 
rise in [Ca2+]i during the initial 30 s 
of ATP stimulation in HUVECs 
cultured for 5 days or 10 days at 
control (5.6 mM) or high (22.2 or 
44.4 mM) concentrations of 
glucose were measured and 
calculated. Each bar value is the 
average of 6 experiments. Bar 
values are means ± SEM. ** 
p<0.01 vs control (t test).  
 
In contrast, [Ca2+]i elevations in either BAECs (Fig. 15) or HUVECs (data not shown) 
evoked by ionomycin (2 µM) were not affected by high glucose culture even for 10 days 
(Fig. 15). These results may explain why high glucose did not interfere with 
ionomycin-stimulated NO production (cf. Figs. 1 and 2) and support the notion that glucose 
overload might specifically impair agonist receptor NO pathway, especially from receptor 
to activation of PLC, IP3 production and subsequent rises in [Ca2+]i.   
































) Fig. 15. High glucose have no 
effect on ionomycin-induced rise 
in [Ca2+]i in BAECs. Ionomycin (2 
µM)-induced  rise in [Ca2+]i in 
BAECs cultured for 10 days at 
control (5.6 mM) or high (22.2 or 
44.4 mM) concentrations of glucose 
were measured. Each trace is the 
superposition of 5 experiments. 
 
3.1.5. High glucose inhibited receptor agonist-evoked Ca2+ mobilization and Ca2+ 
influx  
As mentioned above, dual ways (Ca2+ mobilization from intracellular stores and Ca2+ 
influx from extracellular space) account for the rise in [Ca2+]i. These two events can be 
examined separately as shown in Figs. 16-19; the former can be assessed by lowering 
extracellular Ca2+ to nominal Ca2+ free level (around 100 nM) with EGTA and the latter 
can be determined by restoration of extracellular free Ca2+ to the normal level. Both aspects 
of the [Ca2+]i increase promoted by bradykinin or ATP were significantly reduced by high 
glucose culture.  
After a 5-day culture with 22.2 or 44.4 mM of glucose, bradykinin-induced Ca2+ 
mobilization was reduced by 12% and 20%  (n=10, P<0.01) while  the Ca2+ influx was 
decreased by 17% and 30% (n=10, P<0.01), respectively (Fig. 16A and Table 1). Further 
reduction of bradykinin-induced Ca2+ mobilization and Ca2+ influx was observed after a 
10-day culture under the same conditions; the former was diminished by 20% and 31% 
(n=10, P<0.01) and the latter was down by 26% and 46% (n=10, P<0.01), respectively (Fig. 
16B and Table 1).  





































































































Fig. 16. Effects of high glucose on 
bradykinin (BK)-stimulated Ca2+ 
mobilization and Ca2+ influx in 
BAECs. Cells were cultured with 
control (5.6 mM) or high (22.2 or 
44.4 mM) concentrations of glucose 
for 5 days (A) or 10 days (B). [Ca2+]i 
was measured by loading BAECs 
with the fluorescent Ca2+ probe 
(fura-2). Bradykinin (1 µM)-induced 
Ca2+ mobilization from intracellular 
stores was determined by chelating 
Ca2+ in extracellular buffer to 
nominal Ca2+ free levels by adding 3 
mM of EGTA, whereas 
bradykinin-promoted Ca2+ influx was 
detected by restoration of 
extracellular free Ca2+ to the normal 
level by adding 3 mM of Ca2+ to the 
solution. Each trace is the 
superposition of ten experiments (t 
test). 
 
Table 1. Effects of high glucose on bradykinin-evoked Ca2+ mobilization and Ca2+ 
influx in BAECs  
Condition Control 22.2 mM glucose 44.4 mM glucose 
 [Ca2+]i increase by Ca2+ mobilization (nM) 
5 days 233 ± 43 205 ± 22 a 187 ± 21 a 
10 days 227 ± 38 182 ± 24 a 157 ± 22 a 
 [Ca2+]i increase by Ca2+ influx(nM) 
5 days 520 ± 48 432 ± 44 a 365 ± 21 a 
10 days 524 ± 57 388 ± 32 a 283 ± 39 a 
 
The values in this table are the results from statistical analysis of the data in Fig. 16. Ca2+ mobilization 
was calculated by averaging the increments of [Ca2+]i in the initial 30 s following bradykinin stimulation. 
Ca2+ influx was calculated by averaging the [Ca2+]i overshoots (during the 30 s around the plateau peaks) 
subsequent to Ca2+ restoration. Values are means ± SEM of 10 observations. a P< 0.01 vs. control. 
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Table 2 & Fig. 17 show the effects of excessive glucose on the two parts of [Ca2+]i 
profile in BAECs when ATP was used as a stimulus. The data demonstrated that high 
glucose also impaired ATP-evoked Ca2+ mobilization and Ca2+ influx. The corresponding 
inhibitions in percentages were 21% and 29% (n=8, P<0.01) in Ca2+ mobilization, 20% and 
40% (n=8, P<0.01) in Ca2+ influx after a 5-day culture in 22.2 and 44.4 mM of glucose, 
respectively. A 10-day culture further inhibited the Ca2+ mobilization (by 25% and 38%; 
n=8, P<0.01) and Ca2+ influx (by 21% and 50%; n=8, P<0.01) in these cells. These data 
indicate that high glucose inhibited both Ca2+ mobilization and Ca2+ influx due to 











































































































Fig. 17. Effects of high 
glucose on ATP-stimulated 
Ca2+ mobilization and Ca2+ 
influx in BAECs. Cells were 
cultured with control (5.6 
mM) or high (22.2 or 44.4 
mM) concentrations of 
glucose for 5 days (A) or 10 
days (B). [Ca2+]i was 
measured by loading cells 
with the fluorescent Ca2+ 
probe (fura-2). ATP (1 
µM)-induced Ca2+ 
mobilization and Ca2+ influx 
were measured the same way 
as mentioned in Fig. 16. Each 
trace is the superposition of 
ten experiments (t test). 
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Table 2.  Effects of excessive glucose on ATP-evoked Ca2+ mobilization and Ca2+ 
influx in BAECs  
Condition Control 22.2 mM glucose 44.4 mM glucose 
 [Ca2+]i increase by Ca2+ mobilization (nM) 
5 days 403 ± 42 320 ± 29 a 287 ± 28 a 
10 days 410 ± 36 306 ± 33 a 254 ± 30 a 
 [Ca2+]i increase by Ca2+ influx(nM) 
5 days 610 ± 55 489 ± 47 a 365 ± 23a 
10 days 622 ± 51 490 ± 35 a 311 ± 34 a 
The values in this table are the results from statistical analysis of the data in Fig. 17. Ca2+ mobilization 
was calculated by averaging the increments of [Ca2+]i in the initial 30 sec following ATP stimulation. Ca2+ 
influx was calculated by averaging the [Ca2+]i overshoots (during the 30 sec around the plateau peaks) 
subsequent to Ca2+ restoration. Values are means ± SEM of 10 observations. a P< 0.01 vs. control. 
In addition, Figs. 18 &19 and Tables 3 & 4 show the results of Ca2+ mobilization and 
Ca2+ influx when another type of endothelial cell (HUVECs) was studies. It can be 
concluded from these data that, similar to the observation of Ca2+ mobilization and Ca2+ 
influx in BAECs, glucose overload also reduced both agonist-induced Ca2+ mobilization 
and Ca2+ influx in HUVECs. For example, bradykinin-elicited Ca2+ mobilization and Ca2+ 
influx were allayed by 18% and 32% (n=6, P<0.01) at 22.2 mM of glucose, and by 22% 
and 40% (n=6, P<0.01) at 44.4 mM of glucose after a 5-day culture (Table 3). The 
corresponding percentages of inhibition after a 10-day culture were 36% and 42% (n=6, 
P<0.01) at 22.2 mM of glucose, and 29% and 41% (n=6, P<0.01) at 44.4 mM of glucose 
(Table 3). Similar to the results for bradykinin, ATP induced Ca2+ mobilization were down 
from 383 ± 23 nM in control HUVECs to 342 ± 27 (11%) and 317 ± 29 nM (17%), while 
Ca2+ influx were decreased by 23% and 37%, in cells cultured with high glucose. Longer 
glucose culture further reduced ATP-stimulated Ca2+ mobilization and Ca2+ influx. The 
former was decreased by 24% and 37%, while the latter was reduced by 32% and 38% in 
22.2 and 44.4 mM of glucose, respectively. It seems that Ca2+ influx in HUVECs was more 
severely affected.  





























































































Fig. 18. Effects of high glucose on 
bradykinin (BK)-stimulated Ca2+ 
mobilization and Ca2+ influx in 
HUVECs. Cells were cultured with 
control (5.6 mM) or high (22.2 or 44.4 
mM) concentrations of glucose for 5 
days (A) or 10 days (B). Bradykinin (1 
µM)-induced Ca2+ mobilization from 
intracellular stores was determined by 
chelating Ca2+ in the extracellular buffer 
to nominal Ca2+ free levels by adding 3 
mM of EGTA, whereas 
bradykinin-promoted Ca2+ influx was 
detected by restoration of extracellular 
free Ca2+ to the normal level by adding 3 
mM of Ca2+ to the solution. Each trace is 
the superposition of ten experiments (t 
test). 
 
Table 3.  Effects of chronic high glucose on bradykinin-evoked Ca2+ mobilization and 
Ca2+influx in HUVECs  
Condition Control 22.2 mM glucose 44.4 mM glucose 
 [Ca2+]i increase by Ca2+ mobilization (nM) 
5 days 423 ± 39 345 ± 27 a 287 ± 20 a 
10 days 440 ± 31 282 ± 26 a 256 ± 21 a 
 [Ca2+]i increase by Ca2+ influx(nM) 
5 days 620 ± 55 483 ± 47 a 369 ± 26 a 
10 days 644 ± 45 458 ± 33 a 381 ± 35 a 
The values in this table are the results from statistical analysis of the data in Fig. 18. Ca2+ mobilization 
was calculated by averaging the increments of [Ca2+]i in the initial 30 sec following bradykinin stimulation. 
Ca2+ influx was calculated by averaging the [Ca2+]i overshoots (during the 30 sec around the plateau peaks) 
subsequent to Ca2+ restoration. Values are means ± SEM of 10 observations. a P< 0.01 vs. control. 





























































































Fig. 19. Effects of high glucose on 
ATP-stimulated Ca2+ mobilization 
and Ca2+ influx in HUVECs. Cells 
were cultured with control (5.6 mM) or 
high (22.2 or 44.4 mM) concentrations 
of glucose for 5 days (A) or 10 days 
(B). [Ca2+]i was measured by the 
methods as mentioned above in Fig 18. 
ATP (1 µM)-induced Ca2+ mobilization 
from intracellular stores was 
determined by chelating Ca2+ in the 
extracellular buffer to nominal Ca2+ 
free levels by adding 3 mM of EGTA, 
whereas bradykinin-promoted Ca2+ 
influx was detected by restoration of 
extracellular free Ca2+ to the normal 
level by adding 3 mM of Ca2+ to the 
solution. Each trace is the superposition 
of ten experiments (t test). 
 
Table 4.  Effects of excessive glucose on ATP-evoked Ca2+ mobilization and Ca2+ 
influx in HUVECs  
Condition Control 22.2 mM glucose 44.4 mM glucose 
 [Ca2+]i increase by Ca2+ mobilization (nM) 
5 days 383 ± 23 342 ± 27 a 317 ± 29 a 
10 days 412 ± 35 312 ± 22 a 258 ± 24 a 
 [Ca2+]i increase by Ca2+ influx(nM) 
5 days 750 ± 55 581 ± 40 a 475 ± 42 a 
10 days 924 ± 47 628 ± 36 a 571 ± 46 a 
 
The values in this table are the results from statistical analysis of the data in Fig. 19. Ca2+ mobilization 
was calculated by averaging the increments of [Ca2+]i in the initial 30 sec following ATP stimulation. Ca2+ 
influx was calculated by averaging the [Ca2+]i overshoots (during the 30 sec around the plateau peaks) 
subsequent to Ca2+ restoration. Values are means ± SEM of 10 observations. a P< 0.01 vs. control. 
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Hence, the above results bring forward another question. It is well known that the 
depletion of intracellular calcium stores is the initial force for calcium influx across the 
plasma membrane and also the decisive factor for the amount of calcium influx. Thus, the 
above observed reduction of calcium influx might be due to decreased calcium 
mobilization. In order to investigate whether such inhibition of agonist-evoked endothelial 
Ca2+ signaling was the result of an inhibitory effect on IP3-dependent Ca2+ release, the 
effect of high glucose on [Ca2+]i increases induced by thapsigargin [which causes release of 
Ca2+ from IP3-sensitive intracellular Ca2+ stores by inhibiting the Ca2+-ATPase on smooth 
endoplasmic reticulum 68,135 was tested in BAECs and HUVECs. As shown in Fig. 20, the 
ability of 1 µM of thapsigargin to elevate [Ca2+]i in the presence of extracellular Ca2+ was 
not affected in either BAECs (Fig. 20) or HUVECs (data not shown) after 10-day high 
glucose culture, which suggests that the IP3 releasable Ca2+ pools remain intact. This 
observation demonstrated again that only receptor agonist-elicited [Ca2+]i responses were 

















Fig. 20. High glucose have no effect 
on thapsigargin-induced increases 
in [Ca2+]i in BAECs. Thapsigargin (1 
µM)-induced  increases of [Ca2+]i in 
BAECs cultured for 10 days at control 
(5.6 mM) or high (22.2 or 44.4 mM) 
glucose concentrations were measured 
in normal extracellular Ca2+ 
concentration buffer as described in 
the Materials and methods section. 
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3.1.6. High glucose attenuated both basal and bradykinin-stimulated IP3 formation in 
BAECs  
Since PLC-activating receptor agonists induce an increase of [Ca2+]i by generating 
IP369, the possible effect of high glucose on this second messenger was examined. Previous 
studies have demonstrated that the maximal effect of bradykinin-induced IP3 generation 
occurs after stimulation for 5 sec in human fibroblasts 67. Thus, the current experiments 
with bradykinin were also performed for 5 sec.  
The basal level of IP3 in control BAECs was 0.90 ± 0.06 pmol/mg of protein. Culture 
with 22.2 and 44.4 mM of glucose for 10 days significantly decreased the basal level of IP3 
to 0.44 ± 0.03 and 0.46 ± 0.05 pmol/mg of protein (n=5, P<0.01), respectively (Fig. 21). 
Moreover, bradykinin-stimulated IP3 production (increment over basal) was also 
significantly reduced by 29% and 48% during a 5-s stimulation, and by 46% and 64% over 
a 60-s incubation (n=6, P<0.01) (Fig. 21). Therefore, the impaired intracellular Ca2+ release 
in response to the IP3–generating compounds bradykinin and ATP after high glucose 
treatment might be due to impaired IP3 formation. It is thus reasonable to deduce that high 
glucose might affect PLC activity, the efficiency of substrates for PLC or the receptor-G 












































Fig. 21. Effects of high glucose on 
bradykinin-induced IP3 formation in 
BAECs. Cells exposed to control (5.6 
mM) or high glucose concentrations (22.2 
or 44.4 mM) for 10 days were incubated 
with 1 µM of bradykinin in KRB for 5 or 
60 s at 37°C. IP3 in the cells was extracted 
and measured by radioligand binding 
assay. Values are means ± SEM of three 
experiments. ** p<0.01 vs control (t test). 
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3.1.7. High glucose have no effect on inositol phospholipids in BAECs 
The substrates of PLC include three minor lipid components of the plasma membrane: 
PI, PIP, and PIP2. The levels of these lipids in high glucose cultured BAECs were 
measured by TLC chromatography. Fig 22 showed that the concentration of these three 
inositol phospholipids, PI, PIP or PIP2 was not significantly changed up to 10 days in high 
glucose culture. These results are likely to rule out the possibility that the activity of PLC 
was affected by high glucose due to a shortage or reduction of substrates. Therefore, 
glucose overload may result in defects upstream of PLC or with PLC itself in the NO 

































Fig. 22. Effect of high glucose on the 
concentration of PI, PIP and PIP2 in BAECs.  
BAECs were cultured with either control or high 
glucose for 10 days. A. After labeling with 32P, 
cellular lipids were extracted, separated by 
thin-layer chromatography, and 
autoradiographied as described in the Materials 
and methods section. B. Statistical analysis of the 
contents of 32P -labeled inositol phospholipids. 
Data are the means ± SEM of three independent 
experiments in duplicate (t test).  
 
 
3.1.8. Chronic high glucose reduced the number of bradykinin receptor in BAECs  
To test whether the impairment of the bradykinin-induced IP3 formation by high glucose 
was a direct effect on PLC-coupled receptors, experiments examining the number and the 
affinity of bradykinin receptor on the cell surface were carried out by radioligand saturation 
binding assays. The results showed that only one type of bradykinin receptor was detected 
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in BAECs, as Scatchard plot fitted a single receptor model (Fig. 23). The affinity (Kd) of 
this isoform of bradykinin receptor detected in BAECs was 1.1 ± 0.09 nM; and the total 
number (Bmax) of this receptor was 345 ± 18 fmol/mg of protein. High glucose culture for 
10 days significantly reduced Bmax of bradykinin receptor on the cell surface by 22% at 
22.2 mM and by 32% at 44.4 mM of glucose (declined to 270 ± 16 and 245 ± 23 fmol/mg 
of protein, respectively; P<0.01 vs. control) (Fig. 23A). However, the affinity of bradykinin 
receptor (Kd) was not affected (1.3 ± 0.1 nM at 22.2 mM and 1.1 ± 0.1 nM at 44.4 mM of 
glucose; P>0.05 vs. control) under these conditions (Fig. 23B). 
 
Fig. 23. Effect of high glucose on the 
bradykinin receptor in BAECs. 
Saturation binding (A) and Scatchard 
plot (B) analyses were performed by a 
non-linear-curve-fitting program (Sigma 
Plot; SPSS, Chicago, Ill., USA) to 
determine the dissociation constants and 
the total number of bradykinin receptor. 
Data are from four independent 
observations (t test). Open circles, 
control cells; closed circles, cultured 
with 22.2 mM of glucose; triangles, 
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3.1.9. Section summary 
This part of work attempted to delineate the effects of sustained high glucose culture 
on NO production and the possible alterations of signaling pathways implicated in this 
scenario in two types of endothelial cells. The results showed that high glucose 
significantly reduced NO production stimulated by bradykinin and ATP in both time- and 
dose-dependent manner. The diminished NO formation was more likely due to a decrease 
in eNOS activity rather than a reduction of its mass. Both PLC-activating agonist-promoted 
intracellular Ca2+ mobilization and extracellular Ca2+ entry were affected, which appeared 
not to due to an alteration of IP3-releasable intracellular Ca2+ pools. In addition, 
bradykinin-evoked formation of IP3, one of the products of PLC which leads to [Ca2+]i rises, 
was also deceased following high glucose culture. This abnormality was not attributable to 
a decrease in the substrates for PLC, but might be due to a reduction of the number of 
bradykinin receptor. On the contrary, [Ca2+]i elevation and NO production evoked by a 
Ca2+ ionophore (ionomycin) were not affected by high glucose. These data indicate that 
chronic exposure to high glucose reduces NO generation in endothelial cells probably by 
impairing PLC-mediated Ca2+ signaling pathways which might be the consequence, at least 
in part, of reduced receptor number on the cell membrane.  
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3.2. Effects of fatty acids on NO signaling pathway in endothelial cells 
Apart from hyperglycemia, elevation of blood fatty acids is the other risk factor in the 
pathogenesis of cardiovascular diseases in diabetes. Therefore the effects of fatty acids on 
NO production and the implicated signaling pathway in endothelial cells were also 
investigated in this study.   
3.2.1. Fatty acids impaired receptor agonist induced NO production in endothelial 
cells 
Chronic exposure of BAECs to high fatty acids concentrations (a mixture of palmitate 
and oleate at 0.5 or 1.0 mM) impaired bradykinin-induced NO production in a time- and 
dose-dependent manner (Fig. 24). For example, after a 5-day culture, 0.5 and 1.0 mM of 
fatty acids reduced bradykinin-induced NO formation in BAECs over a 120-min incubation 
by 28% and 40% (n=6, P<0.05), respectively (Fig. 24A). Further reduction of 
bradykinin-stimulated NO production over the same period (reductions of 34% and 49%, 
respectively) occurred following a 10-day culture with high fatty acids (Fig. 24B). 
However, 0.25 mM of fatty acids did not alter NO production even after 10 days culture, 
indicating that fatty acids at this concentration might not be a risk factor for diabetic 
cardiovascular complications. On the other hand, two days culture with high fatty acids 
(0.5 or 1.0 mM) was not able to alter bradykinin-induced NO production in BAECs (data 
not shown)                 
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Fig. 24. Effect of fatty acid 
overdose on NO production 
in BAECs in response to 
bradykinin. BAECs were 
cultured with control (1% 
BSA), normal (0.25 mM) or 
high fatty acids (0.5 or 1.0 
mM) for 5 days (A) or 10 days 
(B). Bradykinin (1 
µM)-stimulated NO production 
were detected in Ca2+ 
containing buffer in 150 min. 
Each data point was the 
average of 6 experiments. 
 
When ATP was used as another stimulus, similar inhibitory effect on NO production 
was observed after a 5 or 10-day culture with high fatty acids concentrations (0.5 and 1.0 
mM) (Fig. 25). During a 120-min incubation with ATP, NO formation was reduced by 39% 
and 42% (n=6, P<0.05) after a 5-day culture with 0.5 and 1.0 mM of fatty acids (Fig. 25A), 
while the reduction reached 41% and 44% (n=6, P<0.05) (Fig. 25B) in BAECs after a 
10-day culture with these two high fatty acids concentrations, respectively. However, a 
2-day culture with fatty acids failed to affect ATP-evoked NO formation in BAECs (data 
not shown). 
A 
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Fig. 25. Effect of fatty acid 
overdose on ATP-induced 
NO production in BAECs. 
BAECs were cultured with 
control (1% BSA) normal (0.25 
mM), or high  fatty acids (0.5 
or 1.0 mM) for 5 days (A) or 10 
days (B). ATP (1 
µM)-stimulated NO production 
were detected and calculated in 
Ca2+ containing buffer over a 
180 min period. Values are 
mean ± SEM of 6 experiments. 
* P< 0.05 vs. control.  
 
 
The effects of fatty acids on NO production stimulated by bradykinin or ATP in 
HUVECs, another type of endothelial cells, were also examined. NO formation in 
HUVECs over a 120 min incubation period with bradykinin (1 µM) was reduced by 40% 
and 49% (n=6, P<0.01) (Fig. 26A) after culturing with 0.5 or 1.0 mM of fatty acids for 5 
days; by 51% and 58% (n=6, P<0.05) (Fig. 26B) after 10 days culture. 0.25 mM of fatty 
acids did not reduce the NO production stimulated by bradykinin in HUVECs either after a 
5-day or 10-day culture..  
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Fig. 26. Effect of fatty acids 
overdose on 
bradykinin-induced NO 
production in HUVECs. 
HUVECs were cultured with 
control (1% BSA), normal 
(0.25 mM) or high fatty acids 
(0.5 or 1.0 mM) for 5 days (A) 
or 10 days (B). Bradykinin (1 
µM)-stimulated NO production 
were detected in Ca2+ 
containing buffer in 150 min. 
Each data point was the 
average of 6 experiments.  
 
When ATP was used, NO production over 120 min of stimulation was lessened by 
44% and 48% (n=6, P<0.01) (Fig. 27A) after a 5-day culture with 0.5 and 1.0 mM of fatty 
acids; while the reduction was by 50% and 52% (n=6, P<0.01) (Fig. 27B) following a 10 
day culture. It is interesting that two day cultures even with the highest concentration of 
fatty acids used in this study (1.0 mM) was unable to impair NO production in HUVECs 
(data not shown). In addition, a 5- or 10-day culture with 0.25 mM of fatty acids failed to 
impair the ATP-evoked NO formation. 
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Fig. 27. Effect of fatty acids 
overload on NO production 
in HUVECs in response to 
ATP. HUVECs were cultured 
with control (1% BSA) or fatty 
acids (0.25, 0.5 or 1.0 mM) for 
5 days (A) or 10 days (B). ATP 
(1 µM)-stimulated NO 
production were detected and 
analyzed in Ca2+ containing 
buffer in 150 min. Values are 
mean ± SEM of 6 experiments. 
* P< 0.05 vs. control.  
 
However, high fatty acids had no effects on ionomycin-induced NO production in 
BAECs (Fig. 28). These data demonstrated that fatty acids selectively inhibited NO 
production induced by receptor agonists. Therefore, high fatty acid-induced impairment(s) 
in NO signaling pathway might occur at the level of trans-membrane receptors or in the 

















































































Fig. 28. Ionomycin-evoked NO 
production was not affected by 
culturing with high fatty acids.  
BAECs were cultured with control (1% 
BSA) or fatty acids (0.25, 0.5 or 1.0 
mM) for 5 days (A) or 10 days (B). 
Ionomycin (2 µM, non-receptor 
agonist)-stimulated NO production were 
detected and analyzed in Ca2+ containing 
buffer at the 120 min incubation time 
point. Values are mean ± SEM of 6 
experiments. * P< 0.05 vs. control.  
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3.2.2. Neither eNOS nor iNOS mass was affected by chronic overload of fatty acids in 
endothelial cells  
In order to test whether an increase in fatty acids is one of the regulators for eNOS or 
iNOS expression, their mass was examined by Western blotting. The results ruled out this 
postulation because there was no significant alteration in eNOS mass in either BAECs (Fig. 
29A) or HUVECs (Fig. 29B) cultured with high fatty acids for 5 or 10 days. In addition, no 
changes in the expression of iNOS were detected in BAECs or HUVECs cultured with 
fatty acids (0.25, 0.5 1.0 mM) in comparison with control (1% BSA) (data not shown). 
These data suggest that the expression of eNOS or iNOS might not be regulated by fatty 
acids, which implies that the upstream signaling pathway in NO formation might be 
affected by high fatty acids.  
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Fig. 29. The expression of eNOS was 
not affected by fatty acids in BAECs 
(A) or HUVECs (B).  Lysates (40 µg 
of protein per lane) from BAECs (A) or 
HUVECs (B) exposed for 5 days (upper 
row) or 10 days (lower row) to control 
(lane 1), 0.25 mM (lane 2), 0.5 (lane 3) 
or 1.0 mM (lane 4) of fatty acids were 
subject to SDS-polyacrylamide gel 
electrophoresis and blotted with a 
monoclonal antibody against eNOS. 




3.2.3. Fatty acids selectively impaired receptor agonist-evoked [Ca2+]i increase in 
endothelial cells  
Since intracellular free Ca2+ level is the most important regulator of eNOS activity, the 
[Ca2+]i profile in endothelial cells cultured with high fatty acids was examined. Bradykinin 
(1 µM) stimulated an increase in [Ca2+]i from 107 ± 26 nM to a peak of 534 ± 67 nM (the 
average of [Ca2+]i rise during 30 s around the peak) in control BAECs (cultured with 1% 
B 
A 
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BSA) (Fig. 30). In cells pretreated with 0.25 mM of fatty acids, the effect of bradykinin on 
[Ca2+]i elevation did not show statistically significant change. The peak of [Ca2+]i was 520 
± 45 nM (n=6, p>0.05) after 5 days culture with 0.25 mM fatty acids. After a 10-day 
culture with 0.25 mM of fatty acids, [Ca2+]i peak was 470 ± 68 nM (n=6, p>0.05), The 
impairments by fatty acids of bradykinin-induced [Ca2+]i rises at the two higher 
concentrations, 0.5 and 1.0 mM, were obvious after 5 days culture, with the peak down to 
431 ± 60 and 341 ± 55 nM, respectively (n=6, p<0.05) (Fig. 30A, C). After a 10-day 
pretreated with fatty acids at these two concentrations, bradykinin-induced increments in 
[Ca2+]i were further decreased to 284 ± 65 nM at 0.5 mM and 253 ± 44 nM at 1.0 mM of 
fatty acids, corresponding to a reduction by 46% and 52% (n=6, P<0.01), respectively (Fig. 
30B, C). Basal [Ca2+]i levels were not affected by fatty acids. 
Fig. 30 Effect of fatty acids on 
bradykinin-induced increases of [Ca2+]i in 
BAECs. Bradykinin (BK; 1 µM)-induced 
increases in [Ca2+]i in BAECs cultured for 5 days 
(A) or 10 days (B) at control (1% BSA), normal 
(0.25 mM) or high (0.5 or 1.0 mM) fatty acids 
concentrations in cell suspensions using the 
fluorescent Ca2+ probe fura-2 as  described in the 
Materials and methods section. Each trace is the 
superposition of 6 experiments. C. The average 
increases in [Ca2+]i during the initial 30 sec of 
bradykinin stimulation. Bar values are means ± 
SEM. ** p<0.01 vs control (t test). Open bars, 5 
days of culture; hatched bars, 10 days of culture. 
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Fig. 31 shows the results when ATP was used as the stimulus under the same culture 
conditions in BAECs. It is clear that sustained culture with high fatty acids exhibited 
similar inhibitory effects on [Ca2+]i rises evoked by receptor agonists, ATP or bradykinin, 
with a little difference in the percentages of the inhibition. At 0.5 and 1.0 mM 
concentrations, fatty acids inhibited ATP induced [Ca2+]i rise by 27% and 32% (n=5, 
P<0.05) after a 5-day treatment. After 10 days culture, the inhibitions were up to 46% and 
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Fig. 31 Effect of fatty acids on 
ATP-induced increases in [Ca2+]i in 
BAECs. ATP (1 µM)-induced increases of 
[Ca2+]i in BAECs cultured for 2, 5 or 10 
days at control (1% BSA), normal (0.25 
mM) or high (0.5 or 1.0 mM) fatty acids 
concentrations in cell suspensions as 
described in Fig 30. The average increases 
in [Ca2+]i during the initial 30 sec of ATP 
stimulation were calculated and statistical 
analyzed.  Bar values are means ± SEM of 
results from 5 experiments. * p<0.05 vs 
control (t test).  
The effects of high fatty acids on [Ca2+]i responses to ATP or bradykinin were also 
examined in HUVECs as shown in Fig. 32. At 0.25 mM, fatty acids did not alter the [Ca2+]i 
increments evoked by either bradykinin (Fig. 32A) or ATP (Fig. 32B) even after 10 days 
culture. However, both 0.5 and 1.0 mM of fatty acids decreased [Ca2+]i rises evoked by 
these two receptor agonists. After 5 days culture under these conditions, [Ca2+]i response to 
bradykinin was inhibited by 36% and 40% (n=5, P<0.01), and by 24% and 30% (n=5, 
P<0.01) in response to ATP. A further degree of inhibition could be observed after a 
10-day culture with high concentrations of fatty acids. [Ca2+]i reactions to bradykinin were 
lessened by 51% and 54% (n=5, P<0.01), and the responses to ATP were reduced by 46% 
and 51 (n=5, P<0.01) at 0.5 and 1.0 mM of fatty acids, respectively. These results and those 
above suggest that reduced NO production by receptor agonists stimulation in high fatty 
acid cultured endothelial cells might be due to a diminished [Ca2+]i response. 
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Fig. 32. Effect of fatty acids on ATP 
(A) or bradykinin (B)-induced 
increases in [Ca2+]i in HUVECs. 
ATP (1 µM) (A) or bradykinin (1 µM) 
(B)-induced increases of [Ca2+]i in 
HUVECs cultured for 2, 5 or 10 days 
at control (1% BSA), normal (0.25 
mM) or high (0.5 or 1.0 mM) fatty 
acids concentrations in cell 
suspensions as  described in the 
Materials and Methods section. The 
average increases in [Ca2+]i during the 
initial 30 sec of ATP or bradykinin 
stimulation were calculated and 
statistical analyzed.  Bar values are 
means ± SEM of results from 5 
experiments. * p<0.05 vs control (t 
test).  
 
However, neither thapsigargin (Fig. 33A) nor ionomycin (Fig. 33B) provoked [Ca2+]i 
rise was affected by fatty acids even after 10 days culture either in BAECs or in HUVECs 
(data not shown). These results demonstrate that receptor agonist-induced NO formation 
was selectively affected by high fatty acids. 
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Fig. 33. Fatty acids had 
no effects on 
thapsigargin (A) or 
ionomycin (B) provoked 
[Ca2+]i rise in BAECs. 
A: Thapsigargin (2 
µM)-induced  increases 
in [Ca2+]i in BAECs 
cultured for 10 days at 
control (1% BSA), 
normal (0.25 mM) or 
high fatty acids (0.5 or 
1.0 mM) concentrations 
of in normal 
extracellular Ca2+ 
concentration buffer. B: 
Ionomycin (2 
µM)-stimulated 
increases in [Ca2+]i in 
BAECs for 10 days at 
control (1% BSA), 
normal (0.25 mM) or 
high fat ty acids (0.5, 
1.0 mM concentrations 
in normal extracellular 
Ca2+ concentration 
buffer.  * p<0.05 vs 
control (t test).  
 
3.2.4. Fatty acids reduced receptor agonist evoked Ca2+ mobilization and Ca2+ influx  
Both aspects of the [Ca2+]i increase promoted by rceptor agonist, Ca2+ mobilization 
from intracellular stores and Ca2+ influx from extracellular space, were significantly 
reduced by 0.5 or 1.0 mM but not by 0.25 mM of fatty acids (Table 5 & Fig. 34). After a 
5-day culture with 0.5 or 1.0 mM of fatty acids, bradykinin-induced Ca2+ mobilization was 
reduced by 19% and 24%, from 325 ± 34 nM down to 263 ± 23 and 246 ± 21 nM (n=7, 
P<0.01), while the Ca2+ influx was reduced by 17% and 30% (n=7, P<0.01), respectively 
(Table 5 & Fig 34A). Further reduction of bradykinin-induced Ca2+ mobilization and Ca2+ 
influx was observed with longer culture time under these conditions. Ca2+ mobilization was 
diminished by 24% and 32% (n=7, P<0.01) and Ca2+ influx was down by 35% and 57% 
(n=7, P<0.01) (Table 5 & Fig. 34B) following a 10-day culture with 0.5 or 1.0 mM of fatty 
acids. 




























































Fig. 34. Effects of fatty acids on 
bradykinin (BK)-stimulated Ca2+ 
mobilization and Ca2+ influx in 
BAECs. Cells were cultured with 
control (1% BSA), normal (0.25 
mM) or high (0.5 or 1.0 mM) 
concentrations of fatty acids for 5 
days (A) or 10 days (B). Bradykinin 
(1 µM)-induced Ca2+ mobilization 
from intracellular stores was 
determined by chelating Ca2+ in the 
extracellular buffer to nominal Ca2+ 
free levels by adding 3 mM of 
EGTA, whereas 
bradykinin-promoted Ca2+ influx 
was detected by restoration of 
extracellular free Ca2+ to the normal 
level by adding 3 mM of Ca2+ to the 
solution. Each trace is the 
superposition of seven experiments 
(t test). 
Table 5. Effects of fatty acid on bradykinin-evoked Ca2+ mobilization and Ca2+ influx 
in BAECs 
Condition 1% BSA 0.25 mM FA 0.5 mM FA 1.0 mM FA 
 [Ca2+]i increase by Ca2+ mobilization (nM) 
2 days 323 ± 33 308 ± 36 301 ± 27 289 ± 34 
5 days 325 ± 34 300 ± 21 263 ± 23* 246 ± 21** 
10 days 311 ± 21 296 ± 26 235 ± 22* 211 ± 24** 
 [Ca2+]i increase by Ca2+ influx (nM) 
2 days 614 ± 58 602 ± 62 588 ± 54 564 ± 47 
5 days 606 ± 61 588 ± 55 505 ± 44* 422 ± 40** 
10 days 626 ± 56 576 ± 48 410 ± 34** 270 ± 32** 
The values in this table are the results from statistical analysis of the data in Fig. 34. Ca2+ mobilization 
was calculated by averaging the increments of [Ca2+]i in the initial 30 s following bradykinin stimulation. 
Ca2+ influx was calculated by averaging the [Ca2+]i overshoots (during the 30 s around the plateau peaks) 
subsequent to Ca2+ restoration. Values are means ± SEM of 7 observations. *P< 0.05, **P< 0.01 vs. 1% BSA. 
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Fig. 35 & Table 6 show that ATP-induced Ca2+ mobilization and Ca2+ influx in 
BAECs were similarly inhibited by culturing with high fatty acids. ATP-elicited Ca2+ 
mobilization was reduced by 22% and 32% (n=7, P<0.01), while the Ca2+ influx was 
reduced by 24% and 41% (n=7, P<0.01) after a 5-day (Fig. 35A) culture with 0.5 or 1.0 
mM of fatty acids, respectively. After a 10-day (Fig. 35B) culture with these two 
concentrations of fatty acids, the Ca2+ mobilization was decreased by 38% and 44% (n=7, 
P<0.01) while the Ca2+ influx was reduced by 38% and 59% (n=7, P<0.01), respectively. 
These data indicate that both Ca2+ mobilization and Ca2+ influx were inhibited by overload 
of fatty acids in BAECs. 
 
Fig. 35. Effects of fatty acids on 
ATP-stimulated Ca2+ mobilization 
and Ca2+ influx in BAECs. Cells were 
cultured with control (1% BSA), 
normal (0.25 mM) or high (0.5 or 1.0 
mM) concentrations of fatty acids for 5 
days (A) or 10 days (B). ATP (1 
µM)-induced Ca2+ mobilization from 
intracellular stores was determined by 
chelating Ca2+ in the extracellular 
buffer to nominal Ca2+ free levels by 
adding 3 mM of EGTA, whereas 
bradykinin-promoted Ca2+ influx was 
detected by restoration of extracellular 
free Ca2+ to the normal level by adding 
3 mM of Ca2+ to the solution. Each 
trace is the superposition of seven 
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Table 6. Effects of fatty acid on ATP-evoked Ca2+ mobilization and Ca2+ influx in 
BAECs 
Condition 1% BSA 0.25 mM FA 0.5 mM FA 1.0 mM FA 
 [Ca2+]i increase by Ca2+ mobilization (nM) 
2 days 403 ± 57 408 ± 39 385 ± 44 328 ± 42 
5 days 414 ± 47 401 ± 31 324 ± 29* 280 ± 30** 
10 days 396 ± 28 390 ± 40 247 ± 26* 221 ± 33** 
 [Ca2+]i increase by Ca2+ influx (nM) 
2 days 644 ± 52 632 ± 57 608 ± 50 594 ± 38 
5 days 646 ± 60 618 ± 53 488 ± 37* 382 ± 36** 
10 days 656 ± 59 616 ± 42 405 ± 42** 266 ± 37** 
 
The values in this table are the results from statistical analysis of the data in Fig. 35. Ca2+ mobilization 
was calculated by averaging the increments of [Ca2+]i in the initial 30 s following ATP stimulation. Ca2+ 
influx was calculated by averaging the [Ca2+]i overshoots (during the 30 s around the plateau peaks) 
subsequent to Ca2+ restoration. Values are means ± SEM of 7 observations. * P< 0.05 vs. 1% BSA. 
Thapsigargin induced [Ca2+]i elevation was not affected by fatty acids as mentioned 
above (cf. Fig. 33). Furthermore, neither Ca2+ mobilization nor Ca2+ influx provoked by 
thapsigargin was impaired in BAECs cultured with fatty acids for up to 10 days (Fig. 36 & 
Table 7). These data indicated that IP3-releasable Ca2+ pool remains intact and thus 
confirmed the hypothesis that fatty acids might selectively impair receptor 

































Fig. 36. Fatty acids impaired 
neither Ca2+ mobilization nor 
Ca2+ influx provoked by 
thapsigargin (TG) in BAECs. 
TG (2 µM)-induced Ca2+ 
mobilization and Ca2+ influx were 
measured in BAECs cultured with 
control (1% BSA) or 0.25, 0.5, 1.0 
mM of fatty acids for 10 days as 
mentioned above. Each trace is the 
superposition of seven 
experiments (t test). 
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Table 7. Effects of fatty acid on thapsigargin-evoked Ca2+ mobilization and Ca2+ 
influx in BAECs 
 
Condition Control 0.25 mM FA 0.5 mM FA 1.0 mM FA 
 [Ca2+]i increase by Ca2+ mobilization (nM) 
5-day 227 ± 36 222 ± 27 216 ± 31  215 ± 33 
10-day 199 ± 23 190 ± 33 182 ± 32 175 ± 34 
 [Ca2+]i increase by Ca2+ influx (nM) 
5-day 321 ± 26 332 ± 32 326 ± 27 314 ± 22 
10-day 328 ± 33 315 ± 21 338 ± 40 325 ± 34 
The values in this table are the results from statistical analysis of the data in Fig. 36. Ca2+ mobilization 
was calculated by averaging the increments of [Ca2+]i in the initial 30 s following thapsigargin stimulation. 
Ca2+ influx was calculated by averaging the [Ca2+]i overshoots (during the 30 s around the plateau peaks) 
subsequent to Ca2+ restoration. Values are means ± SEM of 7 observations. * P< 0.05 vs. 1% BSA. 
3.2.5. The affinity of bradykinin receptor but not its number was affected by fatty 
acids in BAECs 
To test whether the bradykinin receptor was also affected by fatty acids, the number 
and affinity of bradykinin receptor on the cell surface were examined. Fatty acids at 0.25, 
0.5 or 1.0 mM, did not reduce the number of bradykinin receptor in BAECs even after 10 
days culture. The number of bradykinin receptor on cell surface in control cells was 365 ± 
22 fmol/mg of protein; and in cells that had been pretreated with 0.25, 0.5 or 1.0 mM fatty 
acids were 350 ± 17, 350 ± 15, and 340 ± 24 fmol/mg of protein, respectively (n=4, P>0.05 
vs. control). However, 0.5 or 1.0 mM of fatty acids significantly reduced the affinity of 
bradykinin receptor (Fig. 37). Bradykinin receptor affinity in control and 0.25 mM of fatty 
acid-cultured cells was 0.83 ± 0.08 and 0.84 ± 0.09 nmol, respectively (n=4, P>0.05 vs. 
control). In contrast, in cells pretreated with 0.5 or 1.0 mM fatty acids for 10 days, the 
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affinity was 1.21 ± 0.1 and 1.46 ± 0.17 nmol, respectively (n=4, P<0.05 vs. control). 
Therefore, the reduction of NO production and [Ca2+]i elevation in response to stimulation 
by receptor agonists in endothelial cells after culturing with high fatty acids might be in 
part attributable to the reduced receptor affinity.  
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Fig. 37. Effect of fatty 
acids on the affinity of 
bradykinin receptor in 
BAECs. Scatchard plot 
analyses were performed 
by a 
non-linear-curve-fitting 
program (Sigma Plot; 
SPSS, Chicago, Ill., USA) 
to determine the 
dissociation constants of 
bradykinin receptor. Data 
are from four independent 
observations (t test).  
 
3.2.6. Fatty acids have no effect on inositol phospholipids in BAECs 
The decreased [Ca2+]i responses following agonist stimulation in high fatty acid 
cultured endothelial cells could be a consequent of a reduction of substrates for PLC. Thus 
the contents of inositol phospholipids in these cells were measured by TLC 
chromatography as mentioned in the Methods chapter. Culturing BAECs for 10 days with 
0.25, 0.5 or 1.0 mM of fatty acids did not cause significant changes in all three inositol 
phospholipids: PI, PIP and PIP2 (Fig. 38). These findings implicated that fatty acids might 
not alter the lipid substrates of PLC in cell membranes.    





1% BSA       0.25 mM 0.5 mM 1.0 mM FAs Fig. 38. Fatty acids overload have 
no effect on PI, PIP and PIP2 in 
BAECs.  BAECs were cultured 
with control (1% BSA), normal 
(0.25 mM) or high fatty acids (0.5 
and 1.0 mM) for 10 days. After 
labeling with 32P, cell lipids were 
extracted, separated by thin-layer 
chromatography, and 
autoradiographied as described in 
the Materials and Methods chapter. 
Photos are representative of 4 
independent experiments.  
 
3.2.7. Fatty acids changed the morphology of endothelial cells 
The morphology of endothelial cells was modified by fatty acid as shown in Fig. 39 
and Fig. 40. After a 10-day culture, control BAECs grown on culture plates were flat and 
the cell boundary was ambiguous (Fig. 39A). After treatment with 0.25 mM of fatty acids 
the cells were rounding up and the cell boundary became clear. In addition, their density 
was much higher than that of control cells (Fig. 39B), which implied that physiological 
concentration of fatty acids might promote the growth of endothelial cells. However, higher 
concentration of fatty acids, such as 0.5 mM and 1.0 mM, caused the cells to lose their 
normal shiny and smooth surface which became jagged and coarse (Fig. 39C, D). Cells 
cultured with 1.0 mM of fatty acids were also flattened and their boundaries were 
unrecognizable (Fig. 39D).  
 




Fig. 39. Fatty acids changed the 
morphology of BAECs. BAECs 
in coverslip chambers were 
cultured for 10 days (subcultured 
cells at the fifth day from 
seeding) in the following 
condition: 1% BSA (A); 0.25 
mM (B); 0.5 mM (C); and 1.0 
mM (D) of fatty acids. Cell 
morphology was examined under 
differential interference contrast 
(DIC) microscopy. Photos are 
representative of 4 independent 
experiments. 
 
Fig. 40 shows the morphology of HUVECs pretreated without or with different 
concentrations of fatty acids in culture medium for 10 days. The morphological changes in 
HUVECs were similar to that detected in BAECs described above. Exposure to 0.25 mM 
of fatty acids did not induce dramatic alteration, whereas the higher concentrations caused 
remarkable changes in cell shape. These results and those from BAECs indicate that 
pathophysiological concentrations of fatty acids, such as 0.5 and 1.0 mM, might disturb the 





Fig. 40. Fatty acids changed the morphology 
of HUVECs. HUVECs in coverslip chambers 
were cultured for 10 days (subcultured at fifth 
day) in the following condition: 1% BSA (A); 
0.25 mM (B); 0.5 mM (C); and 1.0 mM (D) of 
fatty acids. Cell morphology was examined 
under differential interference contrast 
microscopy. Photos are representative of 4 
independent experiments. 
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3.2.8. Section summary 
This part of work aimed to define the roles of fatty acids in endothelial dysfunction in 
diabetic macrovascular complications. The results indicated that NO production stimulated 
by PLC-activating agonists in endothelial cells was attenuated after a 5-10 day culture with 
high (0.5 or 1.0 mM) concentrations of fatty acids. Such defect was, however, not 
associated with alterations of eNOS or inos mass and inositol phospholipid contents In 
addition, high fatty acids reduced [Ca2+]i increments evoked by these receptor agonists. The 
two components contributing to [Ca2+]i rise, Ca2+ mobilization and Ca2+ influx, were also 
affected. Moreover, bradykinin receptor affinity on the surface of BAECs was decreased by 
high fatty acids. The morphology of BAECs and HUVECs was significantly modified and 
their membrane structures were altered after a 10-day culture with high concentrations of 
fatty acids. However, modest (0.25 mM) fatty acids did not impair agonist-stimulated NO 
formation, [Ca2+]i rise or bradykinin receptor affinity, but might promote endothelial cell 
growth. In contrast, the effects of ionomycin and thapsigargin on NO production and 
[Ca2+]i elevation were not affected by sustained culture with high fatty acids. These data 
indicate that chronic exposure to high concentrations of fatty acids can inhibit NO 
generation in endothelial cells probably by reducing receptor affinity resulting in impaired 
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3.3. Roles of PKC activation and oxidant generation in the impairments 
of NO production and implicated signaling pathways in BAECs exposure 
to elevated concentrations of glucose or fatty acids  
It is known that metabolism of excessive glucose and fatty acids may increase 
diacylglycerol production and thus activate PKC 159,235,236. In addition, the metabolisms of 
excess glucose and fatty acids also increase the formation of oxidants in endothelial cells. 
In order to define the roles of over activated PKC and excessively formed oxidants in the 
above observed alterations in endothelial cells cultured with long-term high glucose or fatty 
acids, this part of study were performed to examine NO production and implicated 
signaling pathways when endothelial cells were co-cultured with cell-permeable PKC 
inhibitors or antioxidants in high glucose or high fatty acids conditioned medium.  
3.3.1. Reduced NO production either by high glucose or fatty acid could be reversed 
by PKC inhibitors or antioxidants 
As shown in Table 8, either a general PKC inhibitor bisindolylmaleimide I (10 µM), 
or a specific PKC-β inhibitor GÖ6976 (20 nM), could ameliorate the impaired NO 
production induced by bradykinin when cells were co-cultured with high glucose. The 
antioxidant N-acetyl–L-cysteine (10 µM) displayed similar recovery effects. 
D-α-tocopherol (vitamin E) (100 µM), an antioxidant but also found to be able to serve as a 
general PKC inhibitor through prevention of diacylglycerol formation presumably by 
activating diacylglycerol kinase 235, could also reverse the reduced NO formation. 
D-α-tocopherol reversed most of the inhibitory effect of high glucose on BAECs after 
either 5 or 10 days culture. During 180 min incubation time with bradykinin, 
D-α-tocopherol restored high glucose reduced NO formation in BAECs by 84% and 80% 
after a 5-day culture, while after a 10-day culture, the reversible effect were 84% and 85% 
at 22.2 mM or 44.4 mM, respectively. Bisindolylmaleimide I improved the diminished NO 
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formation caused by 22.2 or 44.4 mM of glucose by 69%, 60% and 76%, 69% (P<0.05 vs. 
cells with high glucose only) after 5 and 10 days treatment, respectively. This effect could 
also be detected with another PKC inhibitor, GÖ6976, (the corresponding meliorated 
percentages were 60%, 59% and 76%, 67%, respectively) (P<0.05 vs. cells with high 
glucose only). N-acetyl-L-cysteine also reversed the effects of high glucose on NO 
production by 73%, 70% and 77%, 72% (P<0.05 vs. cells with high glucose only) with 5 
and 10 days culture. These data revealed that PKC inhibitors and antioxidants play 
important roles in the impaired endothelial dysfunction caused by high glucose. However, 
it should be noted that the reversible effects of these agents, D-α-tocopherol, 
bisindolylmaleimide, GÖ6976, or N-acetyl-L-cysteine were not in a time-dependent 
manner. For example, the reversible effect of D-α-tocopherol on 22.2 mM of glucose 
reduced NO production after 5 days culture was 84% (within 180 min incubation time with 
bradykinin). However, after 10 days culture the reversible effect was still 84% in the same 
incubation time with bradykinin. In another words, it seemed that these PKC inhibitors and 
antioxidants reached the maximum reversible effects at the fifth day.  These results imply 
that a balance between the activation of PKC/generation of oxidants by high glucose and 
the protecting efforts of those compounds can be reached as early as 5 days co-culture. 
Furthermore, the results revealed that impairment induced by high glucose 
concentrations could not be totally reversed by GÖ6976, N-acetyl-L-cysteine or 
bisindolylmaleimide (Table. 8). For example, a 10-day co-culture of N-acetyl-L-cysteine 
with high glucose could only partially compensate the impaired NO formation during 180 
min incubation stimulated with bradykinin. These data imply that the protective effects of 
these reagents, which act on one target (PKC or oxidants), may not fully antagonize the 
effect of high glucose. On the other hand, D-α-tocopherol wich possesses both anti-PKC 
and antioxidant activities were capable of reversing the total impairment in these 
experiments.  
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Table 8.  PKC inhibitors or antioxidants relieved high glucose-induced inhibition of 
bradykinin-evoked NO production 
 
Co-Treatment (5 days) Condition 
 










 NO production over 90 min (arbitrary unit) 
9.35 ± 0.38 8.97 ± 0.73 8.43 ± 0.86  9.67 ± 0.86 9.22 ± 0.56 
5.10 ± 0.22 a 7.71 ± 0.66 a,b 6.98 ± 0.49 a,b 8.96 ± 0.67 b 7.93 ± 0.52 a,b 
Control 
22.2 mM 
44.4 mM 4.32 ± 0.36 a 7.04 ± 0.49 a,b 6.55 ± 0.55 a,b 8.61 ± 0.90 b 7.38 ± 0.49 a,b 







 NO production over 90 min (arbitrary unit) 
9.28 ± 0.46 8.66 ± 0.47 8.34 ± 0.66  9.55 ± 0.77 9.38 ± 0.47 
4.51 ± 0.36 a 7.60 ± 0.55 b 7.30 ± 0.44 b 8.76 ± 0.57 b 8.12 ± 0.55 b 
Control 
22.2 mM 
44.4 mM 3.63 ± 0.31 a 7.02 ± 0.31 b 6.67 ± 0.45 b 8.69 ± 0.85 b 8.04 ± 0.29 b 
 
BAECs were cultured with indicated concentrations of glucose for 5 or 10 days in the presence or 
absence of PKC inhibitors or antioxidants. Bradykinin-induced NO production was measured as described in 
the Methods section. Values are mean ± SEM of 5 independent experiments. c <0.05 and  a P<0.01 vs. 
individual control;   b <0.01 vs. corresponding glucose concentration with none PKC inhibitor or anoxidant. 
 
When PKC inhibitors or antioxidants were co-treated with high fatty acids (0.5 or 1.0 
mM), the decreased NO production induced by bradykinin was also ameliorated (Table. 9). 
The effects of α-tocopherol were promising and potent. At 5-days in culture, 
bisindolylmaleimide I prevented reduced NO formation due to 0.5 and 1.0 mM of fatty 
acids by 86% and 78% (P<0.05 vs. cells with high fatty acids only), GÖ 6976 reversed 
82% and 73% (P<0.05), and N-acetyl-L-cysteine ameliorated 77% and 75% (P<0.05) in 
BAECs, respectively, during 180 min incubation with bradykinin. Similarly, a 10-day 
culture with N-acetyl-L-cysteine, (82% and 81%); GÖ (88% and 80%) or 
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bisindolylmaleimide I (88% and 81%) (P<0.05 vs. cells with high fatty acids only) also 
relieved the impairment of NO production. These results suggest that activation of PKC or 
formation of oxidants in endothelial cells are implicated in the impaired NO formation in 
response to agonist stimulation after sustained exposure to high glucose or fatty acids.  
Table 9.  PKC inhibitors or antioxidants relieved high fatty acid-induced inhibition 
of bradykinin-evoked NO production 
 












 NO production over 90 min (arbitrary unit) 
7.45 ± 0.22 7.27 ± 0.73 7.12 ± 0.44  7.67 ± 0.89 7.52 ± 0.63 1% BSA  
0.5 mM 5.67 ± 0.96 a 6.89 ± 0.42 b 6.55 ± 0.55 b 7.31 ± 0.49 b 7.04 ± 0.29 b 
1.0 mM 3.84 ± 0.35 c 6.34 ± 0.29 b 6.11 ± 0.34 a, b 6.88 ± 0.66 b 6.61 ± 0.33 b 











 (10 µM) 
 NO production over 90 min (arbitrary unit) 
7.49 ± 0.48 7.21 ± 0.46 7.04 ± 0.64  7.55 ± 0.71 7.44 ± 0.31 1% BSA 
0.5 mM 4.61 ± 0.21 c 6.55 ± 0.28 b 6.11 ± 0.62 b 7.09 ± 0.49 b 6.94 ± 0.52 b 
1.0 mM 3.07 ± 0.31 c 6.13 ± 0.34 a, b 5.99 ± 0.44 a, b 6.72 ± 0.53 b 6.56 ± 0.44 b 
 
BAECs were cultured with indicated concentrations of fatty acids for 5 or 10 days in the presence 
or absence of PKC inhibitors or antioxidants. Bradykinin-induced NO production was measured as 
described in the Methods section. Values are mean ± SEM of 5 independent experiments. a <0.05 and c 
<0.01 vs. individual control; b <0.01 vs. corresponding fatty acids concentration with none PKC inhibitor 
or antioxidant. 
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3.3.2. Decreased [Ca2+]i increment caused by either high glucose or fatty acids 
was meliorated with PKC inhibitors or antioxidant  
Studies were carried out to determine whether the observed reduction of 
agonist-evoked [Ca2+]i rises by high glucose or fatty acids could also be reversed by PKC 
inhibitors or antioxidants, After a 5-day co-culture, bisindolylmaleimide I lessened the high 
glucose effect by 65% and 72% (n=5, P<0.05 vs. cells with high glucose only) (Fig. 41) at 
22.2 and 44.4 mM of glucose, while GÖ 6976 relived the effect of high glucose by 59% 
and 70% (n=5, P<0.01 vs. cells with high glucose only) (Table 10) under the same 
conditions. The protective effects of D-α-tocopherol were more potent, which were up to 
80% and 77% in the case of 22.2 and 44.4 mM of glucose (n=5, P<0.05 vs. cells with high 
glucose only), respectively. Similar effects of these compounds were detected on the 
reduced [Ca2+]i responses to bradykinin after a 10-day culture with 22.2 and 44.4 mM of 
glucose. The respective protective actions were up to 86% and 84% (n=5, P<0.05 vs. cells 
with high glucose only) for bisindolylmaleimide I, 79% and 79% (n=5, P<0.05 vs. cells 
with high glucose only) for GÖ 6976, 60% and 63% (n=5, P<0.05 vs. cells with high 
glucose only) for N-acetyl-L-cysteine, and 83% and 77% (n=5, P<0.05 vs. cells with high 
glucose only) for D-α-tocopherol under the same treatment conditions (Table 10). These 
results suggest that reduced [Ca2+]i responses to bradykinin stimulation in high glucose 
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Fig. 41. Bisindolylmaleimide I 
(Bid) alleviated the 
impairment of high glucose on 
bradykinin-induced [Ca2+]i 
rises in BAECs.  BAECs were 
cultured in control or high 
glucose with 10 µM of Bid for 5 
days. Each trace is the 
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Table 10.  Reversing high glucose-induced inhibition of bradykinin-evoked [Ca2+]i 
rises by PKC inhibitors or antioxidants  
 












 (10 µM) 
 [Ca2+]i (nM) 
Control 533 ± 38 502 ± 36 500 ± 24 540 ± 42  520 ± 53 
22.2 mM 341 ± 28 a 438 ± 25 b 426 ± 31 b 501 ± 33 b   488 ± 49 b 
44.4 mM 231 ± 36 c 422 ± 17 b 414 ± 29 b 470 ± 28 b  447 ± 37 b 
 





 [Ca2+]i (nM) 
Control 530 ± 41  494 ± 23 495 ± 21 546 ± 38 515 ± 36 
22.2 mM 210 ± 28 c  453 ± 27 b  433 ± 30 b 491 ± 27 b  471 ± 22 b 
44.4 mM 174 ± 36 c  441 ± 35 b  424 ± 26 b 463 ± 20 b  436 ± 47 b 
 
BAECs were cultured with various concentrations of glucose for 5 or 10 days in the presence or 
absence of PKC inhibitors or antioxidants. Bradykinin-induced [Ca2+]i rises were determined as described in 
the Methods section. Values are mean ± SEM of 5 independent experiments. a <0.05 and c P<0.01 vs. 
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Fig 42 and Table 11 show the effects of PKC inhibitors and antioxidants on 
bradykinin-induced [Ca2+]i rises when cells were co-cultured with high fatty acids (0.5 or 
1.0 mM) in BAECs. After a 5-day culture, the impaired calcium increments by 0.5 and 1.0 
mM fatty acids were reversed by 75% and 60% (n=5, P<0.05 vs. cells with high fatty acids 
only) by bisindolylmaleimide I, while GÖ 6976 reversed 72% and 49% (n=5, P<0.05 vs. 
cells with high fatty acids only) (Fig. 42 & Table11) under the same conditions. Likewise, 
N-acetyl-L-cysteine meliorated the impairment by 63% and 60% (n=5, P<0.05 vs. cells 
with high fatty acids only), while D-α-tocopherol was able to overturn the reduced [Ca2+]i 
rise by 90% and 88% (n=5, P<0.05 vs. cells with high fatty acids only) in the presence of 
0.5 and 1.0 mM of fatty acids, respectively. In addition, the protective effects of the above 
agents could also be observed after 10 days culture (Table 11). The corresponding 
percentages are 77% and 62% (n=5, P<0.05 vs. cells with high fatty acids only) for 
bisindolylmaleimide-I; 70% and 50% (n=5, P<0.05 vs. cells with high fatty acids only) for 
GÖ 6976; 65% and 63% (n=5, P<0.05 vs. cells with high fatty acids only) for 
N-acetyl-L-cysteine; and 93% and 90% (n=5, P<0.05 vs. cells with high fatty acids only) 
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Fig. 42. PKC inhibitors decreased the 
impairments of [Ca2+]i rises evoked 
by bradykinin in high fatty acids 
cultured BAECs for 5 days.  BAECs 
were cultured with control (1% BSA) 
or 1.0 mM of fatty acids only or 1.0 
mM of fatty acids with D-α-tocopherol 
(VE, 100 µM), bisindolylmaleimide I 
(Bid, 10 µM), or GÖ 6976 (GO, 20 
nM) for 5 days. [Ca2+]i rises were 
detected in the as mentioned 
previously. Each trace is the 
superposition of five independent 
experiments (ANOVA ). 
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Table 11.  Reversing high fatty acid-induced inhibition of bradykinin-evoked [Ca2+]i 
rises by PKC inhibitors or antioxidants 
 












(100 µM)  
N-acetyl-L-cysteine
 (10 µM) 
 [Ca2+]i (nM) 
1% BSA 552 ± 58 522 ± 41 510 ± 28 564 ± 44  533 ± 55 
0.5 mM 399 ± 36 a 498 ± 30 b 486 ± 35 b 522 ± 51 b  504 ± 41 b 
1.0 mM 331 ± 29 c 464 ± 26 b 450 ± 29 b 499 ± 34 b 472 ± 37 b 








(100 µM)  
N-acetyl-L-cysteine
 (10 µM) 
 [Ca2+]i (nM) 
1% BSA 547 ± 51  516 ± 47 504 ± 24 559 ± 32 526 ± 29 
0.5 mM 364 ± 33 c 481 ± 34 b 450 ± 22 b 513 ± 36 b 499 ± 38 b 
1.0 mM 274 ± 37 c  452 ± 20 b 437 ± 39 b 500 ± 45 b 474 ± 42 b 
 
BAECs were cultured with various concentrations of fatty acids for 5 or 10 days in the presence or 
absence of PKC inhibitors or antioxidants. Bradykinin-induced [Ca2+]i rises were determined as described in 
the Methods section. Values are mean ± SEM of 5 independent experiments. a <0.05 and c P<0.01 vs. 




3.3.3. D-α-tocopherol and bisindolylmaleimide I reverses the defected effects of high 
glucose and fatty acids on bradykinin receptor 
Ten days co-culture with D-α-tocopherol or bisindolylmaleimide I also reversed the 
reduced bradykinin receptor number in high glucose cultured BAECs (Table 12). The 
receptor number in control cells was 371 ± 18 fmol/mg of protein, and in cells cultured 
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with 22.2 and 44.4 mM of glucose for 10 days were and 264 ± 14 and 224 ± 29 fmol/mg of 
protein (n=5, P>0.05 vs. control), respectively. When co-cultured with D-α-tocopherol, the 
densities of bradykinin receptor were reversed by 92% and 90% accordingly when 
compared with the number of control cells (P>0.05 vs. control, P<0.05 vs. cells with high 
glucose only). Bisindolylmaleimide I reversed the receptor density by 89.6% and 86% 
(P>0.05 vs. control, P<0.05 vs. cells with high glucose only) respectively, while the affinity 
of the receptor remained unaltered. 










 Bradykinin receptor number (pmol/mg protein) 
Control 371 ± 18 336 ± 22  370 ± 28 
22.2 mM 264 ± 14 a 301 ± 26 b  341 ± 12 b  
44.4 mM 224 ± 29 a 288 ± 14 a, b  334 ± 21 a, b  
 
BAECs were cultured with indicated concentrations of glucose for 10 days in the presence or 
absence of PKC inhibitors. The number of bradykinin receptor was assessed as described in the 
Methods section. Values are mean ± SEM of 5 independent experiments.  a P<0.01 vs. individual 
control;  b <0.01 vs. corresponding glucose concentration with none PKC inhibitor. 
 
When BAECs were exposure to high fatty acids for 10 days, the affinity of bradykinin 
receptors (Kd) was significantly decreased from 0.77 ± 0.08 nM in control cells to 1.34 ± 
0.22 and 1.46 ± 0.16 nM (n=5, P<0.05 vs. control) in the presence of 0.5 and 1.0 mM of 
fatty acids, respectively (Table 13). Bisindolylmaleimide I and D-α-tocopherol were able to 
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bring the reduced bradykinin receptor affinity to near normal levels, without affecting the 
total receptor numbers (Table. 13).  
Table 13. PKC inhibitors prevent high fatty acid-induced reduction of the affinity (Kd) 
of bradykinin receptor in BAECs 
 
Condition 






 Bradykinin receptor affinity (nM) 
1% BSA 0.77 ± 0.08 0.80 ±  0.15   0.75 ± 0.12 
0.25 mM 0.79 ± 0.09 0.84 ± 0.14 0.76 ± 0.11 
0.5 mM 1.34 ± 0.22 a 0.88 ± 0.13 b  0.80 ± 0.12 b  
1.0 mM 1.46 ± 0.16 a 0.90 ± 0.17 b  0.81 ± 0.21 b  
 
BAECs were cultured with indicated concentrations of fatty acids for 10 days in the presence or 
absence of PKC inhibitors. The affinity of bradykinin receptor was assessed as described in the Methods 
chapter. Values are mean ± SEM of 5 independent experiments. a P<0.01 vs. individual control;  b <0.01 vs. 
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3.3.4. D-α-tocopherol protected BAECs from morphology changes induced by fatty 
acid overload 
Sustained exposure of BAECs to high fatty acids led to remarkable changes in the 
morphology of these cells (cf. Fig. 39). Fig. 43 shows the morphology of BAECs after 10 
days co-culture with D-α-tocopherol and various concentrations of fatty acids. The results 
clearly demonstrated that the appearance of jagged and coarse cell surface caused by high 
fatty acid treatment disappeared in the presence of D-α-tocopherol. Furthermore, the 
morphology of BAECs returned to normal after co-culture with D-α-tocopherol. This 
finding suggests that activation of PKC plays a role in the morphological changes of 
BAECs exposed to high concentrations of fatty acids.    
Fig. 43. D-α-tocopherol restored the 
morphological changes induced by 
fatty acids in BAECs for 10 days. 
BAECs were cultured with control 
(1% BSA) (A) or 0.25 (B), 0.5 (C), 1.0 
mM (D) of fatty acids in the presence 
of 100 µM D-α-tocopherol for 10 days. 
Photos are representative of 4 
independent experiments. 
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3.3.5. Section summary 
The results from co-culturing with PKC inhibitors (bisindolylmaleimide I, GÖ6976 
and (D-α-tocopherol) and antioxidants (D-α-tocopherol and N-acetyl-L-cysteine) revealed 
that these compounds were able to reverse the impairments of receptor agonist-induced NO 
production and [Ca2+]i rises, as well as the alteration of receptor number and affinity in 
BAECs exposed to pathological concentrations of glucose and fatty acids. Furthermore, 
D-α-tocopherol could also prevent the morphological changes and protect the plasma 
membrane of BAECs from disturbance by high fatty acids. These data suggest that 
excessive activation of PKC-β and enhanced production of oxidants play an important role 
in the development of dysfunctional endothelium, in particular in the agonist-induced NO 












4.1. Hyperglycemia and NO signaling transduction pathway 
Numerous studies have reported that hyperglycemia or high glucose treatment 
attenuates endothelium-dependent vasodilation mediated by NO following stimulation by 
PLC-activating receptor agonists 26, 64, 123, 150, 234, 235. It has been speculated that chronic 
exposure to high concentrations of glucose would cause the impairment of NO release 
and/or the increased destruction of released NO 59, 64, 236. However, little information 
exists regarding the mechanism by which high glucose alters intracellular signal 
transduction pathways involved in NO production in vascular endothelium. The current 
study has provided strong evidence that the signaling pathway involved in NO production, 
i.e. agonist receptor-IP3-Ca2+-eNOS cascade, is impaired in endothelial cells exposure to 
prolonged high concentrations of glucose in a time- and dose-dependent manner. 
Furthermore, these alterations are probably due to a reduction of the number of receptors 
on the surface of endothelial cells resulting in attenuated PLC activation and subsequent 
[Ca2+]i responses, without a decrease in PLC substrates.  
4.1.1. High glucose and NO production in endothelial cells 
Our data revealed that reduction in NO formation in the presence of high glucose is 
specific to the PLC-activating receptor agonists such as bradykinin and ATP (Fig. 1, 2, 3, 
4 & 5), without impeding the action of Ca2+ ionophore (Fig. 1B & 2B). This indicates that 
the step(s) in the signal transduction pathway between stimulation of receptors and 
activation of eNOS may be affected by high glucose. These findings are in concord with 
the observations in both in vitro and in vivo studies of diabetic animals and patients, in 
which the impaired endothelium-dependent vasodilation occurred only after stimulation 
with receptor agonists such acetylcholine, but not following the application of NO donors 
or Ca2+ ionophores 32, 33, 123, 133, 149, 150, 234. Thus a deficiency in NO, rather than a change 
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in the sensitivity of vascular smooth muscles to NO, contributes to the impaired 
endothelium-dependent vasodilation in diabetes. Such decreased bioavailability of 
endothelial NO appears to be caused primarily by reduced NO synthesis and/or increased 
NO degradation. The results from the present study have demonstrated that sustained 
treatment with high glucose is able to inhibit NO production in endothelial cells. 
4.1.2. eNOS activity and its major regulator – intracellular free Ca2+  
NO synthase was first described in 1987, and three distinct isoforms have since been 
identified. These isoforms were traditionally classified on the basis of their constitutive 
(eNOS and nNOS) versus inducible (iNOS) expression, their different distribution, and 
their calcium-dependence (eNOS and nNOS) or -independence (iNOS). However, such 
distinctions now appear to be far less straightforward.  It is known that gene expression 
of both eNOS and nNOS may be induced under different physiological conditions (e.g. 
hemodynamic shear stress, nerve injury, cytokines and sex hormones) 52. On the other 
hand, iNOS may function as a constitutive enzyme under certain physiological conditions 
in some cells 237.  
Therefore, in this study, the reduction of bradykinin-elicited NO production in 
endothelial cells exposed to high glucose could be due to a decrease of eNOS mass and/or 
an attenuation in the activation of eNOS. However, two lines of evidence may rule out the 
former possibility. First, exposure to high glucose up to either 5 or 10 days did not alter 
eNOS mass in both cultured BAECs (cf. Fig 6) and HUVECs (cf. Fig 7). Second, the 
potency of ionomycin (which supplied sufficient calcium concentration to activate eNOS) 
to stimulate NO generation remained unaffected in BAECs treated with high glucose (cf. 
Fig. 1 & Fig. 2). Thus our results point to an impairment in the activation of eNOS in 
endothelial cells following protracted high glucose culture.  
It should be noted that Cosentino et al reported an increment of eNOS gene 
expression, eNOS mass and NO release after incubation of human endothelium with high 
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glucose (22.2 mM) for 5 days 59. However, other studies indicated a decreased in eNOS at 
the protein level and diminished eNOS activity in endothelial cells after 2-week culture 
with high glucose (22 mM) 62, 191, 236, 238, 239. Results from the current study and also from 
other laboratories 63, 240 failed to detect any significant difference in eNOS expression in 
the presence of high glucose. The underlying reason for the discrepancies among these 
studies is unclear, but might be due to the different culture methods used. The present 
study and the one conducted by Weidig et al 240were carried out in a medium containing 
2% serum during high glucose culture, while some investigations mentioned above were 
conducted using higher concentration of serum (10%) in the medium along with high 
glucose. On the other hand, high glucose also failed to alter the expression of iNOS, 
which is constitutively expressed in endothelial cells at very low level (Fig. 8A & 8B). 
This observation was supported by other studies 240, 241, which found that hyperglycemia 
did not alter eNOS or iNOS protein expression.  
Although the basal activity of eNOS is Ca2+-independent in endothelial cells 242, an 
increase in [Ca2+]i is the essential signal for maximum activation of eNOS by receptor 
ligands (whose release in blood vessels may be regulated by the neural system). In this 
model, activation of eNOS ensues the stimulation of cell surface receptors which activate 
G-protein-coupled PLC, resulting in an increase in [Ca2+]i by mobilizing intracellular 
Ca2+ stores and promoting Ca2+ entry 65-67, 69, 70, 177. Bradykinin and ATP represent two 
important agonists for eNOS activation in the vascular endothelium; they bind to and 
stimulate Ca2+-mobilizing receptors, leading to vaso-relaxation.  
Although the experiments carried out in cell-free systems indicated the importance 
of Ca2+ for eNOS activation, the extent of the role of Ca2+ in eNOS activation by 
PLC-stimulating agonists in the intact cells is uncertain due to the lack of sensitive 
methods to detect NO in living cells. The invention of the novel fluorescent NO probes 
such as DAF-2/DA 243, which can be easily loaded into cells, made it possible to monitor 
the NO formation in living cells and study the relationship between [Ca2+]i levels and NO 
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production. Using various concentration of ionomycin to set [Ca2+]i at different levels 
(Fig. 9A), it was observed that the amount of NO production was well correlated with the 
peak level of [Ca2+]i (Fig. 9B & 9C). A close association of the extent of increase in 
endothelial [Ca2+]i with agonist-evoked relaxation was also found in rabbit aortic valve 244. 
Importantly, when extracellular free Ca2+ level was lowered by a Ca2+ chelator, 
bradykinin-stimulated NO generation was almost completely abolished, whereas 
restoration of extracellular free Ca2+ to the normal level restored eNOS activity (cf. Fig. 
10). These findings strongly indicate that activation of eNOS by PLC-coupled receptor 
agonists such as bradykinin is dependent on an increase of [Ca2+]i and, consequently, a 
change in [Ca2+]i level by the agonists may lead to an alteration in NO formation.  
Results from this study showed that ligands such as bradykinin and ATP could 
elevate [Ca2+]i in endothelial cells to 400-800 nM from a basal level of 50-100 nM, which 
coincided with the studies by other researchers 245-247. A [Ca2+]i peak was reached within 
20-30 s after stimulating with bradykinin or ATP, followed by a plateau phase that 
persisted for a few minutes (Figs. 11-13). A few studies from other researchers have 
revealed impaired, unaltered or even enhanced [Ca2+]i concentration in response to 
stimulation by receptor agonist in endothelial cells cultured at high concentrations of 
glucose for a short period (from a couple of hours to 24 h) 141, 151, 248. In the present study, 
however, two-day culture in high glucose (22.2 or 44.4 mmol/l) did not affect 
bradykinin-evoked [Ca2+]i increases in endothelial cells (data not shown). Since the 
development of dysfunctional vascular endothelium in diabetic subjects involves a 
chronic exposure to high glucose environments, it is thus more relevant to culture 
endothelial cells for a longer period to identify any significant changes. However, few 
studies have been preformed in this regard. For this reason, the current study has 
conducted thorough experiments to examine the effects of chronic high glucose culture (5 
or 10 days) on [Ca2+]i homeostasis in endothelial cells. The data from these experiments 
demonstrated that bradykinin- or ATP-stimulated intracellular Ca2+ profiles in high 
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glucose-cultured endothelial cells were attenuated in a time- and dose-dependent manner 
(Figs. 11-14). The only documented study on the long-term effects of high glucose on 
[Ca2+]i in endothelial cells also reported that 3-6 days of culture with high glucose 
inhibited [Ca2+]i rises evoked by PLC-activating agonists in porcine aortic endothelial 
cells 144. 
It is well known that PLC-activating agonist-evoked [Ca2+]i increase in endothelial 
cells is a result of both IP3-mediated Ca2+ release from intracellular Ca2+ stores and 
stimulated capacitative Ca2+ entry from extracellular space 66, 67, 177, 249, revealing a pattern 
with an initial [Ca2+]i peak (largely due to Ca2+ release from intracellular Ca2+ stores via 
IP3-operated Ca2+ channels) and a protracted [Ca2+]i elevation (mainly due to Ca2+ influx 
from extracellular space) (cf. Figs. 11-13). This study was able to observe these two 
events separately and demonstrated that both Ca2+ mobilization and Ca2+ influx induced 
by bradykinin or ATP were clearly affected by high glucose culture in a dose- and 
time-dependent manner (Figs. 16-19 and Tables 1-4).  
When endothelial cells were stimulated by receptor agonists such as bradykinin and 
ATP, intracellular Ca2+ stores were depleted in Ca2+-free solution. Exposure to 
extracellular Ca2+ again caused a typical biphasic increase of [Ca2+]i due to Ca2+ entry, i.e., 
a big overshoot followed by a lower plateau of [Ca2+]i (Figs. 16-19). It is generally 
accepted that agonist-promoted Ca2+ entry is attributed to the depletion of IP3-sensitive 
Ca2+ stores and this type of Ca2+ entry is thus called store-operated Ca2+ influx, or 
capacitative Ca2+ entry 177, 249, although the nature of the underlying molecular 
mechanism remains unclear 177, 250, 251. Capacitative Ca2+ entry not only enables depleted 
Ca2+ stores to be refilled, but also provides the source of Ca2+ for Ca2+-dependent 
processes and for the maintenance of cellular Ca2+ homeostasis. During prolonged agonist 
stimulation, the observed steady-state level of elevated [Ca2+]i reflects a balance between 
sustained Ca2+ entry from extracellular space and Ca2+ clearance from the cytoplasmic 
compartment. Because of the lack of other significant Ca2+ permeable ion channels in 
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endothelial cells, such as voltage-dependent Ca2+ channels, capacitative Ca2+ entry is 
believed to be the predominant avenue of Ca2+ entry in these cells. 
Literature has reported that both Ca2+ mobilization and Ca2+ influx are important for 
eNOS activation by agonists. Ca2+ release from intracellular stores was required for the 
activation of eNOS by stimulation of flow and agonists in aorta 70. The current study (cf. 
Fig. 10) found that sustained eNOS activation in endothelial cells by agonists required 
Ca2+ influx from extracellular space. When the extracellular Ca2+ concentration was 
reduced to the nominal Ca2+ free level, NO formation was much less than with normal 
extracellular Ca2+ concentration. These findings were supported by studies from other 
researchers 252-257. For example, Lantoine et al reported that the amount of NO released 
was closely associated with Ca2+ entry in histamine-stimulated human endothelial cells 254. 
It has also been demonstrate that NO production was triggered by Ca2+ entry from the 
extracellular space but not by Ca2+ release from store sites 254, since no significant NO 
release was detectable in the absence of a transmembrane Ca2+ gradient, despite the 
marked Ca2+ peak induced by histamine. Results from the current study (cf. Fig. 10) also 
revealed that Ca2+ entry from the extracellular space is necessary to maintain NO 
production, as NO production was reduced significantly when extracellular Ca2+ was 
chelated. These data suggest that the attenuation of capacitative Ca2+ entry may be the 
most critical event contributing to the inhibition of NO production in endothelial cells 
after chronic high glucose culture.  
However, Ca2+ mobilization also seems to be essential for the activation of eNOS. 
As mentioned above, extracellular Ca2+ enters the cell via store-operated cation channels, 
which are activated by depletion of the intracellular Ca2+ stores 258, 259. The initial force 
for the capacitative Ca2+ entry is Ca2+ mobilization (depletion) from IP3 sensitive Ca2+ 
stores. It was reported that IP3 normally releases 50% of the Ca2+ stored in the 
endoplasmic reticulum pool. At a concentration of bradykinin that causes maximum NO 
release only approximately 65% of the available intracellular Ca2+ has been mobilized. 
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The remaining Ca2+ can be released by Ca2+ ionophores 260-262. Because intracellular Ca2+ 
store depletion regulates the activity of the capacitative Ca2+ entry pathways in 
endothelial cells, one might speculate that the effect of high glucose on capacitative Ca2+ 
entry is due to an alteration in the depletion of Ca2+ pools and not an impairment of 
capacitative Ca2+ entry per se. On the other hand, a change in the total releasable Ca2+ 
pools might also be the reason for the reduction of capacitative Ca2+ entry by long-term 
glucose overload. Nonetheless, the data in this study ruled out such possibility, as [Ca2+]i 
elevation by ionomycin was not affected in this case (cf. Fig. 15), indicating intact total 
releasable [Ca2+]i pools. In addition, thapsigargin (a selective inhibitor of Ca2+-ATPase on 
IP3-sensitive Ca2+ stores) induced [Ca2+]i rises in high glucose-cultured endothelial cells 
remained normal (cf. Fig. 20), suggesting that chronic high glucose culture did not alter 
the IP3-releasable Ca2+ stores. Therefore, an impairment of capacitative Ca2+ entry or 
reduction of the force for capacitative Ca2+ entry (e.g. IP3 decrease) might be the 
underlying mechanisms for the decreased ability of PLC-activating agonists to elevate 
[Ca2+]i in endothelial cells.  
4.1.3. Agonist receptor and IP3, the upstream signaling pathway for NO production 
in endothelial cells  
IP3 and its receptors are central to the generation of [Ca2+]i increase (Ca2+ 
mobilization and capacitative Ca2+ entry) following stimulation by PLC-activating 
receptor agonists. IP3 is generated from hydrolysis of PIP2 by PLC activation and diffuses 
into the cytosol and binds to its receptor located in the membrane of intracellular Ca2+ 
stores, resulting in a rapid Ca2+ release and increase in cytosolic Ca2+ levels. Although it 
is clear that both IP3 and Ca2+ are required for IP3 channel opening, the channel is 
effectively gated by IP3 263. There is also persuasive evidence that calmodulin inhibits IP3 
receptor function 264, 265. However, no study has reported that high glucose increases the 
expression of calmodulin in endothelial cells. Moreover, there is no evidence that high 
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glucose affects the expression or the function of IP3 receptor. Therefore, current study 
examined the effect of high glucose culture on IP3, the most important trigger for Ca2+ 
release from Ca2+ pools in endothelial cells.  
In permeabilized cells, an addition of IP3 at non-saturating concentrations leads to 
the release of a fraction of the IP3-sensitive Ca2+ pool. The amount of Ca2+ released 
depends on the concentration of IP3 added. Results from the present study revealed that 
high glucose culture attenuated both basal and bradykinin-stimulated IP3 production in 
endothelial cells (cf. Fig. 22). This finding suggests that the impaired agonist-promoted 
Ca2+ increases might be mainly due to reduced Ca2+ release from intracellular Ca2+ stores 
because of decreased IP3 formation, which in turn also diminished Ca2+ entry. It should be 
noted that a decline in basal IP3 levels occurred in endothelial cells following high 
glucose culture (Fig. 21), suggesting that PLC is under some significant inhibitory 
influence (such as PKC) even in the non-stimulating situation.  
However, the alterations of IP3 generation following chronic high glucose culture 
(Fig. 21) are apparently not due to a reduction of inositol phospholipids, the PLC 
substrates (Fig. 22), as the contents of PI, PIP or PIP2 in endothelial cells were not 
impaired by 10-days high glucose culture. This observation suggested that the reduced IP3 
production could be a defect at any other level in the coupling of receptor, G-protein, and 
PLC.  
Data from the current study demonstrated for the first time that a decrease in the 
number of PLC-activating receptors occurred in endothelial cells following long-term 
exposure to high glucose (cf. Fig. 23), which might be the cause for the impaired 
signaling pathway for NO production. Importantly, such a reduction in the number of 
receptor may affect agonist-induced responses/function in cells, leading to the observed 
impairments of [Ca2+]i responses and NO production upon bradykinin stimulation. 
Bradykinin executes its effects via the selective bind to its type B1 and/or type B2 
receptors. The B2 receptor is constitutively expressed and mediates the majority of the 
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acute vascular actions of bradykinin 266. In contrast, the B1 receptor is generally absent 
from vascular endothelial cells but may be induced following an inflammatory insult. Our 
data indicated that glucose might not be an inducer of B1 receptor expression in 
endothelial cells, as only one type of receptor was detected in our experiments (Fig. 23).  
Bradykinin B2 receptor is coupled through G proteins to the activation of 
phospholipase C, leading to the transient increase in [Ca2+]i characteristic of the 
physiological response to bradykinin. The total number of receptors often limits the 
maximal effect an agonist may produce. The sensitivity of a cell or tissue to a particular 
concentration of agonist may depend not only on the affinity of the receptor for binding 
an agonist (characterized by Kd) but also on the total number of receptors. Since 
receptors initiate a cascade of catalytic biochemical reactions, the response may be 
amplified up to 106 fold. Therefore, a change in the number of receptors may alter the 
downstream responses dramatically and explain the impaired cascade responses (IP3 
generation, [Ca2+]i elevation and NO formation) in endothelial cells after high glucose 
culture in the present study.  
In fact, it has been reported that the expression of bradykinin B2 receptor could be 
regulated by high glucose or activation of PKC. Acute high glucose (a few min to 24 h) 
caused an increment of B2-kinin receptor number in the aorta of diabetic rats and vascular 
smooth muscle cells 267, 268. The mRNA levels of B2-kinin receptor were also 
significantly increased by high glucose as early as 4 h.  However, data in the current 
study showed 22-32% decrease in bradykinin receptor number during high glucose 
culture, which might be sufficient to affect the downstream signaling cascade. This 
discrepancy might be attributable to the different outcomes in the progress of endothelial 
dysfunction when exposed to high glucose at early and late stages.  It is well known that 
distinct responses occur in endothelial cells when they are treated by short- and long-term 
high glucose, and the changes in endothelium function at the early stage of diabetes are 
also different from that at the late stage, as described in more details in Chapter one.  
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Some studies have been conducted to clarify the underlying mechanisms for the 
changes in bradykinin receptor number induced by high glucose. For example, activation 
of PKC by a 5-min pretreatment with TPA impaired bradykinin-induced formation of IP3 
and this appeared to be a direct effect on the bradykinin receptor 69. In such a situation, 
the number of available receptors was reduced by 30%, which was in parallel with the 
activation of PKC and proportionally impaired IP3 release. Because the diminished IP3 
response occurred after one minute, the internalization of the receptor by PKC seemed to 
be the most reasonable explanation.  
4.2. Fatty acids and signal transduction for NO production in 
endothelial cells 
Dyslipidemia represents a major risk factor for development of vascular dysfunction. 
Although literature has implicated fatty acid overload in many human vascular diseases, 
the mechanisms involved in the development of vascular dysfunction remain unsolved. In 
diabetes, dyslipidemia might be another important contributor to the macrovascular 
complications, in addition to hyperglycemia. Thus, the present study was also designed to 
elucidate the effects of long-term fatty acids in cultured endothelial cells.  
Oleic acid and palmitic acid were chosen to represent the major components of 
triglyceride-derived free fatty acids in this study for the following reasons. First, these 
two fatty acids are the most abundant in human plasma and their concentrations are 
higher in diabetic patients than in normal individuals 171, 269. Second, these two fatty acids 
affect several membrane transport and intracellular signaling events linked to vascular 
function 250. Third, palmitic acid and oleic acid are the predominant fatty acids that are 
incorporated into DAG from both the de novo synthesis pathway and the metabolism of 
PC 269, 270. Furthermore, palmitic acid and oleic acid are long chain fatty acids containing 
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an amphiphile molecule with detergent like effect and may easily penetrate into and 
damage the endothelium. Finally, it was reported that palmitate or oleate significantly 
increases the total DAG level in a time- and dose-dependent manner 271. Therefore, it is 
reasonable to speculate that palmitic acid and oleic acid may be the two most important 
fatty acids from triglyceride, and they might play major roles in the fatty acid-induced 
endothelial dysfunction. Three different concentrations of the mixed fatty acids were used: 
0.25 mM (which is within the physiological range to detect the roles of fatty acids in 
maintaining the normal function of endothelial cells), 0.5 and 1 mM (which are 
pathologically high levels). 
4.2.1. Fatty acids and NO formation  
It has been reported that oleic acid affected NOS activity in cultured endothelial cells 
and impaired endothelium-dependent relaxation in vascular rings 171. Our data indicated 
that long term treatment with high (0.5-1 mM) fatty acids specifically reduced 
agonist-induced NO production (cf. Fig. 24 through 28), which may contribute to the 
impaired endothelial-dependent vascular relaxation commonly observed in other in vivo 
studies in diabetic patients 167, 172. Such disturbance of agonist-evoked NO formation by 
high fatty acids in endothelial cells may result from several possible alterations: 1) a lack 
of the substrate for NO synthesis, L-arginine, or cofactors such as BH4; 2) reduced 
expression of NO formation enzyme, eNOS, in endothelial cells; 3) an increase in 
endogenous inhibitors of this enzyme; and 4) an impairment in the step(s) of 
agonist-receptor-PLC-Ca2+-eNOS signaling cascade. Furthermore, reduced bioavailability 
of NO can be caused by increased inactivation of NO as a result of increased production 
of reactive oxygen radicals such as superoxide anion. However, Fig 28 showed that NO 
formation induced by ionomycin, which bypasses the processes from agonist receptor to 
PLC activation to IP3 generation, was not affected by fatty acids. These results excluded 
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the possibility of lack of substrates or cofactors for NO synthesis. And the results from 
ionomycin also did not imply an increase in endogenous inhibitors of eNOS or the 
restriction of the maximum activity of eNOS by high fatty acids. In addition, the mass of 
the enzymes (eNOS or iNOS) themselves was not altered by high fatty acids (Fig. 29; and 
data not shown for iNOS). Therefore, this study investigated the possible alterations in 
the upstream events of the agonist-receptor-PLC- Ca2+-eNOS signaling pathway.  
Similar to the observations in the current experiments, other studies also could not 
demonstrate the regulatory role of fatty acids in the expression of eNOS or iNOS at the 
protein level 166, 168, 169, 171, 179. eNOS is targeted to the cell membrane and the enzyme’s 
intracellular distribution is dynamically regulated by Ca2+-mobilizing agonists in vascular 
endothelial cells, as discussed in detail in Chapter One. eNOS is a 
Ca2+-calmodulin-dependent enzyme and is activated by an increase in [Ca2+]i, following 
the stimulation of diverse G protein-coupled receptors in endothelial cells. In resting 
endothelial cells, eNOS is tonically inhibited by protein-protein interactions with caveolin. 
In response to Ca2+-mobilizing agonists, calmodulin promotes the dissociation of caveolin 
from eNOS and directly activates the enzyme. Therefore, agonist-induced [Ca2+]i, 
elevation, which is the major regulator of eNOS activation, was intensively studied.   
4.2.2. Fatty acids and [Ca2+]i rise 
Agonist-induced [Ca2+]i rise in endothelial cells was significantly reduced after 
long-term treatment with high fatty acids as shown in Fig. 30-32. Interestingly, such 
effect was an agonist specific phenomenon, since [Ca2+]i rises stimulated by calcium 
ionophore, ionomycin (Fig 33B), or thapsigargin (Fig 33A), were not affected. These 
results indicated that the releasable Ca2+ pools were intact in high fatty acid-cultured 
endothelial cells, and the decreased NO formation induced by agonist might be due to 
impaired signal transduction resulting in reduced [Ca2+]i increment. Some researchers 
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reported that even very short-term culture (a couple of minutes) with fatty acids could 
also inhibit the NO production and [Ca2+]i rise in endothelial cells 172, 179. However, 
current study failed to detect significant effects of fatty acids on NO production or 
agonists-induced [Ca2+]i rises in endothelial cells after a 2-day culture (cf. Fig. 30-32). 
The reason for the different observations is unclear, but it might relate to the duration of 
fatty acid culture. As discussed in Chapter One, the triphasic response of increased, 
unaltered and impaired endothelium-dependent relaxation was observed in diabetic 
animal models, depending on the duration of diabetes 149. A 2-day culture period might 
not induce altered NO formation and [Ca2+]i rises in endotehlial cells in vitro because in 
vivo studies have demonstrated that high fatty acids could alter NO formation after 1 and 
2 weeks and there was no alteration of NO before that time point 144, 149-154.  
The data from this study (cf. Fig. 30-32) also showed that only pathophysiological 
concentrations of fatty acids (0.5 or 1.0 mM) impaired agonist-induced [Ca2+]i rises, 
while a physiological concentrations of fatty acid, such as 0.25 mM, did not affect 
agonist-induced [Ca2+]i increment in endothelial cells. These observations are compatible 
with the results from experiments on NO formation. 
Despite the clear reduction in bradykinin-induced [Ca2+]i elevation in the presence of 
extracellular Ca2+, a more detailed analysis of the correlation between fatty acid 
overloading and [Ca2+]i rises in endothelial cells revealed that a moderate decrease in 
intracellular Ca2+ release occurred upon bradykinin stimulation, whereas capacitative 
Ca2+ entry, which was visualized by restoring extracellular Ca2+ to the normal level, was 
strongly reduced (Figs. 34 & 35 and Tables 5 & 6). However, intracellular Ca2+ release 
induced by thapsigargin (Fig 33A), which depletes endoplasmic reticulum independently 
of IP3, was intact in high fatty acid-cultured cells. Furthermore, thapsigargin-triggered 
capacitative Ca2+ entry (Fig. 36 and Table 7) was also not inhibited by fatty acid overload. 
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These data imply an undamaged intracellular Ca2+ pool and the normal ability of the pool 
to release Ca2+ in cells treated with fatty acids.    
It should be noted that Yokoyama et al 177 reported that a very short-term (5 min) 
treatment with fatty acids inhibited Ca2+ mobilization and NO release induced by ATP in 
BAECs. However, Graier et al reported that a couple of hours treatment with fatty acids 
enhanced intracellular Ca2+ release in response to ATP, histamine or thapsigargin in 
endothelial cells 179. They explained that the enhanced intracellular Ca2+ release was 
probably due to an overall increase in intracellularly stored Ca2+. On the other hand, the 
same study also found that capacitative Ca2+ entry was strongly inhibited. The reasons 
accounting for the different results between the current study and those mentioned above 
might be the different fatty acids used and, more relevant, the durations of treatment with 
fatty acids. Different biochemical mechanisms may be involved in the acute and chronic 
action of fatty acids, as discussed above. 
4.2.3. Agonist receptor and the upstream signaling pathway for NO formation in 
fatty acid treated endothelial cells  
Little work was conducted to examine the effects of long-term fatty acid exposure on 
agonist-induced NO production and thus no hypothesis is available for the underlying 
mechanisms. However, a few of pioneer short-term investigations have been done to 
disclose the reasons for the inhibitory effects of fatty acids on NO formation. For example, 
Davda et al reported that short-term (15 to 60 min) culture in oleic acid induced a 
concentration-dependent reduction of eNOS activity in BAECs stimulated with ATP 171. 
They proposed that such an inhibitory effect of oleic acid on eNOS activity resulted from 
a reduction of the concentration or effect of intracellular Ca2+. They also demonstrated 
that oleic acid reduced eNOS activity stimulated with ionomycin. The latter observation 
is, however, conflicting with studies by other researchers 272, 273, which demonstrated that 
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ionomycin-induced eNOS activity was not affected. The possible reason for these 
discrepancies is not clear. However, these mechanisms for the acute effects of fatty acids 
might be quite different from that of long term effects.  
In the current study, long-term culture with high free fatty acids specifically 
impaired agonist-induced [Ca2+]i rise and NO production without altering the eNOS mass. 
In addition, [Ca2+]i rise and NO formation induced by non-agonists such as ionomycin 
and thapsigargin were not affected. These data suggested that early step(s) prior to [Ca2+]i 
elevation in the signaling pathway for agonists-stimulated NO formation may be impaired 
by fatty acids. However, involvement of decreased PLC substrates, such as PI, PIP and 
PIP2, can be excluded, as they were not reduced by fatty acids (cf. Fig. 38). Therefore, 
the possibility for the reduced [Ca2+]i elevation might be due to the receptors itself. 
Receptor numbers and receptor affinity are the two regulatory methods for affecting 
the function of receptors. An important finding in the current study is the observation of 
the reduction of the affinity of bradykinin receptor. Such a change might reduce the 
efficiency of agonist-induced signaling and be responsible for the observed impairments 
of [Ca2+]i increase and NO formation upon stimulation by agonists. For the first time our 
findings imply that reduced bradykinin receptor’s affinity without a change in the 
receptor number might be one of the possible mechanisms for the decreased signaling 
transduction in NO production (cf. Fig. 37).  
However, currently there is still no mechanism proposed for how fatty acids may 
reduce bradykinin receptor affinity. One possible mechanism is that fatty acids increase 
bradykinin receptor’s avidity for localisation in lipid rafts. Lipid rafts are planar domains 
of cell membranes enriched in specific lipids and proteins. Under basal conditions, part of 
bradykinin receptors are located in lipids rafts. Fatty acids, especially palmitic fatty acids, 
by increasing the avidity of bradykinin receptors for lipid rafts, can act as a targeting 
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signal for partitioning bradykinin receptors into rafts. In other words, fatty acylation, 
particularly palmitoylation, promotes localization of bradykinin receptors in lipid rafts. It 
has been proposed that lipid rafts localisation seems to inactivate agonist-induced 
receptor activity by decreasing its agonist affinity 274. Regulating the affinity of 
bradykinin receptors might be an efficient way of modulating specific signaling events. 
And it might be the regulating way used by fatty acids in endothelial cells. It is also 
possible that bradykinin receptors may be desensitized following receptor 
phosphorylation mediated by protein kinases, such as PKC. 
There are some other mechanisms postulated to clarify the impaired signaling 
pathway and reduced NO production by high fatty acids. Kuroki et al reported that 
palmitate or oleate significantly increase the total DAG level in a time and 
dose-dependent manner 271. It was proposed that palmitate and oleate may stimulate DAG 
synthesis through de novo synthesis pathway as occurred at high glucose levels 271. Other 
results 180 suggested that unsaturated fatty acids may inhibit capacitative Ca2+ influx 
possibly because they intercalate into the plasma membrane and directly affect the 
activity of the channels involved. The issue related to DAG and PKC will be discussed 
further in section 4.3.  
4.2.4. Morphology of endothelial cells chronically overloaded with fatty acids  
The present study (cf. Fig. 39 & 40) also observed that pathological concentrations 
(0.5 and 1.0 mM) of fatty acids caused morphological changes in endothelial cells 
(BAECs and HUVECs), indicating a possible impairment of the integrity of endothelial 
membranes and possibly increased endothelial permeability. Such morphological 
alteration might lead to the exposure of subendothelial contents and allow leukocytes 
easier attachment to the vascular wall, the initial stage of atherosclerosis. Indeed, the 
incidence of atherosclerosis in diabetic patients is much higher than that in normal people 
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89. Although the basis for the shape change in endothelial cells is not known, the possible 
mechanisms might be the activation of PKC and excessive production of free radicals, 
which will be discussed in detail later. In addition, it is interesting to observe that a 
physiological concentration of fatty acids, 0.25 mM, promotes endothelial cell growth. 
The significance and mechanism of this finding is unclear.   
 
 
4.3.  Roles of PKC and oxidants in impaired signaling pathway for NO 
formation in endothelial cells chronically exposed to high glucose 
and fatty acids 
4.3.1. PKC activation, oxidants and NO production in long-term glucose or fatty 
acids overloaded endothelial cells  
Results from this study (Table 8 and Table 9) implied that activation of PKC and 
increased oxidant production in glucose- or fatty acid-overload environments might be 
two explanations for the reduced NO production induced by receptor agonist.  
It is known that PKC (especially β and δ isoforms) is excessively activated in 
vascular endothelial cells in high glucose surroundings due to enhanced de novo synthesis 
of diacylglycerol 161, 275, 276}. And fatty acids (oleic acid and palmitic acid) generated by 
phospholipase A2-mediated hydrolysis of phospholipids enhance the DAG-dependent 
activation of PKC isoenzymes 188. Furthermore, it has been shown that increased PKC 
activity is associated with several aspects of diabetic vascular pathology such as basement 
membrane thickening 277, increased vascular permeability 278, and enhanced angiogenesis 
279. However, the role of activation of PKC in the impaired NO signaling pathway was 
poorly understood.  
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Earlier studies showed that acute PKC activation has a negative feedback on the 
pathway linking receptors to PLC stimulation 280, 281. Our results using PKC inhibitors 
suggested that long-term excessive PKC activation is a candidate mechanism for the 
alterations of NO production (Table 8). This notion was demonstrated by other studies. 
Investigations 199 indicated that PKC inhibition in vivo markedly improved endothelial 
dysfunction, normalized vascular superoxide levels, and increased vascular NO 
bioavailability significantly. 
There are still other explanations for the effects of excessively activated PKC on NO 
formation. It was reported that activation of PKC inhibits the activity of the 
phosphatidylinositol 3 kinase pathway, thereby limiting activation of Akt kinase and 
subsequent phosphorylation of NOS in vitro, leading to a decrease in NO production in 
cultured endothelial cells 282. However, this conception is challenged by the current study, 
as ionomycin-induced NO formation was not impaired in glucose-overload endothelial 
cells, indicating that activation of PKC did not inhibit the activation process of eNOS  
per se to a large extent. On the other hand, the regulation of eNOS activity by 
phosphorylation (Ca2+-independent pathway), as discussed in the Introduction chapter, 
plays a major role in unstimulated endothelial cells but not in agonist-stimulated cells. 
Therefore, it is reasonable to propose that excessive activation of PKC might impair 
eNOS activity via Ca2+-dependent pathway rather than directly in endothelial cells 
cultured with high glucose.  
 Our data (Table 9) suggested that fatty acids impaired NO formation at least in part 
via a PKC-dependent manner. This conclusion was also reported by other investigators 121, 
250, 273, 282. Previous studies showed that fatty acids stimulate multiple isoenzymes of PKC 
283.   For instance, pleate acid and palmitate acid can directly activate PKC by 
interacting with the regulatory domain at a site which is distinct from that for DAG 183, 284. 
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Moreover, oleic activates the atypical PKC isoforms which do not have a DAG binding 
site 283, 285, 286. Some researchers even claim that fatty acids are more potent activators of 
the Ca2+-independent than Ca2+-dependent PKC isoforms 283. These effects on signal 
transduction may decrease NO production through receptor-PLC- Ca2+ pathway.  
It should be noted that the PKC inhibitors (bisindolylmaleimide I and GÖ 6976) 
could not completely reverse the impairments on agonist-induced NO production and 
[Ca2+]i rises in endothelial cells due to high glucose or fatty acids. In addition, there were 
no further improvement effects of these PKC inhibitors after 10-day culture than that at 5 
days (Tables 8-11). However, (+)-α-tocopherol acetate (also a well-known antioxidant) 
appeared more efficient than these typical PKC inhibitors. The reason might be due to the 
different actions of (+)-α-tocopherol acetate from bisindolylmaleimide I and GÖ 6976 on 
the function of PKC. It is known that (+)-α-tocopherol acetate serves as a PKC inhibitor 
as well as an antioxidant 287-291. The effect of (+)-α-tocopherol acetate on PKC activity 
was indirect 292, 293, and its inhibitory effect on PKC is via its ability to increase DAG 
kinase activity, which facilitates the conversion of DAG to PA 292, 294.  
The effects of N-acetyl-L-cysteine on agonist-stimulated NO formation suggest that 
oxidation may also be implicated in the pathogenesis of high glucose-induced 
impairments on NO formation and related receptor-agonist linked signaling pathway, in 
addition to excessive PKC activation. Indeed, an increase of reactive oxygen species 
(ROS) generation and oxidative stress occur in vessels following exposure to high 
glucose or in diabetes 132, 200.  
Discussion 
 142
4.3.2. PKC activation, oxidants and agonists induced [Ca2+]i in long-term glucose- or 
fatty acid-overloaded endothelial cells  
Fig. 41, 42 & Table 10, 11 indicated that PKC inhibitors and antioxidants were able 
to reverse the impaired agonists induced [Ca2+]i increment in endothelial cells exposed to 
high glucose or fatty acids for long periods, which implied the involvement of activation 
of PKC and/or the formation of oxidants in the reduced [Ca2+]i increment stimulated by 
agonists. These results were supported by the studies from other researchers. It was 
reported that activation of PKC by phorbol esters generally depressed the ability of 
agonists to stimulate [Ca2+]i rises in endothelial cells 281, 295. Furthermore, Buchan & 
Martin showed that Ca2+ mobilization could be modulated by both PKC and cyclic AMP 
296. They demonstrated that phorbol myristate acetate inhibited bradykinin- and 
ATP-induced Ca2+ release in BAECs, whereas cyclic AMP had the opposite effect. 
Consistent with this result is the suppression of [Ca2+]i oscillation in bradykinin 
stimulated BAECs by activation of PKC with phorbol ester 297.  
Accumulation of superoxide anion is one of the candidates reported for the 
pathogenesis of vascular and/or endothelial damage in diabetic environment. Excess 
glucose causes autooxidation of glucose and noenzymatic protein glycation, both of 
which generate O2- 298. Metabolism of excess glucose via its collateral pathway, the 
polyol pathway, increases the NADH/NAD+ ration, which results in the activation of 
protein kinase C and phospholipase A2 299. Prostaglandins are synthesized by 
cyclooxygenase in diabetic patients, which is capable of generating O2- as an intermediate 
117, 300. Fructose, a product of the polyol pathway, also generates O2-, as it induces protein 
glycation more efficiently than glucose 301. Furthermore, it has been reported that the 




The current study also found that pretreatment with antioxidants, such as 
N-acetyl-L-cysteine and (+)-α-tocopherol acetate, prevented the reduction in both 
bradykinin-stimulated Ca2+ (Table 10 & 11) and NO (Table 8 & 9) production in 
endothelial cells exposed to elevated glucose or fatty acids concentrations. Studies from 
clinical research also indicated that high concentrations of antioxidants were able to 
reverse the local effects of fatty acids on endothelium-dependent vasodilation. For 
example, Pleiner et al. showed that fatty acids induced endothelial dysfunction, and this 
effect was completely reversed by coadministration of N-acetyl-L-cysteine 168. They 
suggested that fatty acids induced vascular oxidative stress could contribute to endothelial 
dysfunction in insulin-resistant patients. Possible mechanisms for the increase of free 
radical production by excessive fatty acids are proposed to be the result of exorbitant 
mitochondrial uncoupling and β-oxidation 121. However, this effect could not be 
explained by a generalized improvement in Ca2+ signaling since the response to the 
receptor-independent agonist, ionomycin, was not enhanced by antioxidant treatment.  
Therefore, the events in upstream pathways of [Ca2+]i elevation might also be affected by 
the activation of PKC or increase of oxidants.  
4.3.3. PKC activation and bradykinin receptor in long-term glucose- or fatty acid- 
overloaded endothelial cells 
Results from this study revealed for the first time that high glucose and high fatty 
acids may modify cellular function at the level of the plasma membrane. Table 12 & 13 
indicate that activation of PKC might account for the decrease in bradykinin receptor 
number in endothelial cells after culture with high concentrations of glucose. By now, 
rare direct evidence showed the regulatory role of PKC in bradykinin receptor number in 
endothelial cells with diabetes environment. PKC has been shown to modulate hormone 
receptor turnover in endothelial cells 303. However, there are a few reports of PKC on 
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other cells types. For example, in smooth muscle cells, Christopher et al 268 examined the 
role of PKC in regulating B2-kinin receptor. They found that inhibition of PKC activity 
prevented the increase in B2-kinin receptor at the mRNA and protein levels, induced by 
acute high glucose. Therefore, they concluded that the regulation of the surface B2-kinin 
receptors in vascular tissue in response to high glucose might be mediated via activation 
of PKC. Even thought the cells used were different between the study mentioned above 
and the current one, it is still reasonable to deduce that excessive activation of PKC may 
affect NO signaling pathway via regulating agonist receptor on the membrane. Long-term 
PKC activation might reduce the expression of B2 receptor in endothelial cells as 
demonstrated in this study.  
In addition to reducing B2 receptor number on the membrane in glucose overloaded 
endothelial cells, PKC could also affect the affinity of B2 receptor in endothelial cells 
after culturing with high fatty acids (Table 13). Regulating the affinity of receptors is one 
of the mechanisms for signal regulation. Data have shown that PKC modulated 
expression of human lung fibroblast B2 bradykinin receptor affinity forms 304. On the 
other hand, it is well known that B2 receptor is able to activate the new PKC-epsilon 
isoform and the atypical PKC-zeta isoform, in addition to the classical PKC-alpha 
isoform 305. The regulation of B2 receptor by PKC might be one of the negative feedback 
mechanisms to terminate signaling transduction, which is critical for the precise 
physiological responses to extracellular stimulation.  
However, it is interesting to notice that the excessive activation of PKC plays a 
different role in endothelial cells in two distinct environments, high glucose or fatty acids. 
B2 receptor number and affinity in endothelial cells were reduced after treatment with 
high glucose and fatty acids, respectively. It seems that even thought PKC is excessively 
activated in both culture conditions, the mechanism by which PKC activation induces 
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endothelial dysfunction is quite different and requires further investigations. In diabetes, 
both hyperglycemia and hyperlipidemia exist; the higher incidence of diabetic 
cardiovascular complications in diabetic patients than that in normal people might be due 
to the decreased receptor number (caused by hyperglycemia) and receptor affinity (caused 
by hyperlipidemia) on the membrane of endothelial cells.       
4.3.4. PKC activation and morphology of fatty acid-overloaded endothelial cells 
The morphological changes of BAECs after a 10-day culture with high fatty acids 
might also be related to the excessive activation of PKC, since (+)-α-tocopherol acetate 
reversed such morphological alterations (Fig. 43). These findings and those discussed 
above, might provide explanations for the clinical findings that PKC inhibitors can 
reverse vascular abnormalities, including altered vascular contractility, blood flow, 
vascular permeability, cell growth as well as the basement membrane thickening, which 
are hallmarks of diabetic related vascular diseases and involves PKC activation 161.  
4.4. Conclusion 
This study was designed to identify the underlying mechanisms for the high 
incidence of cardiovascular diseases in diabetes. Two very common risk factors, high 
glucose and high fatty acids, were investigated to demonstrate their roles in the reduced 
endothelium-dependent NO formation in cultured endothelial cells in this study. Results 
showed that both high glucose and high fatty acids specifically impaired agonists-NO 
signaling pathway. Furthermore, agonists induced both [Ca2+]i mobilization from 
intracellular Ca2+ stores and Ca2+ influx from extracellular space were affected by high 
glucose or high fatty acids. However, the releasable Ca2+ in intracellular Ca2+ stores was 
intact.  The impairment of [Ca2+]i rise to agonists stimulation might be the result of 
decreased formation of IP3 in high glucose cultured endothelial cells as both basal and 
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agonist stimulated IP3 formation were reduced. On the other hand, this reduction of IP3 
formation might not be due to the inefficient substrates of PLC because neither high 
glucose nor high fatty acids changed the contents of PIP or PIP2. This study first 
demonstrated that high glucose reduced receptor numbers and high fatty acids impaired 
the receptor affinity on the cell membrane which reduced the signal transduction of NO 
formation. On the other hand, excessive PKC activation and ROS formation induced by 
high glucose or high fatty acids might be the underlying mechanisms for the alteration of 
receptor numbers and affinity because PKC inhibitors and antioxidants reversed the 
effects of high glucose and high fatty acids.  
4.5. Future study 
This study indicated the effects of high glucose and high fatty acids as well as the 
roles of excessive activation of PKC and production of ROS in endothelial dysfunction. 
The results from the current thesis confirmed the exacerbating roles of high glucose and 
high fatty acids in reducing receptor stimulated NO formation in endothelial cells. Our 
results also elucidated that high glucose or high fatty acids affect the agonist-NO 
signaling pathway by reducing receptor numbers and increasing receptor affinity, 
respectively which disclose the underlying mechanisms for the pathophysiology of high 
glucose and high fatty acids. PKC inhibitors as well as antioxidants reversed the effects of 
high glucose and high fatty acids indicated that the promoting roles of excessive 
activation of PKC and formation of ROS in the impaired NO signal transduction. 
However, results in the current studies did not rule out the possible existence of other 
mechanisms. It was reported that prolonged TPA treatment did not reduce receptor 
numbers with a further reduction of in IP3 formation, which suggests that long term TPA 
treatment reduces bradykinin-induced IP3 formation by acting at a site beyond the 
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receptor, such as IP3 receptors. Further investigations are needed to explain the existence 
of this possibility. Furthermore, it was only reported that the affinity forms of B2 receptor 
could be modulated by PKC in human lung fibroblasts. How excessively activated PKC  
regulate B2 bradykinin receptor numbers and affinity in vascular endothelial cells from 
type 2 diabetes and what are the genes are activated during this procedures still needed 






 (1)  Foster DW. Diabetes mellitus. Wilson JD et al eds, editor. Harrison's Pnnciples of 
Internal Medicine, 12th ed.  1739-1759. 1991. New York, McGraw-Hill.  
 (2)  King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, 
numerical estimates, and projections. Diabetes Care 1998 September;21(9):1414-31. 
 (3)  Bullock WH, Magnuson SR, Choi S, Gunn DE, Rudolph J. Prospects for kinase activity 
modulators in the treatment of diabetes and diabetic complications 1. Curr Top Med 
Chem 2002 September;2(9):915-38. 
 (4)  Reaven GM. The 4th Musketeer-From Dumasa,Alexandre To Bernard,Claudet 
Diabetologia 38[1], 3-13. 1995.  
 (5)  Bogardus C. Agonist- the case for insulin-resistance as a necessary and sufficient cause of 
Type-II diabetes-mellitus. J Lab Clin Med 125[5], 556-558. 1995.  
 (6)  Dowse GK Zimmet PZ, Gareeboo H,George K,Alberti MM,Tuomilehto J,Finch 
CF,Chitson P,Tulsidas H. Abdominal obesity and physical inactivity as risk factors for 
NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. 
Diabetes Care 14[4], 271-282. 1991.  
 (7)  Knowler WC,Bennett PH,Hamman RF,Miller M. Diabetes incidence and prevalence in 
Pima Indians: a 19-foldgreater incidence than in Rochester, Minnesota. Am J Epidemiol 
108, 497-505. 1978.  
 (8)  Dowse GK, Zimmet PZ,Spark RA,Mavo B,Rowley MJ,Mackay IR. Lack of antibodies to 
glutamic acid decarboxylase in young adults of the high diabetes prevalence Wanigela 
people of Papua New Guinea. Diabetes Res Clin Pract. 24[3], 195-198. 1994.  
 (9)  Dowse G, Collins V,Zimmet P,Finch C. Cross-sectional and longitudinal relationship 
between obesity, hypertension and coronary heart disease in Micronesian Nauruans. 
Diabetes Res Clin Pract. 10 Suppl 1, S179-S183. 1990.  
 (10)  Zimmet P, Taylor R,Ram P,King H,Sloman G,Raper LR,Hunt D. Prevalence of diabetes 
and impaired glucose tolerance in the biracial (Melanesian and Indian) population of Fiji: 
a rural-urban comparison. Am J Epidemiol. 118[5], 673-688. 1983.  
 (11) Froguel P. Tracking down genes to cure diabetes: An achievable task for the 21st century? 
Diabetes Metab 23 Suppl 2, 8-13. 1997.  
 (12)  Platz P, Jakobsen BK,Morling N,Ryder LP,Svejgaard A,Thomsen M,Christy M,Kromann 
H,Benn J,Nerup J,Green A,Hauge M. HLA-D and -DR antigens in genetic analysis of 
insulin dependent diabetes mellitus. Diabetologia 21[2], 108-115. 1981.  




 (14)  Miettinen H, Salomaa V. Diabetes and macrovascular disease. J Cardiovasc Risk 1997 
April;4(2):76-82. 
 (15)  Sowers JR, Lester MA. Diabetes and cardiovascular disease. Diabetes Care 1999 
April;22 Suppl 3:C14-C20. 
 (16)  Stergachis A, Shy KK, Grothaus LC, Wagner EH, Hecht JA, Anderson G, Normand EH, 
Raboud J. Tubal sterilization and the long-term risk of hysterectomy. JAMA 264[22], 
2893-2898. 1990.  
 (17)  Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters 
in endothelial and smooth muscle cells. Physiol Rev 2003 January;83(1):183-252. 
 (18)  McMillan DE. Development of vascular complications in diabetes. Vasc Med 
1997;2(2):132-42. 
 (19)  Cooper ME, Gilbert RE, Jerums G. Diabetic vascular complications. Clin Exp Pharmacol 
Physiol 1997 September;24(9-10):770-5. 
 (20)  Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JMC. Insulin action is associated 
with endothelial function in hypertension and type 2 diabetes. Hypertension 35[1], 
507-511. 2000.  
 (21)  Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM. Endothelial Nitric Oxide Production 
and Insulin Sensitivity : A Physiological Link With Implications for Pathogenesis of 
Cardiovascular Disease. Circulation 93[7], 1331-1333. 1996.  
 (22)  Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of 
arterial smooth muscle by acetylcholine. Nature 288[5789], 373-376. 1980.  
 (23)  Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical 
perspective. Endocr Rev 2001 February;22(1):36-52. 
 (24)  Kelm M RJ. Endothelial dysfunction in human coronary circulation: relevance of the 
L-arginine-NO pathway. Basic Res Cardiol. 96[2], 107-127. 2001.  
 (25)  Bayraktutan U. Free radicals, diabetes and endothelial dysfunction. Diabetes Obes Metab 
4[4], 224-238. 2002.  
 (26)  McVeigh GE, Brennan GM, Johnston GD et al. Impaired endothelium-dependent and 
independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. 
Diabetologia 1992 August;35(8):771-6. 
 (27)  Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired 
endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. 
Circulation 1993 December;88(6):2510-6. 
References 
 150
 (28)  Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric 
oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J 
Am Coll Cardiol 1996 March 1;27(3):567-74. 
 (29)  S Sakamoto, K Minami,Y Niwa,M Ohnaka,Y Nakaya,A Mizuno,M Kuwajima,and K 
Shima. Effect of exercise training and food restriction on endothelium-dependent 
relaxation in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous 
NIDDM. Diabetes 47[1], 82-86. 1998.  
 (30)  Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, 
Lucarelli C, D'Onofrio F. Vascular Effects of Acute Hyperglycemia in Humans Are 
Reversed by L-Arginine : Evidence for Reduced Availability of Nitric Oxide During 
Hyperglycemia. Circulation 95[7], 1783-1790. 1997.  
 (31)  Kawano H, Motoyama T, Hirashima O et al. Hyperglycemia rapidly suppresses 
flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 
1999 July;34(1):146-54. 
 (32)  Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, 
Ganten D, Haller H, Luft FC. NF-B Inhibition Ameliorates Angiotensin II¨CInduced 
Inflammatory Damage in Rats. Hypertension 35[1 Pt 2], 193-201. 2000.  
 (33)  Pieper GM, Meier DA, Hager SR. Endothelial dysfunction in a model of hyperglycemia 
and hyperinsulinemia. Am J Physiol 1995 September;269(3 Pt 2):H845-H850. 
 (34)  Gupta S, Sussman I, McArthur CS, Tornheim K, Cohen RA, Ruderman NB. 
Endothelium-dependent inhibition of Na(+)-K+ ATPase activity in rabbit aorta by 
hyperglycemia. Possible role of endothelium-derived nitric oxide. J Clin Invest. 90[3], 
727-732. 1992.  
 (35)  Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs 
endothelium-dependent relaxation by activating protein kinase C. J Clin Invest. 87[5], 
1643-1648. 1991.  
 (36)  Meraji S, Jayakody L, Senaratne MP, Thomson AB, Kappagoda T. 
Endothelium-dependent relaxation in aorta of BB rat. Diabetes 36[8], 978-981. 1987.  
 (37)  Mayhan WG. Impairment of endothelium-dependent dilatation of cerebral arterioles 
during diabetes mellitus. Am J Physiol 1989 March;256(3 Pt 2):H621-H625. 
 (38)  Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological 
activity of endothelium-derived relaxing factor. Nature 1987 June 11;327(6122):524-6. 
 (39)  Brenner BM, Troy JL, Ballermann BJ. Endothelium-dependent vascular responses. 
Mediators and mechanisms. J Clin Invest. 84[5], 1373-1378. 1989.  
 (40)  Dzau VJ. Cardiac renin-angiotensin system : Molecular and functional aspects. Am J Med. 
84[3A], 22-27. 1988.  
References 
 151
 (41)  Halbrugge T, Lutsch K, Thyen A, Graefe KH. Role of nitric oxide formation in the 
regulation of haemodynamics and the release of noradrenaline and adrenaline. Naunyn 
Schmiedebergs Arch Pharmacol. 344[6], 720-727. 1991.  
 (42)  Garg UC. Hassid A. Nitric oxide-generating vasodilators inhibit mitogenesis and 
proliferation of BALB/c 3T3 fibroblasts by a cyclic GMP-independent mechanism. 
Biochem Biophys Res Commun 171[1], 474-479. 1990.  
 (43)  Radomski MW, Palmer RM, Moncada S. The role of nitric oxide and cGMP in platelet 
adhesion to vascular endothelium. Biochem Biophys Res Commun 148[3], 1482-1489. 
1987.  
 (44)  Suzuki M, Asako H, Kubes P, Jennings S, Grisham MB, Granger DN. Neutrophil-derived 
oxidants promote leukocyte adherence in postcapillary venules. Microvasc Res. 42[2], 
125-138. 1991.  
 (45)  Kurose I, Miura S, Fukumura D, Tsuchiya M. Mechanisms of endothelin-induced 
macromolecular leakage in microvascular beds of rat mesentery. Eur J Pharmacol 250[1], 
85-94. 1993.  
 (46)  Al-Sa'doni H, Ferro A. S-Nitrosothiols: a class of nitric oxide-donor drugs. Clin Sci 
(Lond) 98[5], 507-520. 2000.  
 (47)  Woodman RJ, Chew GT, Watts GF. Mechanisms, significance and treatment of vascular 
dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Blood 65[1], 
31-74. 2005.  
 (48)  Flavahan NA, Vanhoutte PM. Endothelial Cell Signaling and Endothelial Dysfunction. 
Am J Hypertens 8[5 Pt 2], 28S-41S. 1995.  
 (49)  Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993 January 
28;361(6410):315-25. 
 (50)  Knowles RG. Nitric oxide synthases. Biochem Soc Trans 1996 August;24(3):875-8. 
 (51)  Feron O, Saldana F, Michel JB, Michel T. The Endothelial Nitric-oxide 
Synthase-Caveolin Regulatory Cycle. J Biol Chem 273[6], 3125-3128. 1998.  
 (52)  Forstermann U, Kleinert H. Nitric oxide synthase: expression and expressional control of 
the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 1995 October;352(4):351-64. 
 (53)  Noris M, Morigi M, Donadelli R et al. Nitric oxide synthesis by cultured endothelial cells 
is modulated by flow conditions. Circ Res 1995 April;76(4):536-43. 
 (54)  Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation 




 (55)  Griffith TM. Shear stress and nitric oxide release: physiological integration of cellular 
mechanisms, physical forces and flow regulation. In: Mathie RT, Griffith TM, editors. 
The haemodynamic effects of nitric oxide.London: Imperial College Press; 1999. p. 22-51. 
 (56)  Hecker M, Mulsch A, Bassenge E, Forstermann U, Busse R. Subcellular localization and 
characterization of nitric oxide synthase(s) in endothelial cells: physiological implications. 
Biochem J 1994 April 1;299 ( Pt 1):247-52. 
 (57)  Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases 
coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene 
expression. Circ Res 1994 February;74(2):349-53. 
 (58)  Lamas S, Michel T, Brenner BM, Marsden PA. Nitric oxide synthesis in endothelial cells: 
evidence for a pathway inducible by TNF-alpha. Am J Physiol 1991 October;261(4 Pt 
1):C634-C641. 
 (59)  Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide 
synthase expression and superoxide anion generation in human aortic endothelial cells. 
Circulation 1997 July 1;96(1):25-8. 
 (60)  Tang Y, Li GD. High glucose impairs bradykinin-induced nitric oxide production in 
endothelial cells by reduction of cytosolic Ca2+ levels. Diabetes 2001;50 (Suppl. 2):A41 
(Abstract). 
 (61)  Zochodne DW, Verge VM, Cheng C et al. Nitric oxide synthase activity and expression 
in experimental diabetic neuropathy. J Neuropathol Exp Neurol 2000 
September;59(9):798-807. 
 (62)  Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide 
synthase expression in retinal vascular endothelial cells is suppressed by high glucose and 
advanced glycation end products. Diabetes 1998 June;47(6):945-52. 
 (63)  Mancusi G, Hutter C, Baumgartner-Parzer S, Schmidt K, Schutz W, Sexl V. 
High-glucose incubation of human umbilical-vein endothelial cells does not alter 
expression and function either of G-protein alpha-subunits or of endothelial NO synthase. 
Biochem J 1996 April 1;315:281-7. 
 (64)  Wennmalm A. Endothelial nitric oxide and cardiovascular disease. J Intern Med 1994 
April;235(4):317-27. 
 (65)  Rubanyi GM, Vanhoutte PM. Calcium and activation of the release of 
endothelium-derived relaxing factor. Ann N Y Acad Sci 1988;522:226-33. 
 (66)  Freay A, Johns A, Adams DJ, Ryan US, Van Breemen C. Bradykinin and inositol 
1,4,5-trisphosphate-stimulated calcium release from intracellular stores in cultured bovine 
endothelial cells. Pflugers Arch 1989 August;414(4):377-84. 
 (67)  Himmel HM, Whorton AR, Strauss HC. Intracellular calcium, currents, and 
stimulus-response coupling in endothelial cells. Hypertension 1993 January;21(1):112-27. 
References 
 153
 (68)  Putney JW, Jr., Broad LM, Braun FJ, Lievremont JP, Bird GS. Mechanisms of 
capacitative calcium entry. J Cell Sci 2001 June;114(Pt 12):2223-9. 
 (69)  Huang HM, Gibson G. Regulation of bradykinin-induced Ins(1,4,5)P3 formation by 
protein kinase C in human fibroblasts. Life Sci 1996;59(18):1533-43. 
 (70)  Hutcheson IR, Griffith TM. Central role of intracellular calcium stores in acute flow- and 
agonist-evoked endothelial nitric oxide release. Br J Pharmacol 1997 
September;122(1):117-25. 
 (71)  Presta A, Liu J, Sessa WC, Stuehr DJ. Substrate Binding and Calmodulin Binding to 
Endothelial Nitric Oxide Synthase Coregulate Its Enzymatic Activity. Nitric Oxide 1[1], 
74-87. 1997.  
 (72)  Kuchan MJ, Frangos JA. Role of calcium and calmodulin in flow-induced nitric oxide 
production in endothelial cells. Am J Physiol 1994 March;266(3 Pt 1):C628-C636. 
 (73)  Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its 
complications: estimates and projections to the year 2010. Diabet Med 1997;14 Suppl 
5:S1-85. 
 (74)  Brakemeier S, Eichler I, Hopp H, Kohler R, Hoyer J. Up-regulation of endothelial 
stretch-activated cation channels by fluid shear stress. Cardiovasc Res 2002 
January;53(1):209-18. 
 (75)  Chen ZP, Mitchelhill KI, Michell BJ et al. AMP-activated protein kinase phosphorylation 
of endothelial NO synthase. FEBS Lett 1999 January 29;443(3):285-9. 
 (76)  Ohara Y, Sayegh HS, Yamin JJ, Harrison DG. Regulation of endothelial constitutive 
nitric oxide synthase by protein kinase C. Hypertension 1995 March;25(3):415-20. 
 (77)  Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial nitric oxide 
synthase in luminal caveolae of endothelium with rapid caveolin dissociation and 
calmodulin association. J Biol Chem. 273[52], 34724-34729. 1998.  
 (78)  Mulsch A, Bassenge E, Busse R. Nitric oxide synthesis in endothelial cytosol: evidence 
for a calcium-dependent and a calcium-independent mechanism. Naunyn Schmiedebergs 
Arch Pharmacol 1989 December;340(6 Pt 2):767-70. 
 (79)  Pickup JC, Keen H, Stevenson RW, Parsons JA, Alberti KG, White M, Kohner EM. 
Insulin  via continuous subcutaneous infusion. Lancet 312[8097], 988-989. 1978.  
 (80)  The Diabetes Control and Complications Trial Research Group. The Effect of Intensive 
Treatment of Diabetes on the Development and Progression of Long-Term Complications 
in Insulin-Dependent Diabetes Mellitus. N Engl J Med. 329[14], 977-986. 1993.  
 (81)  Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner 
RC, Holman RR. Association of glycaemia with macrovascular and microvascular 
References 
 154
complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 
321[7258], 405-412. 2000.  
 (82)  Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N. Glycated 
haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective 
investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322[7277], 15-18. 2001.  
 (83)  Pfeiffer A, Schatz H. Diabetic microvascular complications and growth factors. Exp Clin 
Endocrinol Diabetes 1995;103(1):7-14. 
 (84)  Dahl-Jorgensen K. Diabetic microangiopathy. Acta Paediatr Suppl 1998 
October;425:31-4. 
 (85)  Porte D, Jr., Schwartz MW. Diabetes complications: why is glucose potentially toxic? 
Science 1996 May 3;272(5262):699-700. 
 (86)  Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri 
M. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up 
of the Kumamoto study. Diabetes Research Clinical Practice 48[3], 201-210. 2000.  
 (87)  UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of 
complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352[9131], 837-853. 
1998.  
 (88)  Laakso M LS. Epidemiology of macrovascular disease in diabetes. Diabetes Reviews 5, 
294-315. 1997.  
 (89)  Pyorala K, Laakso M,Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. 
Diabetes Metab Rev 3[2], 463-524. 1987.  
 (90)  Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic 
agents on vascular complications in patients with adult-onset diabetes. II. Mortality 
results. Diabetes 19[Suppl 2], 789-830.  
 (91)  Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG. Effects of 
hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. 
Mortality and selected nonfatal events with insulin treatment. JAMA 240[1], 37-42. 1978.  
 (92)  Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive 
diabetes management on macrovascular events and risk factors in the diabetes control and 
complications trial. Am J Cardiol 75[14], 894-903. 1995.  
 (93)  Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from Coronary Heart 
Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without 
Prior Myocardial Infarction. N Engl J Med 339[4], 229-234. 1998.  
 (94)  Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year 
cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein 
References 
 155
composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. 
Diabetologia 1993 November;36(11):1175-84. 
 (95)  Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict 
coronary heart disease in elderly subjects. Diabetes 1994 August;43(8):960-7. 
 (96)  Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its 
metabolic control are important predictors of stroke in elderly subjects. Stroke 1994 
June;25(6):1157-64. 
 (97)  Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. 
Diabetes Care 1995 February;18(2):258-68. 
 (98)  Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on 
all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 
21[7], 1167-1172. 1998.  
 (99)  Andersson DK, Svardsudd K. Long-term glycemic control relates to mortality in type II 
diabetes. Diabetes Care 18[12], 1534-1543. 1995.  
 (100)  Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor 
glycemic control predict mortality in NIDDM. Diabetes 44[11], 1303-1309. 1995.  
 (101)  Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, Holle R. 
Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the 
Munich General Practitioner Project. Diabetologia 39[12], 1540-1545. 1996.  
 (102)  Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch 
HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: 
the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39[12], 1577-1583. 
1996.  
 (103)  Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of Stroke in Middle-Aged 
Patients With Non¨CInsulin-Dependent Diabetes. Stroke 27[1], 63-68. 1996.  
 (104)  Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and 
hyperglycemia predict coronary heart disease events in middle-aged patients with 
NIDDM. Diabetes 46[8], 1354-1359. 1997.  
 (105)  Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk 
factors for coronary artery disease in non-insulin dependent diabetes mellitus: United 
Kingdom prospective diabetes study (UKPDS: 23). BMJ 316[7134], 823-828. 1998.  
 (106)  Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, Cram KB, 
Hutchinson RG. Relation of carotid artery wall thickness to diabetes mellitus, fasting 
glucose and insulin, body size, and physical activity. Atherosclerosis Risk in 
Communities (ARIC) Study Investigators. Stroke 25[1], 66-73. 1994.  
References 
 156
 (107)  Fuller JH, McCartney P, Jarrett RJ, Keen H, Rose G, Shipley MJ, Hamilton PJ.  
Hyperglycaemia and coronary heart disease: the Whitehall Study. J Chronic Dis 
32[11-12], 721-728. 1979.  
 (108)  Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal 
cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes 
Care 21[8], 1236-1239. 1998.  
 (109)  Behar S, Boyko V,Benderly M, Mandelzweig L, Graff E, Reicher-Reiss H, Schneider H, 
Shotan A, Balkin J, Brunner D,et al. Asymptomatic hyperglycemia in coronary heart 
disease: frequency and associated lipid and lipoprotein levels in the bezafibrate infarction 
prevention (BIP) register. The BIP Study Group. J Cardiovasc Risk 2[3], 241-246. 1995.  
 (110)  Jarrett RJ. Type 2 (non¨Cinsulin-dependent) diabetes mellitus and coronary heart disease: 
chicken, egg, or neither? Diabetologia 26[2], 99-102. 1984.  
 (111)  Schleicher E, Nerlich A. The role of hyperglycemia in the development of diabetic 
complications. Horm Metab Res 1996 August;28(8):367-73. 
 (112)  Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H. 
Modification of low-density-lipoprotein by advanced glycation end-products contributes 
to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A. 91[20], 
9441-9445. 1994.  
 (113)  Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: 
Pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 90[14], 6434-6438. 1993.  
 (114)  Kennedy A, Frank RN, Varma SD. Galactitol accumulation by glucose-6-phosphate 
deficient fibroblasts: A cellular model for resistance to the complications of diabetes 
mellitus. Life Sci 33[13], 1277-1283. 1983.  
 (115)  Hawthorne GC, Bartlett K, Hetherington CS, Alberti KG. The effect of high glucose on 
polyol pathway activity and myoinositol metabolism in cultured human endothelial cells. 
Diabetologia 32[3], 163-166. 1989.  
 (116)  Lorenzi M, Toledo S, Boss GR, Lane MJ, Montisano DF. The polyol pathway and 
glucose 6-phosphate in human endothelial cells cultured in high glucose concentrations. 
Diabetologia 30[4], 222-227. 1987.  
 (117)  Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol 
Med 1994 March;16(3):383-91. 
 (118)  Tomlinson DR, Stevens EJ, Diemel LT. Aldose reductase inhibitors and their potential for 
the treatment of diabetic complications. Trends Pharmacol Sci 15[8], 293-297. 1994.  
 (119)  Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the 
prevention of diabetic complications. Pharmacol Rev 50[1], 21-33. 1998.  
References 
 157
 (120)  Taher MM, Garcia JG, Natarajan V. Hydroperoxide-Induced Diacylglycerol Formation 
and Protein Kinase C Activation in Vascular Endothelial Cells. Arch Biochem Biophys 
303[2], 260-266. 1993.  
 (121)  Inoguchi T, Li P, Umeda F et al. High glucose level and free fatty acid stimulate reactive 
oxygen species production through protein kinase C--dependent activation of NAD(P)H 
oxidase in cultured vascular cells. Diabetes 2000 November;49(11):1939-45. 
 (122)  Sobrevia L, Mann GE. Dysfunction of the endothelial nitric oxide signalling pathway in 
diabetes and hyperglycaemia. Exp Physiol 1997 May;82(3):423-52. 
 (123)  Durante W, Sen AK, Sunahara FA. Impairment of endothelium-dependent relaxation in 
aortae from spontaneously diabetic rats. Br J Pharmacol 1988 June;94(2):463-8. 
 (124)  Kamata K, Miyata N, Kasuya Y. Impairment of endothelium-dependent relaxation and 
changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J 
Pharmacol 1989 June;97(2):614-8. 
 (125)  Hinzen D, Hornykiewicz O, Kobinger W, Pichler L, Pifl C, Schingnitz G. The dopamine 
autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine 
receptors in rodent and primate models of Parkinson's disease: a novel approach to 
treatment. Eur J Pharmacol. 131[1], 75-86. 1986.  
 (126)  Pieper GM, Gross GJ. Oxygen free radicals abolish endothelium-dependent relaxation in 
diabetic rat aorta. Am J Physiol 1988 October;255(4 Pt 2):H825-H833. 
 (127)  Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation 
of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 85[3], 
929-932. 1990.  
 (128)  Poston L, Taylor PD. Glaxo/MRS Young Investigator Prize. Endothelium-mediated 
vascular function in insulin-dependent diabetes mellitus. Clin Sci (Lond). 88[3], 245-255. 
1995.  
 (129)  Duckrow RB. Decreased cerebral blood flow during acute hyperglycemia. Brain Res. 
703[1-2], 145-150. 1995.  
 (130)  Cipolla MJ, Porter JM, Osol G. High glucose concentrations dilate cerebral arteries and 
diminish myogenic tone through an endothelial mechanism. Stroke 28[2], 405-410. 1997.  
 (131)  Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of 
antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised 
placebo-controlled trial. Lancet 360[9326], 23-33. 2002.  
 (132)  Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by 
elevated glucose. Am J Physiol 1992 August;263(2 Pt 2):H321-H326. 
 (133)  Bohlen HG, Lash JM. Topical hyperglycemia rapidly suppresses EDRF-mediated 
vasodilation of normal rat arterioles. Am J Physiol. 265[1 Pt 2], H219-H225. 1993.  
References 
 158
 (134)  Mayhan WG, Patel KP. Acute effects of glucose on reactivity of cerebral microcirculation: 
role of activation of protein kinase C. Am J Physiol. 269[4 Pt 2], H1297-H1302. 1995.  
 (135)  Dorigo P, Fraccarollo D, Santostasi G, Maragno I. Impairment of endothelium-dependent 
but not of endothelium-independent dilatation in guinea-pig aorta rings incubated in the 
presence of elevated glucose. Br J Pharmacol. 121[5], 972-976. 1997.  
 (136)  Kimura C, Oike M, Koyama T, Ito Y. Impairment of endothelial nitric oxide production 
by acute glucose overload. Am J Physiol Endocrinol Metab 2001 
January;280(1):E171-E178. 
 (137)  Kimura C, Oike M, Ito Y. Acute glucose overload abolishes Ca2+ oscillation in cultured 
endothelial cells from bovine aorta: a possible role of superoxide anion. Circ Res 1998 
April 6;82(6):677-85. 
 (138)  Williams SB, Goldfine AB, Timimi FK et al. Acute hyperglycemia attenuates 
endothelium-dependent vasodilation in humans in vivo. Circulation 1998 May 
5;97(17):1695-701. 
 (139)  Regarding "Endothelium-dependent vasodilatation is impaired in both microcirculation 
and macrocirculation during acute hyperglycemia". J Vasc Surg 29[5], 942-943. 1999.  
 (140)  Sobrevia L, Nadal A,Yudilevich DL, Mann GE. Activation of L-arginine transport 
(system y+) and nitric oxide synthase by elevated glucose and insulin in human 
endothelial cells. J Physiol 490[Pt 3], 775-781. 1996.  
 (141)  Pieper GM, Dondlinger L. Glucose elevations alter bradykinin-stimulated intracellular 
calcium accumulation in cultured endothelial cells. Cardiovasc Res 1997 
April;34(1):169-78. 
 (142)  McFarlane SI, Banerji M, Sowers JR. Insulin Resistance and Cardiovascular Disease. J 
Clin Endocrinol Metab 86[2], 713-718. 2001.  
 (143)  Chan NN, Vallance P, Colhoun HM. Nitric oxide and vascular responses in Type I 
diabetes. Diabetologia 2000 February;43(2):137-47. 
 (144)  Salameh A, Dhein S. Influence of chronic exposure to high concentrations of D-glucose 
and long-term beta-blocker treatment on intracellular calcium concentrations of porcine 
aortic endothelial cells. Diabetes 1998 March;47(3):407-13. 
 (145)  Weisbrod RM, Brown ML, Cohen RA. Effect of elevated glucose on cyclic GMP and 
eicosanoids produced by porcine aortic endothelium. Arterioscler Thromb 13[6], 915-923. 
1993.  
 (146)  Magill SB, Dananberg J. Effects of hyperglycemia on vascular endothelium nitric oxide 
metabolism. Sowers JR, editor. Contemporary endocrinology: endocrinology of the 
vasculature.  145-156. 1996. Totowa, N.J, Human Press Inc.  
References 
 159
 (147)  Catalano M, Carzaniga G, Perilli E, Jun T, Scandale G, Andreoni S, Carotta M. Basal 
nitric oxide production is not reduced in patients with noninsulin-dependent diabetes 
mellitus. Vasc Med. 2[4], 302-305. 1997.  
 (148)  Graier WF, Hoebel BG, Paltauf-Doburzynska J, Kostner GM. Effects of superoxide 
anions on endothelial Ca2+ signaling pathways. Arterioscler Thromb Vasc Biol 1998 
September;18(9):1470-9. 
 (149)  Pieper GM. Enhanced, unaltered and impaired nitric oxide-mediated 
endothelium-dependent relaxation in experimental diabetes mellitus: importance of 
disease duration. Diabetologia 1999 February;42(2):204-13. 
 (150)  Johnstone MT, Caulfield TA. Nitric oxide and its role in diabetes mellitus. In: Johnstone 
MT, Veves A, editors. Diabetes and cardiovascular disease.Totowa, New Jesey: Human 
Press Inc.; 2001. p. pp.213-36. 
 (151)  Graier WF, Wascher TC, Lackner L, Toplak H, Krejs GJ, Kukovetz WR. Exposure to 
elevated D-glucose concentrations modulates vascular endothelial cell vasodilatory 
response. Diabetes 1993 October;42(10):1497-505. 
 (152)  Wascher TC, Graier WF, Bahadori B, Toplak H. Time course of endothelial dysfunction 
in diabetes mellitus. Circulation 1994 August;90(2):1109-10. 
 (153)  Tooke JE, Sandeman DD, Shore AC. Microvascular hemodynamics in hypertension and 
diabetes. J Cardiovasc Pharmacol. 18[Suppl 2], S51-S53. 1991.  
 (154)  Smulders RA, Stehouwer CD, Olthof CG et al. Plasma endothelin levels and vascular 
effects of intravenous L-arginine infusion in subjects with uncomplicated 
insulin-dependent diabetes mellitus. Clin Sci (Lond) 1994 July;87(1):37-43. 
 (155)  Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am 
Physicians 111[3], 241-248. 1999.  
 (156)  Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes 
mellitus. Am J Med 108[Suppl 6a], 9S-14S. 2000.  
 (157)  Charles MA, Eschwege E,Thibult N,Claude JR,Warnet JM,Rosselin GE,Girard J,Balkau 
B. The role of non-esterified fatty acids in deterioration of glucose tolerance in Caucasian 
subjects: the Paris Prospective Study. Diabetologia 40[9], 1101-1106. 1997.  
 (158)  Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high 
concentration of fasting plasma non-esterified fatty acids is a risk factor for the 
development of NIDDM. Diabetologia 38[10], 1213-1217. 1995.  
 (159)  Swislocki A, Chen Y, Golay A, Chang M, Reaven G. Insulin suppression of plasma-free 
fatty acid concentration in normal individuals and patients with Type 2 
(non-insulin-dependent) diabetes. Diabetologia 30[8], 622-626. 1987.  
References 
 160
 (160)  R.Bruce, I.Godsland, C.Walton, D.Crook and V.Wynn. Associations between insulin 
sensitivity, and free fatty acid and triglyceride metabolism independent of uncomplicated 
obesity. Metabolism 43[10], 1275-1281. 1994.  
 (161)  Koya D, King GL. Protein kinase C activation and the development of diabetic 
complications. Diabetes 1998 June;47(6):859-66. 
 (162)  Randle PJ, Hales CN, Newsholm EA. The glucose fatty-acid cycle. Its role in insulin 
sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1, 785-789. 1963.  
 (163)  Williamson JR, Garcia A, Renold AE, Cahill GF Jr. Studies on the perfused rat liver. I. 
Effects of glucagon and insulin on glucose metabolism. Diabetes 15[3], 183-187. 1966.  
 (164)  Krebs HA, Hems R, Weidemann MJ, Speake RN. The fate of isotopic carbon in kidney 
cortex synthesizing glucose from lactate. Biochem J. 101[1], 242-249. 1966.  
 (165)  Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes7. 
37[12], 1595-1607. 1988.  
 (166)  Sarabi M, Vessby B, Millgard J, Lind L. Endothelium-dependent vasodilation is related to 
the fatty acid composition of serum lipids in healthy subjects. Atherosclerosis. 156[2], 
349-355. 2001.  
 (167)  Steinberg HO, Tarshoby M, Monestel R et al. Elevated circulating free fatty acid levels 
impair endothelium-dependent vasodilation. J Clin Invest 1997 September 
1;100(5):1230-9. 
 (168)  Pleiner J, Schaller G, Mittermayer F, Bayerle-Eder M, Roden M, Wolzt M. FFA-induced 
endothelial dysfunction can be corrected by vitamin C. J Clin Endocrinol Metab 2002 
June;87(6):2913-7. 
 (169)  Tripathy D, Mohanty P, Dhindsa S et al. Elevation of free fatty acids induces 
inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003 
December;52(12):2882-7. 
 (170)  Kelley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in 
non-insulin-dependent diabetes mellitus. J Clin Invest 94[6], 2349-2356. 1994.  
 (171)  Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend TL, Egan BM. Oleic acid 
inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. 
Hypertension 1995 November;26(5):764-70. 
 (172)  Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid 
elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 
2000 July;49(7):1231-8. 
 (173)  Moers A, Schrezenmeir J. Palmitic acid but not stearic acid inhibits NO-production in 
endothelial cells. Exp Clin Endocrinol Diabetes 1997;105 Suppl 2:78-80. 
References 
 161
 (174)  Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. 
Diabetologia 2002 May;45(5):623-34. 
 (175)  M.Weinblatt, L.Moreland, M.Schiff, S.Baumgartner, E.Tindall, R.Fleischmann, 
K.Bulpitt,A.Weaver, E.Keystone,P.Mease, D.Furst, E.Ruderman, D.Ettlinger, B.Gruber, 
A.Dugan,C.Blosch. Long-term Treatment of DMARD Failing Rheumatoid Arthritis 
Patients with TNF Receptor P75 FC Fusion Protein (TNFR:Fc; ENBREL).  J Invest Med 
46, 228A. 1998.  
 (176)  Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced 
inhibition of glucose uptake. J Clin Invest 1994 June;93(6):2438-46. 
 (177)  Kuroda R, Hirata K, Kawashima S, Yokoyama M. Unsaturated free fatty acids inhibit 
Ca2+ mobilization and NO release in endothelial cells. Kobe J Med Sci 2001 
October;47(5):211-9. 
 (178)  Ronald M.A. Henry, Isabel Ferreira, Piet J.Kostense, Jacqueline M.Dekker,Giel Nijpels, 
Robert J.Heine, Otto Kamp, Lex M.Bouter and Coen D.A.Stehouwer. Type 2 diabetes is 
associated with impaired endothelium-dependent, flow-mediated dilation, but impaired 
glucose metabolism is not: The Hoorn Study. Atherosclerosis 174[1], 49-56. 2004.  
 (179)  Esenabhalu VE, Schaeffer G, Graier WF. Free fatty acid overload attenuates Ca2+ 
signaling and NO production in endothelial cells. Antioxid Redox Signal 2003 
April;5(2):147-53. 
 (180)  Gamberucci A, Fulceri R, Benedetti A. Inhibition of store-dependent capacitative Ca2+ 
influx by unsaturated fatty acids. Cell Calcium 21[5], 375-385. 1997.  
 (181)  Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids on glucose transport 
and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999 
January;103(2):253-9. 
 (182)  Dichtl W, Nilsson L, Goncalves I et al. Very low-density lipoprotein activates nuclear 
factor-kappaB in endothelial cells. Circ Res 1999 May 14;84(9):1085-94. 
 (183)  Griffin ME, Marcucci MJ, Cline GW et al. Free fatty acid-induced insulin resistance is 
associated with activation of protein kinase C theta and alterations in the insulin signaling 
cascade 1. Diabetes 1999 June;48(6):1270-4. 
 (184)  Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular 
complications. Diabet Med 2001 December;18(12):945-59. 
 (185)  Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats 
by an oral PKC beta inhibitor. Science 1996 May 3;272(5262):728-31. 
 (186)  Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein 
kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by 
hyperglycemia in humans. Circ Res 2002 January 11;90(1):107-11. 
References 
 162
 (187)  Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the 
mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in 
diabetes and hypergalactosemia. Diabetes 1994 September;43(9):1122-9. 
 (188)  Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on 
metabolism and cardiovascular complications in diabetes. Diabetologia 2001 
June;44(6):659-73. 
 (189)  Lebovitz HE. Effect of the postprandial state on nontraditional risk factors. Am J Cardiol 
2001 September 20;88(6A):20H-5H. 
 (190)  Li W, Wang W, Liu X. Comparative study of high-glucose effect on phosphatidylcholine 
hydrolysis of cultured retinal capillary pericytes and endothelial cells. Biochim Biophys 
Acta 1222[3], 339-347. 1994.  
 (191)  Hink U, Li H, Mollnau H et al. Mechanisms underlying endothelial dysfunction in 
diabetes mellitus. Circ Res 2001 February 2;88(2):E14-E22. 
 (192)  Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of 
oxidant stress. Circ Res 2000 November 10;87(10):840-4. 
 (193)  Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential 
elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and 
heart of diabetic rats: differential reversibility to glycemic control by islet cell 
transplantation. Proc Natl Acad Sci U S A 1992 November 15;89(22):11059-63. 
 (194)  Lu X, Yang XY, Howard RL, Walsh JP. Fatty acids modulate protein kinase C activation 
in porcine vascular smooth muscle cells independently of their effect on de novo 
diacylglycerol synthesis. Diabetologia 43[9], 1136-1144. 2000.  
 (195)  Shinomura T, Asaoka Y, Oka M, Yoshida K, Nishizuka Y. Synergistic action of 
diacylglycerol and unsaturated fatty acid for protein kinase C activation: its possible 
implications. Proc Natl Acad Sci U S A 88[12], 5149-5153. 1991.  
 (196)  Yoshida K, Asaoka Y, Nishizuka Y. Platelet activation by simultaneous actions of 
diacylglycerol and unsaturated fatty acid. Proc Natl Acad Sci U S A. 89[14], 6443-6446. 
1992.  
 (197)  Goekjian PG, Jirousek MR. Protein kinase C in the treatment of disease: signal 
transduction pathways, inhibitors, and agents in development. Curr Med Chem. 6[9], 
877-903. 1999.  
 (198)  Curtis TM, Major EH, Trimble ER, Scholfield CN. Diabetes-induced activation of protein 
kinase C inhibits store-operated Ca2+ uptake in rat retinal microvascular smooth muscle. 
Diabetologia 46[9], 1252-1259. 2003.  
 (199)  Shimamoto Y, Shimamoto H, Kwan CY, Daniel EE. Differential effects of putative 
protein kinase C inhibitors on the contraction of rat aortic smooth muscle. Am J Physiol. 
264[4 Pt 2], H1300-H1306. 1993.  
References 
 163
 (200)  Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. 
Diabetes Care 1996 March;19(3):257-67. 
 (201)  Watts GF, Playford DA. Dyslipoproteinaemia and hyperoxidative stress in the 
pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an 
hypothesis. Atherosclerosis 1998 November;141(1):17-30. 
 (202)  Hunt JV, Dean RT, Wolff SP. Hydroxyl radical production and autoxidative 
glycosylation. Glucose autoxidation as the cause of protein damage in the experimental 
glycation model of diabetes mellitus and ageing. Biochem J 1988 November 
15;256(1):205-12. 
 (203)  Vlassara H. Recent progress on the biologic and clinical significance of advanced 
glycosylation end products. J Lab Clin Med 1994 July;124(1):19-30. 
 (204)  Lee TS, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of 
glucose concentration: proposal for a mechanism in the development of diabetic vascular 
complications. Proc Natl Acad Sci U S A 1989 July;86(13):5141-5. 
 (205)  Harlan JM, Levine JD, Callahan KS, Schwartz BR, Harker LA. Glutathione redox cycle 
protects cultured endothelial cells against lysis by extracellularly generated hydrogen 
peroxide. J Clin Invest 1984 March;73(3):706-13. 
 (206)  Wohaieb SA, Godin DV. Alterations in free radical tissue-defense mechanisms in 
streptozocin-induced diabetes in rat. Effects of insulin treatment. Diabetes 1987 
September;36(9):1014-8. 
 (207)  Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP. Elevated 
levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995 
September;44(9):1054-8. 
 (208)  Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J et al. Relationships between plasma 
measures of oxidative stress and metabolic control in NIDDM. Diabetologia 1997 
June;40(6):647-53. 
 (209)  Wojtczak L, Schonfeld P. Effect of fatty acids on energy coupling processes in 
mitochondria. Biochim Biophys Acta 1993 November 2;1183(1):41-57. 
 (210)  Carlsson C, Borg LA, Welsh N. Sodium palmitate induces partial mitochondrial 
uncoupling and reactive oxygen species in rat pancreatic islets in vitro. Endocrinology 
1999 August;140(8):3422-8. 
 (211)  Bakker SJ, IJzerman RG, Teerlink T, Westerhoff HV, Gans RO, Heine RJ. Cytosolic 
triglycerides and oxidative stress in central obesity: the missing link between excessive 
atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis 2000 
January;148(1):17-21. 
 (212)  Hennig B, Meerarani P, Ramadass P, Watkins BA, Toborek M. Fatty acid-mediated 
activation of vascular endothelial cells. Metabolism 2000 August;49(8):1006-13. 
References 
 164
 (213)  Toborek M, Hennig B. Fatty acid-mediated effects on the glutathione redox cycle in 
cultured endothelial cells. Am J Clin Nutr 1994 January;59(1):60-5. 
(214)  Takeshi Nishikawa,  Diane  Edelstein, Xue Liang Du,  Sho-Ichi  Yamagishi, Takeshi         
       Matsumura, et al.  Normalizing  mitochondrial  superoxide production blocks  three        
       pathways of hyperglycaemic damage. Nature 404[ 6779], 787-790. 2000.  
 
 (215)  Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 
2001 December 13;414(6865):813-20. 
 (216)  GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza 
nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids 
and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 
354[9177], 447-455. 1999.  
 (217)  Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic 
review. J Intern Med. 251[5], 372-392. 2002.  
 (218)  Lonn E, Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, 
Mann JF, Gerstein HC, HOPE Study, MICRO-HOPE Study. Effects of vitamin E on 
cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of 
the HOPE study and MICRO-HOPE substudy. Diabetes Care 25[11], 1919-1927. 2002.  
 (219)  Chowienczyk PJ, Brett SE, Gopaul NK et al. Oral treatment with an antioxidant 
(raxofelast) reduces oxidative stress and improves endothelial function in men with type 
II diabetes. Diabetologia 2000 August;43(8):974-7. 
 (220)  Gazis A, White DJ, Page SR, Cockcroft JR. Effect of oral vitamin E (alpha-tocopherol) 
supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabet Med 
1999 April;16(4):304-11. 
 (221)  Darko D, Dornhorst A, Kelly FJ, Ritter JM, Chowienczyk PJ. Lack of effect of oral 
vitamin C on blood pressure, oxidative stress and endothelial function in Type II diabetes. 
Clin Sci (Lond) 103[4], 339-344. 2002.  
 (222)  Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves 
endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes 
mellitus. J Clin Invest. 97[1], 22-28. 1996.  
 (223)  Van Etten RW, de Koning EJ, Verhaar MC,Gaillard CA, Rabelink TJ. Impaired 
NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes 
mellitus is restored by acute administration of folate. Diabetologia 45[7], 1004-1010. 
2002.  
 (224)  Regine Heller, Felix Munscher-Paulig, Rolf Grabner, and Uwe Till. L-Ascorbic Acid 




 (225)  Hirose H, Lee YH, Inman LR, Nagasawa Y, Johnson JH, Unger RH. Defective fatty 
acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic 
implications for obesity-dependent diabetes. J Biol Chem 1996 March 8;271(10):5633-7. 
 (226)  Milburn JL, Jr., Hirose H, Lee YH et al. Pancreatic beta-cells in obesity. Evidence for 
induction of functional, morphologic, and metabolic abnormalities by increased long 
chain fatty acids. J Biol Chem 1995 January 20;270(3):1295-9. 
 (227)  Nakatsubo N, Kojima H, Kikuchi K et al. Direct evidence of nitric oxide production from 
bovine aortic endothelial cells using new fluorescence indicators: diaminofluoresceins. 
FEBS Lett 1998 May 8;427(2):263-6. 
 (228)  Kojima H, Sakurai K, Kikuchi K et al. Development of a fluorescent indicator for the 
bioimaging of nitric oxide. Biol Pharm Bull 1997 December;20(12):1229-32. 
 (229)  Li GD, Milani D, Dunne MJ et al. Extracellular ATP causes Ca2+-dependent and 
-independent insulin secretion in RINm5F cells. Phospholipase C mediates Ca2+ 
mobilization but not Ca2+ influx and membrane depolarization. J Biol Chem 1991 
February 25;266(6):3449-57. 
 (230)  Martin Poenie, Janet Alderton, Roger Y.Tsien & Richard A.Steinhardt. Changes of free 
calcium levels with stages of the cell division cycle. Nature 315[6015], 147-149. 1985.  
 (231)  Limbird LE. Cell Surface Receptors: A Short Course on Theory and Methods. 2 ed. 
Boston: Kluwer academic Publishers; 1996. 
 (232)  Linseman DA, Sorensen SD, Fisher SK. Attenuation of focal adhesion kinase signaling 
following depletion of agonist-sensitive pools of phosphatidylinositol 4,5-bisphosphate. J 
Neurochem 1999 November;73(5):1933-44. 
 (233)  Medh JD, Weigel PH. Separation of phosphatidylinositols and other phospholipids by 
two-step one-dimensional thin-layer chromatography. J Lipid Res 1989 May;30(5):761-4. 
 (234)  Karasu C, Altan VM. The role of endothelial cells on the alterations in vascular reactivity 
induced by insulin-dependent diabetes mellitus: effects of insulin treatment. Gen 
Pharmacol 1993 May;24(3):743-55. 
 (235)  Farkas K, Sarman B, Jermendy G, Somogyi A. Endothelial nitric oxide in diabetes 
mellitus: too much or not enough? Diabetes Nutr Metab 2000 October;13(5):287-97. 
 (236)  Ding Y, Vaziri ND, Coulson R, Kamanna VS, Roh DD. Effects of simulated 
hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am 
J Physiol Endocrinol Metab 2000 July;279(1):E11-E17. 
 (237)  Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB, Erzurum SC. Continuous 
nitric oxide synthesis by inducible nitric oxide synthase in normal human airway 
epithelium in vivo. Proc Natl Acad Sci U S A. 92[17], 7809-7813. 1995.  
References 
 166
 (238)  Noyman I, Marikovsky M, Sasson S,Stark AH, Bernath K, Seger R, Madar Z. 
Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in 
endothelial cells. Nitric Oxide. 7[3], 187-193. 2002.  
 (239)  Guo X, Chen LW, Liu WL, Guo ZG. High glucose inhibits expression of inducible and 
constitutive nitric oxide synthase in bovine aortic endothelial cells. Acta Pharmacol Sin 
2000 April;21(4):325-8. 
 (240)  Weidig P, McMaster D, Bayraktutan U. High glucose mediates pro-oxidant and 
antioxidant enzyme activities in coronary endothelial cells. Diabetes Obes Metab. 6[6], 
432-441. 2004.  
 (241)  Yang AL, Tsai SJ, Jiang MJ, Jen CJ, Chen HI. Chronic exercise increases both inducible 
and endothelial nitric oxide synthase gene expression in endothelial cells of rat aorta. J 
Biomed Sci 2002 March;9(2):149-55. 
 (242)  Boo YC, Sorescu GP, Bauer PM et al. Endothelial NO synthase phosphorylated at 
SER635 produces NO without requiring intracellular calcium increase. Free Radic Biol 
Med 2003 October 1;35(7):729-41. 
 (243)  Stepniakowski KT, Lu G, Davda RK, Egan BM. Fatty acids augment 
endothelium-dependent dilation in hand veins by a cyclooxygenase-dependent 
mechanism. Hypertension 1997 December;30(6):1634-9. 
 (244)  Amano K, Hori M, Ozaki H, Karaki H. Agonist-dependent difference in the relationship 
between cytosolic Ca2+ level and release of vascular relaxing factors in the endothelium 
of rabbit aortic valve. Eur J Pharmacol 1999 February 5;366(2-3):215-21. 
 (245)  Buckley BJ, Barchowsky A, Dolor RJ, Whorton AR. Regulation of arachidonic acid 
release in vascular endothelium. Ca(2+)-dependent and -independent pathways. Biochem 
J. 280[Pt 2], 281-287. 1991.  
 (246)  Buchan KW, Martin W. Bradykinin induces elevations of cytosolic calcium through 
mobilisation of intracellular and extracellular pools in bovine aortic endothelial cells. Br J 
Pharmacol. 102[1], 35-40. 1991.  
 (247)  Schilling WP, Rajan L, Strobl-Jager E. Characterization of the bradykinin-stimulated 
calcium influx pathway of cultured vascular endothelial cells. Saturability, selectivity, and 
kinetics. J Biol Chem. 264[22], 12838-12848. 1989.  
 (248)  Wascher TC, Toplak H, Krejs GJ, Simecek S, Kukovetz WR, Graier WF. Intracellular 
mechanisms involved in D-glucose-mediated amplification of agonist-induced Ca2+ 
response and EDRF formation in vascular endothelial cells. Diabetes 1994 
August;43(8):984-91. 
 (249)  Tran QK, Ohashi K, Watanabe H. Calcium signalling in endothelial cells. Cardiovasc Res 
2000 October;48(1):13-22. 
 (250)  Ordway RW, Singer JJ, Walsh JV, Jr. Direct regulation of ion channels by fatty acids. 
Trends Neurosci 1991 March;14(3):96-100. 
References 
 167
 (251)  Trebak M, Bird GS, McKay RR, Putney JW, Jr. Comparison of human TRPC3 channels 
in receptor-activated and store-operated modes. Differential sensitivity to channel 
blockers suggests fundamental differences in channel composition. J Biol Chem 2002 
June 14;277(24):21617-23. 
 (252)  Korenaga R, Ando J, Ohtsuka A et al. Close correlation between cytoplasmic Ca++ levels 
and release of an endothelium-derived relaxing factor from cultured endothelial cells. Cell 
Struct Funct 1993 April;18(2):95-104. 
 (253)  Loeb AL, Izzo NJ, Jr., Johnson RM, Garrison JC, Peach MJ. Endothelium-derived 
relaxing factor release associated with increased endothelial cell inositol trisphosphate 
and intracellular calcium. Am J Cardiol 1988 October 5;62(11):36G-40G. 
 (254)  Lantoine F, Iouzalen L, Devynck MA, Millanvoye-Van Brussel E, David-Dufilho M. 
Nitric oxide production in human endothelial cells stimulated by histamine requires Ca2+ 
influx. Biochem J 1998 March 1;330:695-9. 
 (255)  Luckhoff A, Pohl U, Mulsch A, Busse R. Differential role of extra- and intracellular 
calcium in the release of EDRF and prostacyclin from cultured endothelial cells. Br J 
Pharmacol 1988 September;95(1):189-96. 
 (256)  Koyama T, Kimura C, Park SJ, Oike M, Ito Y. Functional implications of Ca2+ 
mobilizing properties for nitric oxide production in aortic endothelium. Life Sci. 72[4-5], 
511-520. 2002.  
 (257)  Lin S, Fagan KA, Li KX, Shaul PW, Cooper DM, Rodman DM. Sustained endothelial 
nitric-oxide synthase activation requires capacitative Ca2+ entry. J Biol Chem 2000 June 
16;275(24):17979-85. 
 (258)  Missiaen L, Robberecht W, van den Bosch L, Callewaert G, Parys JB, Wuytack F, 
Raeymaekers L, Nilius B, Eggermont J, De Smedt. Abnormal intracellular 
ca(2+)homeostasis and disease. Cell Calcium 28[1], 1-21. 2000.  
 (259)  Hofer AM, Fasolato C, Pozzan T. Capacitative Ca2+ entry is closely linked to the filling 
state of internal Ca2+ stores: a study using simultaneous measurements of ICRAC and 
intraluminal [Ca2+]. J Cell Biol. 140[2], 325-334. 1998.  
 (260)  Lytton J, Westlin M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic 
reticulum Ca-ATPase family of calcium pumps. J Biol Chem. 266[26], 17067-17071. 
1991.  
 (261)  Kijima Y, Ogunbunmi E, Fleischer S. Drug action of thapsigargin on the Ca2+ pump 
protein of sarcoplasmic reticulum. J Biol Chem. 266[34], 22912-22918. 1991.  
 (262)  Dolor RJ, Hurwitz LM, Mirza Z, Strauss HC, Whorton AR. Regulation of extracellular 
calcium entry in endothelial cells: role of intracellular calcium pool. Am J Physiol. 262[1 
Pt 1], C171-C181. 1992.  
 (263)  Taylor CW, Laude AJ. IP3 receptors and their regulation by calmodulin and cytosolic 
Ca2+. Cell Calcium.2002 Nov-Dec;32(5-6):321-34. 32[5-6], 321-334. 2002.  
References 
 168
 (264)  Adkins CE, Morris SA, De Smedt H, Sienaert I, Torok K, Taylor CW. Ca2+-calmodulin 
inhibits Ca2+ release mediated by type-1, -2 and -3 inositol trisphosphate receptors. 
Biochem J. 345 Pt 2, 357-363. 2000.  
 (265)  Missiaen L, Parys JB, Weidema AF, Sipma H, Vanlingen S, De Smet P, Callewaert G, De 
Smedt H. The bell-shaped Ca2+ dependence of the inositol 1,4, 5-trisphosphate-induced 
Ca2+ release is modulated by Ca2+/calmodulin. J Biol Chem. 274[20], 13748-13751. 
1999.  
 (266)  Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, 
and kininases. Pharmacol Rev. 44[1], 1-80. 1992.  
 (267)  Christopher J, Jaffa AA. Diabetes modulates the expression of glomerular kinin receptors. 
Int Immunopharmacol. 2[13-14], 1771-1779. 2002.  
 (268)  Christopher J, Velarde V, Zhang D, Mayfield D, Mayfield RK, Jaffa AA. Regulation of 
B(2)-kinin receptors by glucose in vascular smooth muscle cells. Am J Physiol Heart Circ 
Physiol 2001 April;280(4):H1537-H1546. 
 (269)  Inoguchi T, Xia P, Kunisaki M, Higashi S, Feener EP, King GL. Insulin's effect on protein 
kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J 
Physiol. 267[3 Pt 1], E369-E379. 1994.  
 (270)  Wolf BA, Easom RA, Hughes JH, McDaniel ML, Turk J. Secretagogue-induced 
diacylglycerol accumulation in isolated pancreatic islets. Mass spectrometric 
characterization of the fatty acyl content indicates multiple mechanisms of generation. 
Biochemistry 28[10], 4291-4301. 1989.  
 (271)  Kuroki T, Inoguchi T, Umeda F, Nawata H. Effect of eicosapentaenoic acid on 
glucose-induced diacylglycerol synthesis in cultured bovine aortic endothelial cells. 
Biochem Biophys Res Commun. 247[2], 473-477. 1998.  
 (272)  Davda RK, Chandler LJ, Guzman NJ. Protein kinase C modulates receptor-independent 
activation of endothelial nitric oxide synthase 1. Eur J Pharmacol 1994 February 
15;266(3):237-44. 
 (273)  Morrison KJ, Pollock D. Impairment of relaxations to acetylcholine and nitric oxide by a 
phorbol ester in rat isolated aorta 1. Br J Pharmacol 1990 October;101(2):432-6. 
 (274)  Chini B, Parenti M. G-protein coupled receptors in lipid rafts and caveolae: how, when 
and why do they go there? J Mol Endocrinol 2004 April;32(2):325-38. 
 (275)  Meier M, King GL. Protein kinase C activation and its pharmacological inhibition in 
vascular disease. Vasc Med 2000;5(3):173-85. 
 (276)  King GL, Ishii H, Koya D. Diabetic vascular dysfunctions: a model of excessive 
activation of protein kinase C. Kidney Int Suppl 1997 September;60:S77-S85. 
References 
 169
 (277)  Ayo SH, Radnik RA, Glass WF 2nd, Garoni JA, Rampt ER, Appling DR, Kreisberg JI. 
Increased extracellular matrix synthesis and mRNA in mesangial cells grown in 
high-glucose medium. Am J Physiol. 260[2 Pt 2], F185-F191. 1991.  
 (278)  Wolf BA, Williamson JR, Easom RA, Chang K, Sherman WR, Turk J. Diacylglycerol 
accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin 
Invest 1991 January;87(1):31-8. 
 (279)  Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, 
Jirousek MR, King GL. haracterization of vascular endothelial growth factor's effect on 
the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 
98[9], 2018-2026. 1996.  
 (280)  Ryu SH, Kim UH, Wahl MI et al. Feedback regulation of phospholipase C-beta by 
protein kinase C. J Biol Chem 1990 October 15;265(29):17941-5. 
 (281)  Brock TA, Capasso EA. Thrombin and histamine activate phospholipase C in human 
endothelial cells via a phorbol ester-sensitive pathway. J Cell Physiol 1988 
July;136(1):54-62. 
 (282)  Hirata K, Kuroda R, Sakoda T et al. Inhibition of endothelial nitric oxide synthase activity 
by protein kinase C. Hypertension 1995 February;25(2):180-5. 
 (283)  Khan WA, Blobe G, Halpern A et al. Selective regulation of protein kinase C isoenzymes 
by oleic acid in human platelets 1. J Biol Chem 1993 March 5;268(7):5063-8. 
 (284)  el Touny S, Khan W, Hannun Y. Regulation of platelet protein kinase C by oleic acid. 
Kinetic analysis of allosteric regulation and effects on autophosphorylation, phorbol ester 
binding, and susceptibility to inhibition 1. J Biol Chem 1990 September 
25;265(27):16437-43. 
 (285)  Nakanishi H, Exton JH. Purification and characterization of the zeta isoform of protein 
kinase C from bovine kidney 1. J Biol Chem 1992 August 15;267(23):16347-54. 
 (286)  Glatz JF, Borchers T, Spener F, van der Vusse GJ. Fatty acids in cell signalling: 
modulation by lipid binding proteins 3. Prostaglandins Leukot Essent Fatty Acids 1995 
February;52(2-3):121-7. 
 (287)  Bursell SE, King GL. Can protein kinase C inhibition and vitamin E prevent the 
development of diabetic vascular complications? Diabetes Res Clin Pract 1999 
September;45(2-3):169-82. 
 (288)  Bursell SE, Clermont AC, Aiello LP et al. High-dose vitamin E supplementation 
normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. 
Diabetes Care 1999 August;22(8):1245-51. 
 (289)  Koya D, Haneda M, Kikkawa R, King GL. d-alpha-tocopherol treatment prevents 
glomerular dysfunctions in diabetic rats through inhibition of protein kinase 
C-diacylglycerol pathway. Biofactors 1998;7(1-2):69-76. 
References 
 170
 (290)  Rosen P, Toeller M. Vitamin E in diabetes. Increased oxidative stress and its prevention 
as a strategy to prevent vascular complications? Int J Vitam Nutr Res 1999 
May;69(3):206-12. 
 (291)  Cinar MG, Ulker S, Alper G, Evinc A. Effect of dietary vitamin E supplementation on 
vascular reactivity of thoracic aorta in streptozotocin-diabetic rats. Pharmacology 2001 
January;62(1):56-64. 
 (292)  Lee IK, Koya D, Ishi H, Kanoh H, King GL. d-Alpha-tocopherol prevents the 
hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) 
pathway in vascular smooth muscle cell by an increase of DAG kinase activity. Diabetes 
Res Clin Pract. 45[2-3], 183-190. 1999.  
 (293)  Koya D, Lee IK, Ishii H, Kanoh H, King GL. Prevention of glomerular dysfunction in 
diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol. 8[3], 426-435. 
1997.  
 (294)  Tran K, Proulx PR, Chan AC. Vitamin E suppresses diacylglycerol (DAG) level in 
thrombin-stimulated endothelial cells through an increase of DAG kinase activity. 
Biochim Biophys Acta. 1212[2], 193-202. 1994.  
 (295)  Carter TD, Hallam TJ, Pearson JD. Protein kinase C activation alters the sensitivity of 
agonist-stimulated endothelial-cell prostacyclin production to intracellular Ca2+. Biochem 
J 1989 September 1;262(2):431-7. 
 (296)  Buchan KW, Martin W. Modulation of agonist-induced calcium mobilisation in bovine 
aortic endothelial cells by phorbol myristate acetate and cyclic AMP but not cyclic GMP. 
Br J Pharmacol. 104[2], 361-366. 1991.  
 (297)  Sage SO, Adams DJ, van Breemen C. Synchronized oscillations in cytoplasmic free 
calcium concentration in confluent bradykinin-stimulated bovine pulmonary artery 
endothelial cell monolayers. J Biol Chem. 264[1], 6-9. 1989.  
 (298)  Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus 
and ageing. Free Radic Biol Med. 10[5], 339-352. 1991.  
 (299)  Keogh RJ, Dunlop ME, Larkins RG. Effect of inhibition of aldose reductase on glucose 
flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. 
Metabolism 1997 January;46(1):41-7. 
 (300)  Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van 
den Enden M, Kilo C, Tilton RG. Hyperglycemic pseudohypoxia and diabetic 
complications. Diabetes. 42[6], 801-813. 1993.  
 (301)  Suarez G, Rajaram R, Oronsky AL, Gawinowicz MA. Nonenzymatic glycation of bovine 
serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated 
by glucose. J Biol Chem. 264[7], 3674-3679. 1989.  
 (302)  Arai K, Iizuka S, Tada Y, Oikawa K, Taniguchi N. Increase in the glucosylated form of 
erythrocyte Cu-Zn-superoxide dismutase in diabetes and close association of the 
References 
 171
nonenzymatic glucosylation with the enzyme activity. Biochim Biophys Acta. 924[2], 
292-296. 1987.  
 (303)  Hachiya HL, Takayama S, White MF, King GL. Regulation of insulin receptor 
internalization in vascular endothelial cells by insulin and phorbol ester. J Biol Chem. 
262[13], 6417-6424. 1987.  
 (304)  Dalemar LR, Ivy Jong YJ, Wilhelm B, Baenziger NL. Protein kinases A and C rapidly 
modulate expression of human lung fibroblast B2 bradykinin receptor affinity forms. Eur 
J Cell Biol 1996 March;69(3):236-44. 
 (305)  Acosta J, Hettinga J, Fluckiger R et al. Molecular basis for a link between complement 
and the vascular complications of diabetes. Proc Natl Acad Sci U S A 2000 May 
9;97(10):5450-5. 
 
 
